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In an effort to develop a biohybrid artificial organ, mammalian cells were 
engineered with several properties to make them adept in secreting therapeutic 
proteins and surviving low oxygen levels in an encapsulated environment.  Three cell 
lines, C2C12, Jurkat, and HEK293, were investigated for their ability to secrete 
human interleukin 2 (hIL2), which can serve as an anti-cancer agent.  An intracellular 
fluorescent protein marker was independently expressed using an internal ribosome 
entry site sequence so that hIL2 remained active and free for secretion.  DsRed 
fluorescent protein markers were used since red light is known to be transmissible 
through mammalian tissue.  Transient transfection of all three cell lines proved that 
internal red fluorescence measurements were indeed linearly correlated with the 
concentration of hIL2 secreted.  To increase the survivability of encapsulated 
cultures, cells were engineered with an anti-apoptotic gene, bcl-2∆, placed under the 
control of a hypoxia sensitive promoter.  This protective system was found to lessen 
both hypoxia induced necrosis and apoptosis.  To complete the biohybrid system, a 
  
novel hydrogel (mTG-Gel), utilizing microbial transglutaminase (mTG) to 
enyzmatically crosslink gelatin, was developed as a biocompatible cellular scaffold 
for encapsulating the engineered cells.  These gels were stable at physiological 
temperature (37 oC) and could be tailored for enzymatic stability.  Specifically, 
HEK293 cells that were metabolically engineered with all the previous characteristics 
were encapsulated in 4% mTG-Gels.  In situ analysis of DsRed fluorescence showed 
that cells overlayed with mTG-Gel exhibited reductions in fluorescence with 
increasing height of gel.  Human IL2 diffusion through the hydrogel into overlaying 
media was found to exhibit the expected dependence on the square of the gel 
thickness.  Diffusion cells were used to determine an effective diffusion coefficient 













TISSUE AND METABOLIC ENGINEERING OF 













Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Professor Timothy A. Barbari, Chair 
Professor William E. Bentley 
Professor William A. Weigand 
Associate Professor Peter Kofinas 
























© Copyright by 

















I dedicate the culmination of my learning to my parents: 




I would like to acknowledge all the friends that I have grown to love and 
respect at the University of Maryland.  Thank you for all the wonderful intellectual 
discussions about life and science.  I cherish your friendships, and for these I feel that 
I am not alone. 
 
I would like to give thanks to my advisors, Tim Barbari and Bill Bentley, for 
their dedication to my research and development of my intellectual spirit.  You have 
taught me the meanings of scientific rigor, patience, and humility.  I am honored to be 
your student. 
 
Finally, I would like to give thanks to my sisters and parents for their 
continual support and encouragement throughout my life.  You have filled me with 
goodness and confidence, and are the foundation of my achievements.  There are no 
words to express my fortune to be in this family. 
iii  
Table of Contents 
 
1. Introduction ............................................................................................................1 
1.1 Research Motivation ...................................................................................1 
1.2 Eukaryotic Protein Expression System.......................................................4 
1.2.1 Transcriptional Regulations ................................................................4 
1.2.2 Translation of mRNA .........................................................................4 
1.2.3 Monocistronic vs. Polycistronic Translation ......................................5 
1.2.4 Internal Ribosome Binding Site (IRES) Bicistronic System ..............5 
1.2.5 Antibiotic Resistance and Cell Selection:...........................................5 
1.2.6 Secreteable Protein Processing [37]....................................................6 
1.2.6.1 Sorting Signals and the Endoplasmic Reticulum .....................................6 
1.2.6.2 Glycosylation and Post-Translational Modification.................................7 
1.3 Fluorescent Protein Markers .......................................................................8 
1.3.1 Green Fluorescent Protein (GFP)........................................................9 
1.3.1.1 Biochemical and Physical Properties .......................................................9 
1.3.1.2 GFP Variants for Mammalian Applications...........................................10 
1.3.2 New Red Fluorescent Protein (RFP) Markers ..................................12 
1.3.2.1 DsRed – Discosoma sp (sea coral) .........................................................12 
1.3.2.2 HcRed – Heteractis crispa (sea anemone) ..............................................14 
1.4 Biohybrid Artificial Organs ......................................................................14 
1.4.1 Cell Source........................................................................................15 
1.4.2 Molecular Diffusion and Device Design ..........................................15 
1.4.3 Immuno-Protection ...........................................................................18 
1.5 Hypoxia.....................................................................................................20 
1.5.1 Mammalian Oxygen Homeostasis ....................................................20 
1.5.2 Molecular Biochemistry....................................................................21 
1.5.3 Normal Physiological Causes ...........................................................22 
1.5.4 Conditions in Encapsulation that Cause Hypoxia.............................22 
1.5.5 Hypoxia-Induced Cell Death and Bcl-2∆ Protection........................23 
1.6 Cell Lines ..................................................................................................24 
1.6.1 C2C12 ...............................................................................................24 
1.6.2 HEK293 ............................................................................................24 
1.6.3 Jurkat.................................................................................................25 
1.7 Human Interleukin 2 (hIL2)......................................................................25 
1.8 Cellular Scaffolds and Gelatin Hydrogels ................................................26 
2. Integrated Non-Invasive System for Quantifying Secreted Human 
Therapeutic hIL2 ..................................................................................................28 
2.1 Introduction...............................................................................................28 
2.2 Materials and Methods..............................................................................29 
2.2.1 Cell Culture - Passaging and Maintenance .......................................29 
2.2.2 Vector Constructs..............................................................................30 
2.2.3 Transfections.....................................................................................33 
2.2.4 ELISA ...............................................................................................34 
2.2.5 Flow Cytometry ................................................................................34 
iv  
2.2.6 Fluorescence Microscopy .................................................................36 
2.3 Results and Discussion .............................................................................37 
2.3.1 Correlating DsExDR with Intracellular hIL2 ...................................37 
2.3.2 Correlating DsExDR with Secreted hIL2 from Attachment 
Cells ..................................................................................................39 
2.3.3 Correlating DsExDR with Secreted hIL2 from Suspension 
Cells ..................................................................................................40 
2.3.4 Examining IRES – mediated Co-expression of DsExDR 
and hIL2 Proteins..............................................................................41 
2.4 Conclusions...............................................................................................45 
2.5 Acknowledgements...................................................................................46 
3. Counteracting Apoptosis and Necrosis with Hypoxia Responsive 
Expression of Bcl-2∆............................................................................................47 
3.1 Introduction...............................................................................................47 
3.2 Materials and Methods..............................................................................49 
3.2.1 Cell Culture Media and Maintenance ...............................................49 
3.2.2 Construction of Recombinant Plasmids............................................49 
3.2.3 Transfections.....................................................................................52 
3.2.4 Hypoxic Chambers............................................................................53 
3.2.5 Flow Cytometry of EYFP Recombinant Proteins.............................55 
3.2.6 Viability Assay..................................................................................55 
3.2.7 Apoptosis Assay................................................................................56 
3.2.8 Fluorescence Microscopy .................................................................57 
3.3 Results and Discussion .............................................................................57 
3.3.1 Differential Hypoxic Induction of Protein Production .....................57 
3.3.2 Transient Expression of Heterologous Proteins under 
Hypoxic Condition............................................................................61 
3.3.3 Bcl-2∆ Protection of Cells under Hypoxic Stress.............................63 
3.4 Conclusions...............................................................................................64 
3.5 Acknowledgements...................................................................................65 
4. Biocompatible Cellular Scaffold for Encapsulating Cells ...................................67 
4.1 Introduction...............................................................................................67 
4.2 Materials and Methods..............................................................................69 
4.2.1 Maintenance of Cell Cultures ...........................................................69 
4.2.2 Cell Encapsulation and Culture ........................................................69 
4.2.3 In Situ Cell Proliferation Assay ........................................................70 
4.3 Results and Discussion .............................................................................71 
4.4 Conclusions...............................................................................................75 
5. Transglutaminase Crosslinked Gelatin Hydrogels as Tissue Engineering 
Scaffolds ...............................................................................................................76 
5.1 Introduction...............................................................................................76 
5.2 Material and Methods ...............................................................................76 
5.2.1 Transglutaminase Crosslinked Gelatin Hydrogels............................76 
5.2.2 Thermal and Proteolytic Degradation of mTG Crosslinked 
Hydrogels..........................................................................................77 
5.3 Results and Discussion .............................................................................78 
v  
5.3.1 Thermal and Proteolytic Stability of mTG-Gels...............................78 
5.3.2 Tuneable Degradability of HybriGels...............................................81 
5.4 Conclusions...............................................................................................85 
6. Diffusion of hIL2 from Encapsulated Cells .........................................................87 
6.1 Introduction...............................................................................................87 
6.2 Materials and Methods..............................................................................88 
6.2.1 Maintenance of Cell Cultures ...........................................................88 
6.2.2 mTG-Gel Formation .........................................................................88 
6.2.3 Plasmid Constructs............................................................................89 
6.2.4 Cell Transfection and Encapsulation ................................................91 
6.2.5 Fluorescence Microscopy and ELISA ..............................................93 
6.2.6 Diffusion Cell Experiments ..............................................................94 
6.3 Results and Discussion .............................................................................97 
6.3.1 Therapeutic Protein Secretion by Encapsulated HEK293 ................97 
6.3.2 Mathematical Modeling of hIL2 Release .......................................103 
6.3.3 Obtaining the Fluxes and Diffusion Coefficient of hIL2 
Secreted by HEK293.......................................................................106 
6.3.4 Measuring Diffusion Coefficient of hIL2 in mTG-Gel ..................111 
6.4 Conclusions.............................................................................................112 
7. Summary ............................................................................................................113 
7.1 Integrated Non-Invasive System for Quantifying Secreted 
Human Therapeutic hIL2 .......................................................................113 
7.2 Counteracting Apoptosis and Necrosis with Hypoxia Responsive 
Expression of Bcl-2∆..............................................................................114 
7.3 Biocompatible Cellular Scaffold for Encapsulating Cells ......................115 
7.4 Transglutaminase Crosslinked Gelatin Hydrogels as Tissue 
Engineering Scaffolds ............................................................................115 
7.5 Diffusion of hIL2 from Encapsulated Cells............................................116 
8. Bibliography.......................................................................................................117 
vi  
List of Tables 
Table 1.1 Spectroscopic properties of fluorescent proteins. ................................13 
Table 3.1 Transfection Protocol for C2C12 in 6- and 12-well tissue culture 
plates. ...................................................................................................53 
Table 5.1 Thermal and enzymatic degradation rates for various forms of 
hydrogels..............................................................................................82 
Table 6.1 hIL2 flux determined form the thinnest overlay (0.16 cm) must 
be rescaled by the level of DsExDR fluorescence found in the 
thicker overlays..................................................................................110 
vii  
List of Figures  
Figure 1.1 Three dimensional representation of β-can and α-helix 
structure of GFP......................................................................................10 
Figure 1.2 Excitation (A) and emission (B) spectra of fluorescent 
proteins....................................................................................................13 
Figure 1.3 Rate of insulin secretion as a function of oxygen partial 
pressure in perifused rat islets [56]. ........................................................16 
Figure 1.4 Oxygen penetration profiles for spheres (A) and slab (B) of 
various diameters [56].............................................................................17 
Figure 1.5 Oxygen penetration profiles for spheres (A) and slabs (B) 
surrounded by an avascular diffusion barrier [56]. .................................18 
Figure 1.6 Cellular and humoral immune responses experienced by 
implanted cells. .......................................................................................19 
Figure 2.1 The bicistronic vector, pF2, contains an internal ribosome 
entry site (IRES) gene sequence, which allows for the 
independent production of secreteable hIL2 and DsExDR red 
fluorescent marker proteins.....................................................................32 
Figure 2.2 Destabilized DsRed-Express fluorescence in mammalian 
cells was measured using a FACS Calibur flow cytometer 
(FSC = 1.00, SSC = 394, FL2 = 683 for Jurkat cells and FSC 
= 0.485, SSC = 288 and FL2 = 538 for HEK293 and C2C12 
cells).  Histograms were obtained only after gating live cells 
from dead ones using a FSC-SSC dot plot within 10,000 cell 
samples....................................................................................................36 
Figure 2.3 HEK293 and C2C12 attachment cells were transfected with 
pF2 (0, 0.2, 0.5, 0.8, 1.2, 1.6, and 2.0 mg-DNA per 2 x 105 
cells) for the bicistronic expression of Destabilized DsRed-
Express (DsExDR) red fluorescent protein and secretion of 
human interleukin-2 (hIL2).  Both cell lines secreted large 
amounts of hIL2 on the order of nanograms per million cells 
(A, D).   The presence of hIL2 within HEK293 cells was also 
measured.  These cells lines were able to express similar 
quantities of the intracellular red fluorescent protein (B, E).  
The elevated concentration of DsExDR at the highest levels 
of transfection resulted in decreases of fluorescence 
measurements in both cell lines.  This was indicative of self-
quenching.  Strong linear correlations between the two 
proteins were observed in both cell lines when the last data 
points were omitted (C, F).  A linear correlation of DsExDR 
with intracellular hIL2 was also present in HEK293 cells.  
Jurkat cells were transfected with five higher concentrations 
of the bicistronic plasmid pF2 (1.1, 1.7, 2.6, 3.4, and 5.1 mg-
DNA per 2 x 105 cells).  This cell line secreted hIL2 
concentrations that were three orders of magnitude lower 
than the previous cells (G).  This may be due to two factors 
viii  
that are inherent to Jurkat cells.  The first is the notoriously 
low transfection efficiency of this line, evident by 
observation under fluorescence microscopy and the lack of 
DsExDR self-quenching at the highest pF2 transfection level 
(H).  The second is the presence of natural regulatory 
mechanisms for controlling the secretion of hIL2, which is an 
intrinsic product of T-cells.  A linear correlation was found 
among all concentrations of secreted hIL2 and DsExDR 
fluorescence in Jurkat cells (I). ...............................................................38 
Figure 2.4 The functionality of using the IRES bicistronic expression 
system among the three cell lines (Jurkat, C2C12, and 
HEK293) can be compared by plotting the expression of 
DsExDR and secretion of hIL2, each normalized by the 
respective data point at which the recommended transfection 
level was made (Jurkat = 1.1 mg, C2C12 & HEK293 = 0.8 
mg).  A slope of unity indicates that both proteins are 
accumulating at equal rates.  Jurkat cells have the most 
balanced accumulation rate, while C2C12 and HEK293 cells 
accumulated slightly more fluorescent protein per hIL2 
secreted. ..................................................................................................42 
Figure 3.1 The hypoxic incubation system is composed of individual 
hypoxic chambers placed upon a rocker platform within a 
CO2 incubator.  Each chamber is connected to its own gas 
tank via a bubble column, which humidifies and warms the 
incoming air.  The gas environment within each chamber is 
determined by the premixed composition of the compressed 
gas cylinders.  Mix gas flows at 0.5 L/min.  The chambers 
and bubble columns are each 1L in volume.  Dissolve oxygen 
content in tissue cultures plates with 1mL of media is 
monitor by a Clark-type dissolved oxygen probe and OM4 
Oxygen Meter (Microelectrodes)............................................................54 
Figure 3.2 Kinetic measurements of dissolved oxygen content within a 
1mL mock culture were made to ensure that cells were 
exposed to the intended hypoxic environments.   A 0 % O2 
gas mixture was directed into a rocking hypoxic chamber 
(0.5 L/min, 37 oC), which contained the mock culture.  
Steady state was reached in approximately 1 hour. ................................54 
Figure 3.3 C2C12 cells transfected with pO2Ybp and p5HRE-d2EGFP 
were compared for their ability to hypoxically induce 
fluorescent protein production.  Cells were exposed to five 
oxygen concentrations (0.0, 0.5, 1.0, 2.0, 5.0, 21.0 %) and 
assayed after an 18 hour incubation.  C2C12 cultures 
transfected with pO2Ybp produced enhance yellow 
fluorescent protein (EYFP) in a similar fashion to those 
transfected with p5HRE-d2EGFP produced destabilized 
enhance green fluorescent protein (d2EGFP).  EYFP 
ix  
fluorescence, however, was higher than EGFP at every O2 
concentration.  This is most likely due to the short, 2-hour 
half-life of the destabilized EGFP.  Both transfections 
indicated that a decrease in O2 content is able to 
exponentially induce fluorescence..........................................................58 
Figure 3.4 C2C12 cells were transfected with either pCYp, pCYbp, 
pO2Yp, or pO2Ybp expression vectors and incubated for 30 
hrs under various hypoxic conditions (0.0, 0.5, 1.0, 2.0, 5.0, 
or 21.0 % O2 plus 5% CO2, and a balance of N2 ) beginning 
at 24 hours post-transfection (hpt).  Cells that were 
transfected with the hypoxia sensitive promoters showed 
increased fluorescence with a decrease in O2 concentration.  
Cells that contained the CMV promoter, however, displayed 
an opposite trend despite their overall higher levels of 
fluorescence at all oxygen concentrations.  This decrease in 
fluorescence was indicative of metabolic stress due to 
hypoxia.  In all C2C12 culture, it was clear that the presence 
of Bcl-2∆ was helpful to the cells’ protein production 
capabilities. .............................................................................................60 
Figure 3.5   C2C12 cells were transfected with either pCYp, pCYbp, 
pO2Yp, or pO2Ybp expression vectors and monitored for 24 
hrs when grown under a 2% O2 hypoxic environment 
beginning at 24 hpt.  All transfections, besides pO2Yp, 
showed an increase in EYFP fluorescence within the 24 
hours.  Although this phenomenon was expected for cells 
containing hypoxia inducible promoters, those without were 
apparently unencumbered within the exposure period.  All 
myoblasts that were able to express Bcl-2∆ were able to 
produce more EYFP than their deficient counterparts.  This 
indicated the production advantage of having the anti-
apoptotic protein.  Myoblasts that were transfected with 
pO2Yp, had neither the bcl-2∆ gene, nor the brute capability 
of the CMV promoter, and thus lagged in EYFP production 
as time progressed...................................................................................62 
Figure 3.6   The protective nature of Bcl-2∆ against hypoxia can be more 
accurately accessed through measurements of necrosis and 
apoptosis in the host.  C2C12 cells that were transfected with 
either pO2Ybp and pO2Yp were exposed to five hypoxic 
environments (0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 % O2 plus 5% 
CO2, balance N2 ) for 30 hours beginning at 24 hpt.  
Myoblasts that were able to express Bcl-2∆ were able to 
sustain both a higher level of viability, as well as lowered 
levels of apoptosis.  Thus, Bcl-2∆ was successful in not only 
enhancing protein production, but also the long term health 
of the host cells under hypoxic stress. ....................................................64 
x  
Figure 4.1   In situ monitoring of proliferation for gelatin encapsulated 
cells was attempted with both SYTO-16 and Hoechst 33342 
nucleic acid dyes.  SYTO-16 staining produced a non-linear 
relationship, while Hoechst 33342 staining generated a linear 
correlation of 5.05 x 105 cells/RFU (r2 = 0.98).  This 
calibration curve was generated from HEK293 cells 
encapsulated in 60 µL of 4% mTG-Gel in 96-well plate using 
a 4 hr incubation period. .........................................................................71 
Figure 4.2   HEK293 cells (2,000 cells/well) were encapsulated in the 
mTG crosslinked gelatin hydrogels (60 µL/well) were 
initially seeded into 96-well plates with white walls and clear 
bottoms.  Hoechst 33342 staining (4 hr incubation) showed 
that encapsulated cells were growing in clusters, and 
proliferating at a linear rate of approximately 0.03 day-1 (r2 = 
0.95). .......................................................................................................72 
Figure 4.3   HEK293 cells stained with Hoechst 33342 nuclear dye can be 
seen proliferating while they are encapsulated in mTG 
crosslinked gelatin hydrogels.  Cells formed spherical 
clusters and proliferated linearly with time. ...........................................72 
Figure 4.4   Encapsulated HEK293 cells were released by masticating the 
mTG-Gels followed by a 20 minute incubation with a 0.25% 
Trypsin + 0.03% EDTA solution at 37 oC.  Released cells 
appeared as clusters (A), as well as singlets (B).  Both of 
these forms of released cells were able to re-attach to tissue 
culture plates under normal incubation conditions (37 oC, 8% 
CO2)........................................................................................................74 
Figure 5.1 Exposure of the three hydrogels (T-Gel, mTG-Gel, and 
HybriGel) in a 37 oC bath of DPBS showed that only the 
uncrosslinked T-Gel was susceptible to thermal degradation.................78 
Figure 5.2 Although 4% mTG-Gels were thermally stable, they were 
slightly less resistant to proteolysis by trypsin.  HybriGels 
were developed by first thermally cooling gelatin and then 
crosslinking with a 10% mTG overlay.  The resultant 
hydrogel was both thermally stable and as proteolytically 
resistant as the T-Gels.............................................................................79 
Figure 5.3 Gelatin hydrogels formed with initial cooling, to create a 
physical gel, before crosslinking with mTG were found to be 
consistently more resistant to proteolysis as compared to 
hydrogels that were crosslinked before cooling (mTG-Gels).  
An explanation may be that thermal cooling allows gelatin to 
first self-organize into a tight network of polypeptides 
through hydrogen bonding.  Once gelatin has formed this 
network, there are more potential junction points where 
crosslinking can occur, creating a denser permanent 
hydrogel.  mTG-Gels, however, were unable to form this 
tight network since mTG is immediately crosslinking gelatin 
xi  
polypeptides.  The result is a less tightly packed hydrogel 
with a larger mesh size, which may be more susceptible to 
proteolytic attack.....................................................................................80 
Figure 5.4 The proteolytic degradation rate of HybriGels was found to 
be adjustable based on the amount of gelatin in the hydrogel 
(4, 10, 15, and 25%).  A disproportionate drop in degradation 
rate between 4% and 10% HybriGels may indicate that below 
a critical mesh size the trypsin may be limited to the surface 
of denser gels. .........................................................................................83 
Figure 5.5 A study to elucidate the mechanism by which trypsin 
degrades 10% HybriGels.  Proteolysis occurs mainly by 
surface erosion. .......................................................................................84 
Figure 5.6 Swelling studies were done to determine how proteolytic 
degradation rates would be affected by water content.  10% 
and 15% HybriGels that were pre-soaked in DPBS overnight 
(*) were found to be more susceptible than their non-soaked 
counterparts.............................................................................................85 
Figure 6.1 Transient DsRed fluorescence in HEK293 cells transfected 
with the pF2 expression vector, and overlayed with three 
mTG-Gel thicknesses..............................................................................98 
Figure 6.2 Transient DsRed fluorescence in HEK293 cells transfected 
with the pF3 expression vector, and overlayed with three 
mTG-Gel thicknesses..............................................................................98 
Figure 6.3 HEK293 cells were transfected with the pF2 expression 
vector, and overlayed with three mTG-Gel thicknesses.  hIL2 
was measured in the media that was covering the mTG-Gel 
overlays.  Rates have units of ng/hr-106 cells. ......................................101 
Figure 6.4 HEK293 cells were transfected with the pF2 expression 
vector, and overlayed with three mTG-Gel thicknesses.  hIL2 
was measured in the media that was covering the mTG-Gel 
overlays.  Rates have units of ng/hr-106 cells. ......................................101 
Figure 6.5 HEK293 cells were transfected with the pF3 expression 
vector, and overlayed with three mTG-Gel thicknesses.  
HIL2 was measured in the media that was covering the mTG-
Gel overlays.  Rates have units of ng/hr-106 cells. ...............................102 
Figure 6.6 HEK293 cells were transfected with the pF3 expression 
vector, and overlayed with three mTG-Gel thicknesses.  
HIL2 was measured in the media that was covering the mTG-
Gel overlays.  Rates have units of ng/hr-106 cells. ...............................102 
Figure 6.7 Normalized hIL2 accumulation and time were plotted to 
reveal a transition from transient to steady state diffusion of 
hIL2.  An analysis of the steady state flux, indicated by the 
linear regression (circled points) shows that HEK293 
transfected with pF2 were producing hIL2 at a rate of 0.94 
pg/cm2 hr. .............................................................................................108 
xii  
Figure 6.8 Analysis of the steady state flux (circled points), show that 
HEK293 cells transfected with pF3 were producing hIL2 at 
double the rate (1.83 pg/cm2 hr) of cells transfected with 
pF2. .......................................................................................................108 
Figure 6.9 Comparison of data with simulated hIL2 accumulation using 
diffusion coefficients obtained from steady state analysis and 
fluxes scaled by DsExDR fluorescence for each overlay 
thickness................................................................................................110 
Figure 6.10 Well inserts filled with three thicknesses of 4% mTG-Gels 
were used as diffusion cells to measure the diffusion 
coefficient of hIL2. ...............................................................................112 
xiii  
1. Introduction 
1.1 Research Motivation 
Biohybrid artificial organs combine the usage of living cells along with 
synthetic materials for the treatment of serious and chronic human ailments.  
Encapsulation therapy has already been used for treating several human diseases, 
including chronic pain [1] and Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's 
disease [2].  In order to further expand the application of this technology, however, 
several technical challenges must yet be surmounted.  The objectives of this research 
are to address three major challenges found in creating a viable biohybrid artificial 
organ: (i) Design an in situ method for detecting therapeutic proteins secreted from 
encapsulated engineered cells; (ii) Lessen the level of necrosis and apoptosis induced 
by hypoxia, and (iii) Develop a biocompatible cellular scaffold and encapsulation 
material for the metabolically engineered cells. 
To explore the first of these considerations, cells will be engineered to secrete 
human interleukin-2 (hIL2), as a model therapeutic protein.  hIL2 is a polypeptide 
hormone and is a natural component of the body’s immune system.  This molecule 
normally functions to simulate the differentiation of enhanced cytotoxic cells, which 
have been shown to be effective in fighting cancer and AIDS.  In order to gauge how 
reliably hIL2 can be secreted in an encapsulated device, it may also be important to 
have an indicator for tracing its production.  The indicator, however, should be self-
contained, as well as detectable even when the device is implanted subdermally.  To 
address this issue, the usage of a self-fluorescing protein marker may be an ideal 
candidate for tracing therapeutic protein production and secretion.  DsRed is one of 
1 
such proteins, and is unique in that it emits red fluorescent light, which is translucent 
through tissues.  Thus, the co-expression of DsRed may provide a self-sufficient, and 
yet non-invasive means, for detecting hIL2 production in a transplanted device. 
The second challenge that will be studied is the issue of inadequate oxygen 
supplies inside a biohybrid artificial organ.  This problem is especially critical for 
devices that may be implanted for months and ideally, years, while cells can tolerate 
deficient oxygen levels for only a few days at best.  When the metabolic demand of 
oxygen exceeds levels that are available, cells experience a physiological state known 
as hypoxia, which has been shown to diminish engineered therapeutic protein 
production and cell viability.  Several extracellular approaches that focus on increasing 
the flux of oxygen have been taken to mitigate this issue in biohybrid organs.  
Strategies include inducing vascularization around the implant [3], electrochemically 
generating oxygen by decomposing water around the membrane [4] , as well as using 
synthetic oxygen carriers [5, 6]. 
An alternative approach of counteracting hypoxia is to obstruct apoptosis and 
necrosis signaling pathways, which are used to induce cell death.  Bcl-2∆ is an anti-
apoptotic agent, which has been shown to enhance a cell’s resistance to both hypoxia-
induced apoptosis and necrosis [7-9].  Encapsulated cells that are producing hIL2 can 
also be engineered to produce this protein as a protective agent against hypoxia.  
Furthermore, the bcl-2∆ gene can be designed to be expressed only under low oxygen 
conditions.  This functionality can be achieved by placing the gene under the control of 
a hypoxia sensitive promoter [10, 11].  In analogy to the production of the model 
therapeutic protein, a yellow fluorescent marker can be expressed for indicating the 
2 
level of Bcl-2∆ production and indirectly, the oxygen concentration experienced by the 
encapsulated cells. 
The third challenge of this work is to develop a biomaterial that can serve as a 
cellular scaffold, as well as a substance for encapsulating the engineered cells.   For this 
purpose, gelatin was selected as the foundational biomaterial due to its native role as 
the major building block of extracellular matrices [12-14].  Using gelatin offers a high 
biocompatibility towards encapsulated cells and host tissue alike, alleviating the issues 
of pyrogenicity and immuno-rejection [12].  Since physical hydrogels are susceptible to 
melting at physiological temperatures a permanently crosslinked hydrogel is more 
desirable as a scaffold or encapsulation material.  Although uv-light and chemical 
crosslinker are typically used for this purpose, they typically elicit cytotoxic side-
effects that detract from their efficacy [15-20] .  To overcome this compromise between 
physiological stability and compatibility, a biological enzyme that has the natural 
function of crosslinking proteins may be used with gelatin hydrogels.  
Transglutaminase is one of such innocuous and ubiquitous proteins that are naturally 
used among many plant and animal species to create permanent peptide bonds between 
individual proteins [21, 22].  A form of this enzyme, microbial transglutaminase 
(mTG), was selected as the crosslinker of choice due to it biochemical stability and 
wide approval for use in the food industry [21, 23].  Enzyme crosslinked gelatin 
hydrogels are thus not only thermally stable but also have tunable proteolytic 
degradation properties, allowing the matrix to serve as either a cellular scaffold that can 
decompose with time, or a permanent encapsulation material that will protect 
engineered cells from degradation or attack by the host’s immune system.  An 
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additional property that makes gelatin hydrogel even more amenable to this project is 
that the matrix is optically clear, which would then permit more light transmission that 
is pertinent to the first phase of this project. 
1.2 Eukaryotic Protein Expression System 
1.2.1 Transcriptional Regulations 
Gene expression in eukaryotes is highly complex, as compared to prokaryotic 
cells, containing many more regulatory mechanisms at both the transcriptional and 
translational levels.  Differences begin with eukaryotes having three separate RNA 
polymerases (I, II, III) rather than just one found in prokaryotes.  Regulation differs in 
two important aspects from the typical bacteria.  First, eukaryotic RNA polymerases 
require several general transcription factors to assemble on the promoter gene sequence 
prior to transcription.  Second, gene regulatory proteins bound to multiple 
enhancer/repressor sequences, which can be thousands of nucleotides away from the 
promoter, are often used to control mRNA polymerization.  Even after an mRNA is 
synthesized, it must undergo many extensive modifications, such as the addition of a 
5’-Cap (7-methylguanosine), and 3’-polyA tail (polyadenine) or possibly splicing 
before it can become fully functional.  In most mammalian cells, only approximately 
1% of all DNA sequences are transcribed into functional mRNAs.   
1.2.2 Translation of mRNA 
Mature mRNA expression is subject to post-transcriptional controls.  These 
methods, although less prevalent than transcriptional controls, are crucial to the 
expression of most genes.  Eukaryotic cells typically utilize the functionalities of the 5’-
Cap and 3’-polyA tail to modulate mRNA activity and stability.   
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1.2.3 Monocistronic vs. Polycistronic Translation 
As opposed to bacterial mRNAs, which have Shine-Dalgarno sequences, 
eukaryotic mRNAs utilize the 5’-Cap to bind a small ribosomal subunit for initiating 
translation.  Ribosomal subunits that bind begin scanning the nucleotide sequence for 
the first AUG start codon.  Although there are rare incidences of “leaky scanning” in 
eukaryotes, where a second or third start codon is recognized, the first AUG typically 
determines the reading frame and start site for translation.   This form of expression is 
call monocistronism.  Bacterial mRNAs often contain several ribosomal binding sites, 
giving rise to several proteins from one transcript.  Thus prokaryotes are polycistronic. 
1.2.4 Internal Ribosome Binding Site (IRES) Bicistronic System 
Some eukaryotes and viral mRNAs employ an alternative 5’-cap independent 
mechanism for initiating translation.  This form of protein expression initiates with 
ribosomes binding to an internal ribosome entry sites (IRES).  It is believed that IRES 
systems are used in crucial genes sequences in case there is a disruption to the 
availability of initiation factors, which are required for the normal cap-dependent 
translation machinery.  Disruption can be due to stress [24-26], apoptosis [27, 28], or 
G2-M cell cycle transitions [29].  The IRES gene sequence derived from 
encephalomyocarditis virus (EMCV) is typically used to create bicistronic mRNA in a 
variety of cell cultures, such as C2C12, NIH 3T3, CHO, HeLa, and COS-7 [30]. 
1.2.5 Antibiotic Resistance and Cell Selection:  
Protein synthesis requires a smooth spatial and temporal coordination of DNA, 
RNA, and regulatory proteins.  This network of molecules is intricately complex and 
offers many opportunities for disruptions.  Certain antibiotics, which are naturally 
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produced by one organism in defense towards another, exploit this complexity.  
Antibiotics that are used for cell selection in mammalian cell culture are typically 
inhibitors of protein synthesis.  Three antibiotic selection agents used in various 
constructs in this proposal include hygromycin, geneticin (G418), and puromycin.  The 
first two antibiotics are aminoglycosides and act by binding to the 30S ribosomal 
subunits, thereby preventing them from participating in the ribosome complex.  
Puromycin is an aminoneucleoside.  It functions as an aminoacyl t-RNA analog, and 
competes with endogenous tRNAs during peptide synthesis, causing translation to 
prematurely terminate [31-36].  Cell cultures that contain genes that can produce 
enzymes to deactivate the antibiotics are immune to these effects.  This form of 
resistance selection method is important in creating permanent stable cell lines in 
mammalian cultures. 
1.2.6 Secreteable Protein Processing [37] 
1.2.6.1 Sorting Signals and the Endoplasmic Reticulum 
All mRNA in eukaryotic cells, other than those manufactured in the 
mitochondria and plastid, are expressed by free or membrane-bound ribosomes found 
in the cytosol.  The final destination of a protein depends on which type of sorting 
signal it has.  Proteins have several possible sites for distribution, including the nucleus, 
mitochondria, plastids (plants), peroxisomes, and endoplasmic reticulum (ER).  
Proteins that are to be excreted extracellularly are mediated from the ER to the Golgi 
network and secretory vesicles, which are used to deliver payloads to the exterior of a 
cell. 
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There are at least two forms of sorting signals for proteins.  A signal peptide is 
typically a 15-60 continuous amino acid sequence found on either the amino (N) or 
carboxyl (C) -terminus of a protein.  The immunoglobulin (Ig) κ-chain secretion leader 
sequence, used in the vector constructs, is of this form, which contains a 63 amino acid 
sequence on the N-terminus [38, 39].  C-terminal signal peptides, such as KDEL (Lys-
Asp-Glu-Leu), are used for retaining proteins in the lumen of the ER.  The second, 
more sophisticated, sorting signal is the signal patch.  This recognition site is three 
dimensional, and is formed when separate peptide sequences come together in a folded 
protein.  This type of signal is not typically used by secreted proteins. 
In mammalian cells, the transport of proteins into the ER commonly occurs 
through a co-translational process, where proteins are translocated as they are 
synthesized.  Co-translation ensures that secreted proteins, which typically are meant to 
have hydrolase activity, are never in contact with the cytosol.  Although post-
translational translocation is also known to occur, it is usually found in yeast ER and 
bacterial plasma membranes.   
1.2.6.2 Glycosylation and Post-Translational Modification 
As a protein is translated and translocated into the lumen of the ER, it is still 
bound to the membrane by its secretion signal.  A signal peptidase is required to cleave 
the N-terminal sorting signal before the protein can be released.  Before a protein is 
freed, however, it may receive several forms of modifications.  Sulfyhydryl groups are 
catalytically attached to cysteine residues, which form disulfide bonds between 
different regions of a polypeptide.  This modification helps the protein attain its 
predetermined, three-dimensional form.  Exposed asparagine (N) residues are also 
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processed by the addition of prefabricated blocks of oligosaccharides, which may be 
trimmed later.  This N-linked glycosylation is exclusive to eukaryotes, and helps give a 
protein a rigid structure and resistance to degradation.  Protein folding is sometimes 
further assisted by chaperone proteins found in the ER.   
Secretory proteins that enter the ER are automatically shuttled to the Golgi 
complex for further processing.  Incomplete or misfolded proteins, however, are 
retained and recycled.  As particular glycoproteins enter the Golgi, N-linked 
oligosaccharides may be further trimmed or augmented.  Certain OH-groups on serine 
or threonine side chains may also receive O-linked glycosylation. 
As a secreteable protein awaits its final destination out of a cell, it has one of 
two possible paths for secretion.  All cells contain a constitutive secretory pathway, 
which is the default route.  Cells that specialize in secreting products on demand, such 
as hormones, neurotransmitters, and digestive enzymes, utilize a regulated secretory 
pathway.  The sorting signal used by this pathway is not well known, but is believed to 
be a signal patch.  Thus, the secretion pathway taken may be more dependent on the 
protein rather than the cell type.   
1.3 Fluorescent Protein Markers 
Bioluminescence is a relatively rare trait in nature, but can be found in many 
phylogenetically different groups [40] such as bacteria, dinoflagellates (plankton), 
cnidarians (jellyfish), and fireflies [40, 41].  In these organisms, the biochemical and 
physiological mechanisms for emitting light are distinct and are not evolutionarily 
conserved.   
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Natural functions for bioluminescence fall into three classes: defensive (distract 
or frighten predators), offensive (lure prey), and communication (courtship and mating) 
[42, 43].   Among the various molecules used in bioluminescence, fluorescent proteins 
are unique in that they are able to emit light when stimulated by exogenous radiation.  
Green fluorescent protein (GFP), found in various coelenterates, is of particular value 
as a biological marker, since it is able to fold and fluoresce independent of any 
cofactors or enzymatic substrates. 
1.3.1 Green Fluorescent Protein (GFP) 
Green fluorescence in Aequorea victoria jellyfish was first reported by 
Davenport and Nichol in 1955 [44].  Shimomura and colleagues later purified the 
protein extract in 1962 [45].  Interest in green fluorescent protein, however, did not 
begin to explode until thirty years later when the gene was cloned and expressed by 
Prasher and Chalfie [42].   Since that time, GFP has been expressed in a wide variety of 
prokaryotic and eukaryotic organism for innumerable applications.   
1.3.1.1 Biochemical and Physical Properties 
Most of the attributes of GFP were discovered from studies on Renilla 
reniformis (sea pansy) and Aequorea victoria (hydrozoan jellyfish), although there are 
at least twenty other naturally occurring GFPs that have been studied.  All known forms 
have a molecular weight around 27 kDa, with an acidic, compact, and globular β-can 
structure (Figure 1.1).  GFP derived from jellyfish is unique in that it is preferentially 











Figure 1.1 Three dimensional representation 
of β-can and α-helix structure of GFP.  
 
The β-can is composed of eleven beta-strands, which surround and protect the 
chromophore that is in the center.  The top and bottom of the can are sealed by short 
loop regions and distorted alpha helices.  This unique structure creates surprising 
chemical stability, offering protection to typical fluorescence quenching agents such as 
acrylamide, halides, and molecular oxygen.  The full length protein contains 238 amino 
acids, and has a C-terminal sequence of His-Gly-Met-Asp-Glu-Tyr-Lys [46].  This tail, 
unlike the bulk of the protein, is somewhat susceptible to proteolytic attacks by 
carboxypeptidases, proteinase K, and pronase [47].  The wild-type GFP has two 
excitation peaks, a major peak at 395nm, and a minor peak at 475nm [48].  The molar 
extinction coefficients are respectively 27,600 and 14,000 M-1cm-1 [49].  The normal 
emission peak is at 508nm.  GFP has a fluorescence quantum efficiency of 0.72-0.78 
[50]. 
1.3.1.2 GFP Variants for Mammalian Applications 
The physical and biochemical simplicity of GFP, as well as its resistance to 
proteolytic, thermal, and pH-dependent degradation makes the molecule an ideal 
marker.  Over the course of usage, many variants have been optimized for expression 
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and detection under mammalian cell systems.  A common mutant is S65T-GFP, which 
has a fluorescence signal several times stronger than the wild-type by substituting 
Ser65 with Thr [51].  Other multiple amino acid, red-shifted variants, such as EGFP, 
were designed to be brighter and have an excitation peak match that of an argon laser, 
which is commonly used with fluorescent activated cell sorters (FACS).  EGFP, 
currently licensed by Clontech Laboratories, Inc., has excitation and emission peaks at 
488nm and 507nm, respectively.  The variant is optimized for mammalian expression 
by the addition of a Kozak consensus translation initiation site at the beginning of the 
gene [52], the deletion of potentially inhibitory sequences, and containing 190 silent 
mutations using preferred human codons [53, 54].  Besides being easier to express, the 
final protein is 35 times more intense than the wild-type [55-60].  Several other variants 
and their properties, such as ECFP, and EYFP (to be used in this study), which are 
offered by Clontech, are listed in Table 1.1. 
GFP and its variants from A. victoria have since been expressed as fusion 
products in many mammalian cell types including BHK, CHO, COS, GH3, HeLa, NIH 
3T3, cc12, NRK, PTK1, and C2C12 mouse cells [50, 52, 61, 62].  Applications are 
varied, including time-lapse imaging, double-labeling, photobleaching, subcellular 
distribution, protein function and expression experiments.   Advancements in 
microscopy, spectroscopy, and imaging instruments are already offering more sensitive 
and accurate detection of this reporter protein.  Future novel applications will depend 
on the further optimization of GFP expression and spectral properties [63, 64].   
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1.3.2 New Red Fluorescent Protein (RFP) Markers 
Since the inception of fluorescent protein markers, many variants with different 
spectral properties have been created for multi-labeling purposes.  The creation of red 
fluorescent GFP mutants, however, has been elusive.  Relatively recent studies have 
shown that GFP can be made to emit red light.  However, this requires photoactivation 
of the fluorescent molecule under conditions of low oxygen with a laser [65].   More 
recently, researchers have sought a solution to this problem by using chromophores 
found in two other oceanic organisms, the common sea corals and anemones. 
1.3.2.1 DsRed – Discosoma sp (sea coral) 
DsRed fluorescent protein is derived from the sea coral, Discosoma sp.  The 
chromoprotein extracted from the coral is not naturally fluorescent, but simply red.  The 
characteristic of fluorescence is created through a combination of random and site-
directed mutagenesis techniques [66, 67].  Although this molecule only has 26-30% of 
its amino acid sequence resembling GFP, the two fluorophores share many similar 
biochemical features.  Like GFP, DsRed contains a 11-stranded β-can structure with 
central α-helices sealing the ends [68].  The red fluorescent protein also does not 
require any additional cofactors or substrates for proper folding, and is 
spectroscopically stable under a wide range of pH (5-12) [69].  Differences include its 
necessity to form tetramers rather than monomers for fluorescence, and its fluorescence 
is sensitive to mild detergents, such as sodium dodecyl sulfate (SDS).  An early version 
of this marker, DsRed1, had the tendency to form large insoluble aggregates and was 
slow to fold.  DsRed2 is the latest variant developed at Clontech, which contains three 
mutations for faster appearance of fluorescence (< 24 hr), and three others for lessening 
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aggregation.  This improved molecule has excitation and emission peaks at 561 and 
587nm, respectively (Table 1.1).  It is also the first red fluorescence protein marker 
marketed to complement GFP variants for multi-labeling experiments (Figure 1.2). 
Table 1.1 Spectroscopic properties of fluorescent proteins [70, 71]. 
 
Fluor. Protein Ex/Em Max (nm) Extinction Coeff (M-1cm-1) Quantum Yield
DsRed2 561 / 587 43,800 0.55
DsRed-Express 557 / 579 31,000 0.42
HcRed1 588 / 618 20,000 0.015
EGFP 488 / 508 55,000 0.60
EYFP 514 / 527 84,000 0.61




Figure 1.2 Excitation (A) and emission (B) spectra of fluorescent proteins [Clontech] [71]. 
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1.3.2.2 HcRed – Heteractis crispa (sea anemone) 
The most applicably advanced red fluorescent protein marker is HcRed, which 
is extracted from the sea anemone, Heteractis crispa.  Similar to DsRed, this new 
protein was generated by mutating a naturally non-bioluminescent chromophore.  
HcRed, however, does not form aggregates nor tetramers for fluorescence.  The 
fluorophore is stable as a dimer, and thus requires less units of protein to fluoresce as 
brightly as DsRed.  The maximum excitation and emission peaks are also at longer 
wavelengths of 488 and 615nm, respectively, referred to as far-red fluorescence.  The 
advantages of these wavelengths include the use of less energetic or damaging light for 
excitation, and higher transmittance of red light. 
1.4 Biohybrid Artificial Organs 
Biohybrid artificial organs are implantable biomedical devices, engineered to 
incorporate live cells or tissue within a synthetic immuno-isolation barrier.  
Development of these devices began in the 1970’s with experimental implantations, 
such as those using Langerhan’s islets for the treatment of diabetes.  Biohybrid organs 
are distinguished from traditional implants in that both allogenic and xenogenic cells 
can be safely used.  Cells may also be genetically engineered to resist harsh 
environmental conditions or produce particular proteins that are not native to the cell 
type.  Besides considering the type of cells to be encapsulated, other major design 
challenges include maintaining high viability, and providing protection for the cells 
from the immune system.   
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1.4.1 Cell Source 
The choice of cells used for encapsulation will typically determine the density 
required, since different cell types have different metabolic activities and secretion 
rates.  Applications for treating the central nervous system require only low 
concentrations of neuroactive compounds due to their natural potency.  The number of 
cells required for such applications appears to be 106-107, which is equivalent to a 
volume of 1-10 µL, and is easily accommodated in an encapsulation device [69].  
Treatment of diabetes, however, may require larger quantities of therapeutics and cells.  
It is estimated that 109 cells or nearly a 1 mL volume is necessary for provide enough of 
the therapeutic compound [72].  Devices with large volumes prove difficult to implant 
due to an increase in the diffusional distance for nutrients and oxygen to travel to all 
encapsulated cells.  
1.4.2 Molecular Diffusion and Device Design 
In order to maintain cell viability, an encapsulation device must provide 
adequate freedom for nutrients and oxygen to diffuse inward and metabolic wastes to 
leave.  While nutrients such as glucose and macromolecules like albumin, growth 
factors, and transferrin may be needed for cell survival, the adequate supply of oxygen 
is the most critical factor for maintaining cell viability.  In an encapsulated cell mass, a 
necrotic core of cells usually develops for devices with a diameter larger than 150 µm 
[73].  Although necrosis may still occur for well oxygenated cells with high 
metabolisms, the lack of oxygen (hypoxia) is usually the leading cause of death or 
lowered cellular functionalities.   Perifused rat islets have been shown to have secretion 
rates of insulin of 100, 50, and 2% compared, to normoxic conditions (140 mmHg), as 
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the partial pressure of oxygen is dropped to 60, 27, and 5 mmHg, respectively (Figure 
1.3) [72]. 
 
Figure 1.3 Rate of insulin secretion as a function of oxygen partial pressure in perifused rat islets [74, 
75]. 
Several geometric configurations have been designed for balancing cell mass 
and performance with oxygen requirements.  Intravascular arteriovenous shunts are the 
most technically advanced, and have been extensively tested on large animals [76].  
These devices, however, require major surgical procedures for integration into the 
vascular system of the host, and are subject to the dangers of blood clots.  Thus, there is 
motivation for developing extravascular devices that can circumvent these difficulties.   
There are three main geometric configurations used for extravascular designs.  
Spherical microcapsules have a typical diameter range of 500 to 800 µm.  The 
production method for this configuration results in the encapsulation of a very low 
volume fraction of cells, and offers an advantage in mass transfer.  Tubular devices, 
such as hollow fibers, share similar advantages with microcapsules and additionally, are 
more readily retrievable.  Islets encapsulated in tubular diffusion chambers with an 
internal diameter of 2.2 mm have shown viable tissue near the inner surface.  Larger 
tubes with a 4.8 mm internal diameter, however, indicate a large core of necrotic cells 
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due to oxygen depletion [72].  Planar chambers formed by parallel membranes are the 
third type of design.  These devices were initially used to study immune rejection of 
transplantations.  Planar configurations, however, typically elicit a larger immune 
response than the other geometric forms. 
Using a theoretical model for oxygen diffusion and consumption, described by 
Michaelis-Menten kinetics, spheroids offer the least diffusional resistance to oxygen. 
The following parameters were used in a simulation by Colton CK, 1995 [72]: the 
maximum oxygen consumption rate, Vmax = 3 x 10-8 mol/cm3-s; Michaelis constant, Km 
= 0.44 mmHg; effective oxygen diffusion coefficient D = 1.6 x 10-5 cm2/s; and Bunsen 
solubility coefficient a =1.02 µM/mmHg.  The surface oxygen partial pressure was 
taken as pO2 = 40 mmHg, which is the typical value found in microvasculatures.  
Figure 1.4 indicates that for a slab with a thickness of 150µm, the oxygen level is 
completely depleted at the center plane.  However, the oxygen environment in the 
sphere does not become anoxic until the diameter is increased to 250µm.   
 
B A
Figure 1.4 Oxygen penetration profiles for spheres (A) and slab (B) of various diameters [72]. 
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In situations where avascularization occurs, and the oxygen source is further 
removed from the encapsulated cells, the spheroid is clearly advantageous over the 
planar conformation (Figure 1.5). 
                                                             
 
A B
Figure 1.5 Oxygen penetration profiles for spheres (A) and slabs (B) surrounded by an avascular 




The primary objective of an immuno-isolation barrier in a biohybrid artificial 
organ is to provide protection for transplanted cells from the immune system of the 
host.  An immune response can be triggered by three possible sources, cell surface 
antigens, secreted proteins, and cell debris from dead cells.  Recognition of antigens by 
the host organism can signal cellular and humoral immune responses (Figure 1.6). 
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Figure 1.6 Cellular and humoral immune responses experienced by implanted cells. 
Cellular responses include the activation of macrophages, cytotoxic cells, and 
other immune cells.  Preventing these cells from passing through the membrane is 
relatively easy since their sizes are on the same order as the encapsulated cells.  
Macrophages, however, have the added ability to secrete low molecular weigh reactive 
metabolites.  These oxygen and nitrogen intermediates may include free radicals, 
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hydrogen peroxides, and nitric oxides, which kill surrounding cells non-discriminately.  
The humoral response also poses a serious threat to transplanted cells since 
lymphokines, cytokines, and antibodies are small and may be able to pass through the 
membrane barrier.   
1.5 Hypoxia 
Oxygen is one of the most critical molecules used by aerobic organisms since it 
is the terminal electron acceptor in metabolic pathways.  The ability of organisms to 
adapt to low oxygen conditions, or hypoxia, is crucial to survival.  In mammals, oxygen 
homeostasis is maintained meticulously at both the systemic and cellular levels. 
1.5.1 Mammalian Oxygen Homeostasis 
Oxygen concentrations in the body are monitored by chemoreceptors in the 
arterial and pulmonary neuroepithelial bodies.  Low concentrations of oxygen transduce 
an increased number of nerve signals to the brain, which in turn increase both 
respiratory and circulatory rates of an animal [78].  On the intracellular level, hypoxia 
induces the expression of many genes that help adapt cells to the lowered availability of 
oxygen.  Erythropoietin (EPO) expression increases the production of red blood cells, 
and is utilized to expand the oxygen carrying capacity of blood.  Transferrin provides 
the transport of iron, which is necessary for heme proteins [79].  Vascular endothelial 
growth factors (VEGF) are over-expressed to promote the formation of new blood 
vessels [80].  Nitric oxide and carbon monoxide, which are generated from inducible 
nitric oxide synthase (iNOS) [81] and heme oxygenase 1 (HO-1) [82], respectively, 
help reduce vascular tone so that blood can flow more freely.  Cell metabolisms are 
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also optimized as GLUT-1 expression enhances the uptake of glucose, and elevated 
amounts of glycolytic enzymes allow cells to increase anaerobic ATP synthesis. 
1.5.2 Molecular Biochemistry 
The molecular mechanism for sensing oxygen is centered on the protein call the 
hypoxia-inducible factor 1 (HIF-1).  This transcriptional activator is triggered by many 
upstream signal transduction pathways and is, in turn, responsible for inducing 
downstream target gene expression that are used to regulate oxygen homeostasis.  
Effectors of this central activator are not limited to hypoxia, but also include nitric 
oxide, cytokine, and growth factor signaling, embryonic development, and pathological 
stresses. 
HIF-1 is a heterodimer, composed of an HIF-1α subunit (120 kDa) and an HIF-
1β subunit (91-94 kDa).  It was first recognized as an oxygen sensor by its ability to 
bind and activate erythropoietin gene expression.  Purification and microsequencing of 
the protein indicates that the second subunit is identical to a previously identified aryl 
hydrocarbon receptor nuclear translocator (ARNT) protein, whereas HIF-1α is a newly 
recognized protein.  Under normal physiological conditions, both subunits are 
constitutively expressed.  HIF-1α level, however, is continually controlled by 
ubiquitination, which marks it for proteasomal degradation.  Under hypoxic conditions, 
where cells are exposed to O2 levels below 6%,  the level of expression exponentially 
increases [83]. 
The amino (N)-terminal half of HIF-1α (1-390 amino acids, AA) is determined 
to be necessary and sufficient for dimerization with HIF-1β and DNA binding.  The 
carboxyl (C)-terminal half contains two transactivation domains (531-575, 786-826 
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AA) and one regulation domain.  The actual molecular mechanism that mammalian 
cells use to sense and transduce oxygen levels for regulating HIF-1α expression and 
activity is still unclear.  Many mechanisms have been postulated [84-88], but recent 
studies indicate that reactive oxygen species (ROS), such as hydrogen peroxides, are 
either directly or indirectly responsible for regulating HIF-1α pathways [89].    
1.5.3 Normal Physiological Causes 
Hypoxic conditions can be caused by a wide variety of environmental or 
physiological stimuli.  Increased metabolism from exercise is a common cause, while 
exposure to high altitudes or embryonic development can also trigger hypoxia-induced 
pathways.  Pathological infections, vascular diseases, and cancer are also common 
causes. 
1.5.4 Conditions in Encapsulation that Cause Hypoxia 
Several geometric configurations for encapsulating foreign cells for 
implantation have been investigated.  These include spherical microencapsulations, 
planar diffusion chambers, and tubular hollow fibers.  Regardless of the configuration, 
the transport of molecular oxygen from the host tissue into the encapsulated cells faces 
several diffusional barriers.  These include the surrounding host tissue (particularly if 
an avascular fibrotic wall develops), the immuno-isolation membrane, and the mass of 
foreign cells themselves.  In the relatively stagnant environment of an encapsulated 
device, it is typical to find a central core of cells deprived of necessary oxygen 
concentrations.   
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1.5.5 Hypoxia-Induced Cell Death and Bcl-2∆ Protection 
Hypoxic stress can induce cell death by both necrosis and apoptosis.  The 
propensity towards either pathway is highly dependent on the cell type [90].  The first 
pathway, however, is typically the result of severe and prolonged exposure to a 
stimulus such as the deprivation of oxygen.  Characteristics of necrosis are cell 
membrane disruption, mitochondrial swelling, and lost of cytosolic structures.  
Apoptosis, also known as programmed cell death, is a more gradual and organized 
process characterized by chromatic condensation, DNA cleavage, cell size shrinkage, 
and cell membrane blebbing. 
Bcl-2 belongs to a family of regulatory proteins that have the ability to prevent 
or delay apoptosis.  Its activity was first described by Vaux et al. in 1988 as being able 
to protect cells from apoptosis induced by deprivation of the hormone IL3 [91].  It was 
later discovered that Bcl-2 could prevent apoptosis induced by other factors, including 
serum deprivation, heat shock, chemotherapy agents, ethanol, and hypoxia [89, 92-95].  
More recently, Bcl-2 has also been shown to inhibit necrosis induced by hypoxia and 
inhibition of mitochondrial respiration [96].  
Since the discovery of Bcl-2, other members of this family of regulatory 
proteins have been discovered.  Members include proteins that are anti-apoptotic (Bcl-
2, Bcl-xL, Bcl-w) and pro-apoptotic (Bax, Bak, Bik, and Bid).  A commonality among 
the members is four Bcl-2 homologous domains, BH (1-4), which may all be present, 
but not all active in a single protein.  Activity of BH3 has been shown to be necessary 
for the efficacy of pro-apoptotic members [96-98], while BH1, 2, and 4 are required for 
anti-apoptotic effects [9, 99].  Recent studies also indicate that a nonconserved region 
of peptides between BH3 and BH4, encoding an unstructured loop, is responsible for 
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attenuating the anti-apoptotic effects of Bcl-2 and Bcl-xL.  Bcl-2∆ is a deletion mutant 
of the human Bcl-2 protein, made by deleting amino acids 32-80.  In comparisons to the 
full-length protein, the deletion mutant showed enhanced ability to inhibit apoptosis.  It 
is postulated that this loop region is a negative regulatory domain used for post-
translational modifications of Bcl-2 proteins [2]. 
1.6 Cell Lines 
1.6.1 C2C12 
The C2C12 is a murine myoblast cell line, subcloned from the skeletal leg 
muscle cells of an adult C3H mouse.  The original culture was ordered from American 
Type Cell Culture (ATCC; CRL-1772, MD, USA).  C2C12 cells are not carcinomas 
and are undifferentiated.  These cells were selected for use in this project due their 
previous demonstration of endogenous HIF-1 activity, and its ability to stimulate 
hypoxic response elements of transfected genes.  C2C12 cells engineered to secrete 
human erythropoietin have been successfully encapsulated in hollow microporous 
fibers for implantation in mouse animal models [100-103]. 
1.6.2 HEK293 
The human embryonic kidney cell lined, Flp-InTM HEK293, is an attachment 
dependent strain that was obtained from Invitrogen Corporation.  This particular clone 
was modified from the basal cell line, CRL-1573 (ATCC)[104], to express zeocin 
resistance and contains a single stably integrated Flp Recombinase Target (FRT) site 
within its genome[105].  When Flp-In HEK cells are used in conjunction to FRT 
expression vectors and the Flp recombinase enzyme, the likelihood of obtaining a 
recombination event is not only dramatically higher, but also specific to the FRT 
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site[106, 107].  Thus, selecting a stable isogenic cell line is greatly facilitated compared 
to traditional random recombination techniques.  Cells that have properly integrated the 
expression vector at the FRT site will exhibit hygromycin resistance, zeocin sensitivity, 
lost of β-galactosidase activity, and expression of gene of interest. 
1.6.3 Jurkat 
Jurkat cells are a suspension cell line derived from human T-cell leukemia, TIB-
152 (ATCC) [108].  This strain of cells was originally obtained from Invitrogen, and is 
also a Flp-In modified clone.  Although Jurkat cells are attachment independent, they 
can still be grown in tissue culture flasks.  Advantages of using a suspension cell line 
are its ease of handling during passage, transfection, and cell sampling.  Jurkat cells, 
however, tend to have a poor transfection efficiency and protein production capabilities. 
1.7 Human Interleukin 2 (hIL2) 
Interleukin-2 (IL2) is a polypeptide hormone and belongs to a class of 
molecules called cytokines.  The term cytokine was first used to describe molecules 
produced by and influencing only the immune system in an autocrine manner.  It was 
later discovered that these hormones have a far reaching paracrine effect.    
Interleukin-2 is perhaps the most extensively studied lymphokine.  It has 
profound influences in the development, expansion, and activation of T cells, natural 
killer (NK) cells, and B-cells [109].  The glycoprotein is produced by activated T 
lymphocytes.  It has a molecular weight of 15-18 kDa depending on the pattern of 
glycosylation [110-112].  Incubation of human peripheral blood lymphocytes with IL2 
for 4-7 days induces the generation of lymphokine activated killer (LAK) cells, which 
are generated from NK cells.  LAK cells are shown to mediate enhanced cytotoxic 
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activity against NK-resistant tumor cell lines and freshly isolated tumor cells with little 
effect on normal cells [101, 113].   IL2 is also responsible for augmenting the release of 
other cytokines including IFN-γ, GM-CSF, TNF-α, and TNF-β, to form a network of 
responses to infections [100].  The critical role of IL2 in activating cytotoxic cells has 
led to clinical trials for the treatment of cancer [114, 115] and AIDS [1], and is thus a 
relevant choice as a model therapeutic protein for production in the encapsulated 
device. 
1.8 Cellular Scaffolds and Gelatin Hydrogels 
In engineering artificial tissues and organs, the incorporation of a cellular 
scaffold is crucial for providing a physical support matrix for cells to attach and grow 
on once implanted into a host.  Hydrogels are the most commonly used scaffolds due to 
their high water content (≥ 30% by weight) and structural similarity to macromolecular-
based components in the body [13].  This type of support matrix can be formed from 
both synthetic polymers, such as poly (lactide-co-glycolide) (PLG), poly (glycolic acid) 
(PGA), and copolymers (PLGA) or natural biopolymer, such as collagen, hyaluronate, 
fibrin, alginate, and chitosan [12].  Synthetic polymers often give more flexibility for 
tailoring the gelling mechanism and mechanical properties of the hydrogel, but face a 
challenge in coaxing cells to adhere and typically elicit immunogenic responses from 
the host.  Scaffolds made with natural polymers are often times more biocompatible 
with host tissues, as well as encapsulated cells, and have adequate physical strengths.  
Of all natural biopolymers used in tissue engineering, collagen is the most widely 
utilized due to its natural and dominant role as the building block of mammalian 
extracellular matrices[12].  Collagen, however, is expensive to produce and contains 
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much variability among production lots.  The basic protein element of collagen is 
gelatin, and is relatively inexpensive.  Gelatin can be derived from collagen by simple 
acidic decomposition (producing gelatin A) or alkaline treatment (producing gelatin B).  
This biomaterial has similar biocompatibility properties as collagen, and has also been 
used to deliver growth factor, as well as promote vascularization of regenerative 
tissues.  A shortcoming of physical gelatin hydrogels is that it is thermally reversible 
under physiological temperatures (37oC).  To overcome this disadvantage, however, it 
is possible to permanently crosslinking the gelatin peptides with a crosslinker.  
Although this crosslinking is traditionally done with uv-light or chemical crosslinkers 
(e.g. glutaraldehyde or diphenylphosphoryl azide) [20, 116, 117] these elements 
themselves raise an issue of cytotoxicity, which detracts from their overall applicability 
.  An alternative method for creating a permanent gelatin hydrogel is to use a natural 
biological enzyme to form covalent peptide bonds among the gelatin proteins.  A 
microbial transglutaminase (mTG) is one of such enzymes, which is also highly 
biocompatible as it is approved for use in many food manufacturing processes in 
various countries, including the United States [21].  However, the further 
characterization of the biocompatibility and degradability of mTG crosslinked 
hydrogels when they are applied as cellular scaffolds still remains unexplored.  This 
reach seeks to elucidate these properties of these hydrogels, and advance its application 
in tissue engineering.
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2. Integrated Non-Invasive System for Quantifying Secreted 
Human Therapeutic hIL2 
2.1 Introduction 
Biohybrid artificial organs are implantable biomedical devices, engineered to 
incorporate live cells within a synthetic immuno-isolation barrier.  Development of 
these devices began in the 1970’s with experimental implantations, such as those 
using Langerhan’s islets for the treatment of diabetes.  Since then, encapsulation 
therapy has been used for ameliorating other persistent ailments, including chronic 
pain [2] and amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease [100-103].  
Cancer, which is the second leading cause of mortality in the United States, is one of 
such chronic diseases that may be a target for treatment with biohybrid implants.  
Human interleukin-2 (hIL2) is a natural polypeptide hormone, which has a key role in 
activating a network of immune responses within the body [100].  The critical role of 
hIL2 has led to clinical trials for the treatment of several deadly diseases, including 
cancer [114, 115] and AIDS [118, 119].  The clinical efficacy of hIL2 makes it an 
appropriate therapeutic protein for development of usage in biohybrid organs. 
The objective of this portion of the work was to engineer mammalian cells to 
secrete hIL2 as a potential anti-cancer therapeutic, in a manner ultimately suitable for 
encapsulation behind an immuno-protective membrane.  In order to gauge the 
productivity of cells performing in this capacity, it is ideal to have a reporter system 
that can accurately and non-invasively indicate the differential secretion of hIL2.  To 
meet these criteria, a destabilized form of the DsRed-Express fluorescent protein, 
DsExDR, was selected for co-expression with hIL2.  This fluorescent protein emits 
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red light (emission maximum is 579 nm), which is translucent through tissue [120], 
and is hypothesized to discreetly trace hIL2 secretion.  Additionally, this low toxicity 
protein has a quick maturation and degradation rate (half-life is ~12 hours) to produce 
a finer differential signal as compared with other fluorescent proteins.  Although 
expressing DsExDR in fusion with hIL2 may offer the closest correlation between the 
two proteins (1:1), an internal ribosome entry site (IRES) enables the respective genes 
to be translated independently from a single monocistronic mRNA.  Thus, with 
appropriate translocation signals, the therapeutic protein can be secreted without 
secretion of the marker.  Three cell lines (C2C12, HEK293, Jurkat) were transfected 
with this bicistronic construct and tested as potential hosts for producing hIL2.  The 
specific intracellular red fluorescence, as measured by flow cytometry, was correlated 
with ELISA measurements for secreted hIL2.  
2.2 Materials and Methods 
2.2.1 Cell Culture - Passaging and Maintenance 
Three mammalian cells lines, C2C12, HEK293, and Jurkat, were used in this 
work.  C2C12 is a murine myoblast subcloned from the skeletal leg muscle of an 
adult C3H mouse (American Type Cell Culture, ATCC).  This cell line is attachment 
dependent and has been shown to efficiently produce exogenous interleukin-2 [121].  
HEK293 is a human embryonic kidney cell line, which was selected for comparison 
based on its high transfection and protein production efficiencies [108].  This 
particular strain, Flp-In™-293 (Invitrogen), contains an Flp-In Recombinase Target 
(FRT) sequence in its genome.  When used in combination with an expression vector 
that also contains an FRT sequence, a stable polyclonal cell line can be selected in 
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approximately two weeks with hygromycin (200-400 µg/mL).  This cell line is also 
attachment dependent, but is readily detached with minimal trypsinization (3-5 min, 
37oC).  The Jurkat cell line, Flp-In™-Jurkat (Invitrogen) also contains an FRT 
sequence within it genome.  These cells grow in a suspended form and are derived 
from human T-cells [122]. 
All cell lines were cultured in Dulbecco’s Modified Eagle’s Media containing 
glucose (4.5 g/L), GlutMAX™ I (3.97 mM), and 10% fetal bovine serum (FBS, 
Sigma).  Media for both FRT cell lines also contained zeocin (100 mM) in order to 
maintain the stability of their FRT insertions.  Cells were subcultured every two to 
three days in 75cm2-tissue culture flasks (Costar) as the population approached 80-
90% confluency.  Attachment cells were passaged by first removing the old media, 
and rinsing the flask with Dulbecco’s Phosphate Buffer Solution without Ca2+ or 
Mg2+ (DPBS-cm, Invitrogen).  Washed cells were then incubated in 1.5 mL of a 
0.25% Trypsin with 0.03% EDTA solution (Sigma) for 5-10 minutes in a 37oC, 8% 
CO2 incubator.  The Jurkat suspension cells did not require trypsinization, and a 
fraction of the previous culture was simply aliquoted into a new flask during 
passaging.  All cells were passaged with a 1:4 to 1:10 split ratio, and supplemented 
with fresh complete media up to 12 mL for further growth. 
2.2.2 Vector Constructs 
The expression vector used in this study, pF2, contains an assembly of four 
gene elements:  the human interleukin-2 (hIL2) gene, its Ig-κ secretion signal, an 
internal ribosome entry site (IRES), and a Destabilized DsRed-Express (DsExDR) 
fluorescent protein marker.  The secreteable hIL2 (ShIL2) fragment was first derived 
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from a previously constructed vector called pSIEG.  This vector was made by PCR 
extraction of the hIL2 gene from pBlueBacHis2-GFPuv/hIL2 [51], using the 
following primers:  5’-AAT GTC GAC AAA TGG CAC CTA CTT CAA GTT CTA 
CAA A-3’ and 5’-ATT ACC GGT TTC TTG TCA TCG TCA TCT CAA GTT AGT 
GTT GAG ATG ATG CTT TG-3’.  The first primer contained a Sal I restriction site, 
and the second primer has enterokinase (EK) and Age I restriction sites.  The blunt 
PCR fragment was first ligated to pCR-Blunt II-TOPO (pCR) (Invitrogen) before 
digesting with Sal I and Age I restriction enzymes.  The digested fragment was then 
ligated into the corresponding unique cloning sites of pEGFP1-N1 (Clontech).  Hind 
III and Not I were then used to restrict the hIL2-EK-EGFP fusion gene for ligation 
into pSecTag2A/hygro (Invitrogen) in order to add on the Ig-κ secretion signal. 
The following primers were used to extract ShIL2 from pSIEG: 5’-GAA GAT 
CTG CCG CCA CCA TGG AGA CAG ACA CAC TCC TGC TAT-3’ and 5’-GGA 
TCC GCG TTA TCA AGT TAG TGT TGA GAT GAT GCT TTG ACA AAA-3’.  
The first primer contained a Bgl II restriction site and a Kozak consensus sequence, 
which was used to further increase translation efficiency in eukaryotic cells [122, 
123].  The second primer introduced a BamH I restriction site.  A pCR plasmid was 
again used as an intermediary cloning vector.  The secreteable hIL2 gene was excised 
with Bgl II and BamH I and then ligated into pIRES2-DsRed2 (Clontech) in order to 
pick up the IRES bicistronic element.  The vector constructed thus far is called 
pShIRDs, and was initially used in a transient experiment to gauge the optimal time 
point for detection of red fluorescence. 
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The ShIL2-IRES fragment was then extracted by PCR and ligated to pDsRed-
Express-DR (Clontech) in order to add on the red fluorescent protein marker gene.  
The following primers: 5’-GAA GAT CTG CCG CCA CCA TGG AGA CAG ACA 
CAC TCC TGC TAT-3’ 5’-TCC CCG CGG GGA TGT GGC CAT ATT ATC ATC 
GTG TTT TTC AAA G-3’ were used.  The first primer was the same as the one used 
in the previous cloning procedure.  The second primer contained a Sac II restriction 
site.  pCR was again used as an intermediary cloning vector.  The final expression 
vector, pF2, was constructed by digesting the ShIL2-IRES-DsExDR fragment from 
pCR using Bgl II and Sac II restriction enzymes and ligating it to the respective 














Figure 2.1 The bicistronic vector, pF2, contains an internal ribosome entry site (IRES) gene 
sequence, which allows for the independent production of secreteable hIL2 and DsExDR red 




Procedures for transfecting the HEK239 and C2C12 attachment dependent 
cell lines were developed for 24-well tissue culture plates (Costar) in a suspended 
form.  Cells were passaged, at most, two days before transfection so that they would 
remain in a non-confluent, growing state at the moment of harvest.  For collection, 
cultures were trypsinized (1.5 mL Trypsin/EDTA, 5 min, 37oC), centrifuged (500 x g, 
5 min, 25oC (RT)) and resuspended to yield 2 x 105 cells/well using 0.5 mL/well of 
complete media without antibiotics.  DNA and LipofectAmine 2000 (LF2000) 
(Invitrogen), were independently mixed with OptiMEMI (Invitrogen) in 5 mL 
polystyrene tubes and incubated for 5 min at RT.  The two solutions were then 
combined and incubated for 20 min before proportional volumes were aliquoted to 
respective wells to obtain 0, 0.2, 0.5, 0.8, 1.2, 1.6, and 2.0 µg-DNA/well 
concentrations. 
Transfections of Jurkat suspension cells were developed in 6-well plates.  
Cells were collected by the same procedure as before, and inoculated at a density of 
3.5 x 105 cells/well using 1.5 mL/well of complete media without antibiotics.  The 
concentrations used in the transfections were 2.0, 3.0, 4.5, 6.0, and 9.0 µg -DNA/well.  
If these values were normalized by the same number of cells used in the HEK293 and 
C2C12 experiments, the concentrations would be equivalent to 1.1, 1.7, 2.6, 3.4, and 
5.1 µg -DNA/well.  These higher concentrations of DNA were used due to the low 
transfection efficiency of Jurkat cells.  
In all cases, the transfection volumes were the same and the samples taken for 
protein analysis were at 24 hrs post-transfection. 
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2.2.4 ELISA 
Supernatant samples containing secreted hIL2 from the attachment cell lines 
were collected from each well and centrifuged at 2000 x g for 5 min to remove cells 
that are suspended in the media.  Supernatants from Jurkat cells were collected by 
centrifugation at 500 x g in order to preserve the cells for flow cytometry.  
Supernatant samples were immediately transferred to a -80oC freezer until assayed.  
To collect intracellular hIL2 samples, cells were lysed by adding 100 µL of M-Per 
(Pierce-Endogen).  The samples were allowed to incubate for 10 min with gentle 
shaking at RT before centrifugation at 14,000 x g for 15min.  Measurements for the 
concentrations of both secreted and intracellular hIL2 were made with an OptEIA 
Human IL-2 ELISA Kit II (BD Pharmingen).  Human IL2 standards were made by 
serially diluting a 500 pg/mL hIL2 stock provided in the kit.  A highly linear 
correlation was obtained with eight concentrations, including a zero (r2 > 0.98).  
Standards were assayed in duplicates as instructed by the manufacturer, while 
supernatant samples were always assayed in triplicate.  The calculation for the final 
concentrations of hIL2 secreted takes into account the different culture volumes due 
to the transfection procedure. 
2.2.5 Flow Cytometry 
Attachment cell samples were collected by first detaching them from the wells 
with Trypsin/EDTA (300 µL /well).  A fresh aliquot of DPBS-cm, with 10% FBS 
(300 µL /well) was added to each to neutralize the Trypsin before centrifuging at 500 
x g for 5 min.  The supernatant was then carefully aspirated and the cell pellet gently 
resuspended in 300 µL of DPBS-cm.  Half of each of these cell suspensions was used 
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for ELISA assays of intracellular hIL2, and the other half for flow cytometry.  These 
samples were then supplemented with 150 µL of DPBS-Ca2+, -Mg2+, with 7.4% 
paraformaldehyde to fix the cells.  Samples were kept in a 4oC refrigerator until they 
were ready for the flow cytometer.  Red fluorescence of C2C12, HEK293, and Jurkat 
cells was measured by a FACSCalibur™ (BD Biosciences, Immunocytometry) flow 
cytometer equipped with a 15 mW, 488 nm, air-cooled argon-ion laser and three color 
detectors (FL1=530/30, FL2=585/42, FL3=670LP), which was kindly provided by 
D.M. Mosser (University of Maryland, College Park).  FL2 was used for the detection 
of Destabilized DsRed-Express fluorescent proteins.  The cytometer was used with 
the following settings:  FSC = 1.00, SSC = 394, FL2 = 683 for Jurkat cells and FSC = 
0.485, SSC = 288 and FL2 = 538 for HEK293 and C2C12 cells.  Ten thousand cells 
were analyzed in each sample.  Fluorescence measurements were made only on live 
cells, which were gated by the upper right quadrant of an FSC-SSC dot plot.  
Histogram plots of the live cells were then used to determine the number of cells and 
their corresponding fluorescence intensities that were above background (Figure 2.2).   
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Figure 2.2 Destabilized DsRed-Express fluorescence in mammalian cells was measured using a 
FACS Calibur flow cytometer (FSC = 1.00, SSC = 394, FL2 = 683 for Jurkat cells and FSC = 0.485, 
SSC = 288 and FL2 = 538 for HEK293 and C2C12 cells).  Histograms were obtained only after gating 
live cells from dead ones using a FSC-SSC dot plot within 10,000 cell samples. 
 
All fluorescence data were reported in Total Relative Fluorescent Units 
(RFU), which is defined as the product of the number of cells and the mean 
fluorescence intensity above background.  This unit more accurately reflects the total 
number of fluorescence molecules within a cell sample and was used for correlations 
to hIL2 secretion levels. 
2.2.6 Fluorescence Microscopy 
Fluorescent cells were observed using an Olympus BX60 fluorescent 
microscope equipped with a DsRed2 filter cube (Exciter HQ540/40x, Dichroic 
Q570LP BS, Emitter HQ600/50m EM).  Cell cultures were removed from flasks by 
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either trypsinizing attached cells or by simply pipetting out suspension cultures.  
Samples were washed and resuspended in DPBS-cm in order to minimize the 
background autofluorescence of the media.  Cells were then placed on a microscope 
slide with a cover slip before imaging.   
2.3 Results and Discussion 
2.3.1 Correlating DsExDR with Intracellular hIL2  
Before exploring the utility of red fluorescent markers as indicators of 
secreted hIL2 concentrations, it was necessary to see if the bicistronic vector would 
produce both proteins and if useful correlations between fluorescence and 
intracellular hIL2 concentrations could be obtained.  Similar internal correlations, 
using fusional constructs between hIL2 and GFP, have been successfully obtained 
[124, 125].   To examine the bicistronic construct in this work, the cell line with the 
highest transfection efficiency, HEK293, was selected for trial studies.  Transfections 
were performed in 24-well tissue culture plates using 0.2, 0.5, 0.8, 1.2, 1.6, and 2.0 
µg of the pF2 vector for every 2 x 105 cells in each well.  Non-transfected cells were 
used as negative controls for both hIL2 and DsExDR expressions.  ELISAs of the 
intracellular fraction showed that hIL2 concentrations increased linearly with 
transfection DNA level when transfected with up to 1.6 µg of pF2 plasmid (Figure 
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Figure 2.3 HEK293 and C2C12 attachment cells were transfected with pF2 (0, 0.2, 0.5, 0.8, 1.2, 1.6, 
and 2.0 mg-DNA per 2 x 105 cells) for the bicistronic expression of Destabilized DsRed-Express 
(DsExDR) red fluorescent protein and secretion of human interleukin-2 (hIL2).  Both cell lines 
secreted large amounts of hIL2 on the order of nanograms per million cells (A, D).   The presence of 
hIL2 within HEK293 cells was also measured.  These cells lines were able to express similar quantities 
of the intracellular red fluorescent protein (B, E).  The elevated concentration of DsExDR at the 
highest levels of transfection resulted in decreases of fluorescence measurements in both cell lines.  
This was indicative of self-quenching.  Strong linear correlations between the two proteins were 
observed in both cell lines when the last data points were omitted (C, F).  A linear correlation of 
DsExDR with intracellular hIL2 was also present in HEK293 cells.  Jurkat cells were transfected with 
five higher concentrations of the bicistronic plasmid pF2 (1.1, 1.7, 2.6, 3.4, and 5.1 mg-DNA per 2 x 
105 cells).  This cell line secreted hIL2 concentrations that were three orders of magnitude lower than 
the previous cells (G).  This may be due to two factors that are inherent to Jurkat cells.  The first is the 
notoriously low transfection efficiency of this line, evident by observation under fluorescence 
microscopy and the lack of DsExDR self-quenching at the highest pF2 transfection level (H).  The 
second is the presence of natural regulatory mechanisms for controlling the secretion of hIL2, which is 
an intrinsic product of T-cells.  A linear correlation was found among all concentrations of secreted 
hIL2 and DsExDR fluorescence in Jurkat cells (I).
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of DNA was used.  Measurements of DsExDR fluorescence showed a similar 
trend (Figure 2.3B).  The highest concentration of pF2 transfected, however, resulted 
in a drop in total fluorescence rather than a plateaued value as found in intracellular 
hIL2 measurements.  While untested, it is speculated that this is due to aggregation 
and self-quenching of DsExDR proteins in high density [108].  A linear correlation 
between the intracellular hIL2 concentration and DsExDR fluorescence can be seen 
when the highest DNA concentration datum is omitted (r2 = 0.901) (Figure 2.3C).  
These results show that DsExDR is a suitable biomarker for hIL2 production and 
suggests that it should be tested as a measure for extracellular hIL2. 
2.3.2 Correlating DsExDR with Secreted hIL2 from Attachment Cells 
The examination of correlations between red fluorescence and hIL2 
measurements was continued by examining secreted hIL2 from the HEK293 cells, as 
well as an additional attachment dependent cell line, C2C12.  Transfections with pF2 
vectors were performed in 24-well plates of constant volume (0.5 mL).  These 
cultures were transfected with DNA concentrations identical to the previous 
intracellular hIL2 study: 0.2, 0.5, 0.8, 1.2, 1.6, and 2.0 µg-DNA per 2 x 105 cells in 
each well.  ELISAs of supernatant samples derived from HEK293 cultures and 
sampled after 24 hrs showed a linear rise in the amount of hIL2 secreted beginning 
from the lowest level of DNA transfected (Figure 2.3A). The relationship between red 
fluorescence and secreted hIL2 concentrations also followed a strong linear 
correlation (r2 = 0.931) for all DNA concentrations below 2.0 µg in HEK293 cells 
(Figure 2.3C). 
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The C2C12 cells exhibited a similar trend in hIL2 secretion as was observed 
for the HEK293 cells.  It is noteworthy, however, that the amount of secreted hIL2 
from C2C12 cells was approximately four times higher than that from HEK293 cells 
for every concentration of transfected pF2 (Figure 2.3D).  DsExDR fluorescence 
measurements in C2C12 cells displayed a rising trend to a maximum followed by a 
slight decrease at the highest DNA concentration, which was analogous to the 
behavior found in HEK293 cells (Figure 2.3E).   The datum derived from this highest 
DNA concentration was again omitted from regression analysis and the correlation 
between DsExDR fluorescence and hIL2 secretion followed a strong linear 
relationship (r2 = 0.996) (Figure 2.3F).   
2.3.3 Correlating DsExDR with Secreted hIL2 from Suspension Cells 
Jurkat cells were similarly transfected with the pF2 bicistronic vector to 
examine if the previous results can be extended to suspension type cells.  Jurkat 
cultures were transfected with five higher concentrations of pF2 due to their lower 
transfection efficiencies (1.1, 1.7, 2.6, 3.4, and 5.1 µg-DNA per 2 x 105 cells), in 6-
well tissue culture plates.  The transfected Jurkat cultures exhibited little hIL2 
secretion below the second lowest concentration of DNA used.  Significant hIL2 
secretion only began at the 1.7 µg transfection concentration (Figure 2.3G).  The level 
of hIL2 secretion approached a limit when 5.1 µg of pF2 was used.  The total level of 
protein secreted from the Jurkat cells was three orders of magnitude lower than the 
attachment cells (1-15 pg/106 cells vs. 10 ng/106 cells).  This could be due to both a 
lower transfection efficiency for Jurkat cells, and the likelihood that Jurkat cells 
temper or otherwise regulate hIL2 secretion.  As much as one order of magnitude can 
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be attributed to the difference in transfection efficiency of Jurkat cells (~10%) and 
those of C2C12 and HEK293 (~80%), which was observed by fluorescence 
microscopy.  The low level of transfection efficiency in Jurkat cells was also evident 
by the absence of DsExDR self-quenching at high plasmid concentrations.  The 
remaining orders of magnitude can be associated with the restricted secretion rates of 
hIL2 from Jurkat T-cells, which are natural producers of hIL2 and have many 
regulatory mechanisms for controlling hIL2 secretion [126].  Intracellular analyses of 
hIL2 were not performed to confirm this hypothesis.  
The total fluorescence measurements showed a pattern of DsExDR expression 
that was similar to hIL2 secretion (Figure 2.3H).  Unlike the previous two cell lines 
examined, Jurkat cells did not exhibit a quenching of fluorescence intensity at the 
highest level of DNA transfection.  A linear regression of all values resulted in a 
linear correlation (r2 = 0.972) (Figure 2.3I).  This positively demonstrated that red 
fluorescence measurements could also be used to deduce the amount of hIL2 secreted 
by suspension cell lines.   
2.3.4 Examining IRES – mediated Co-expression of DsExDR and hIL2 Proteins 
It was of interest to see whether the secreted hIL2 was correlated one to one 
with DsExDR, as would be expected for a direct fusion protein expressed 
intracellularly [72].  To accomplish this, we plotted normalized DsExDR fluorescence 
levels against normalized hIL2 secretion concentrations (Figure 2.4).  For each cell 
line, the point of normalization was based upon the optimal DNA concentration 
recommended for transfection by the manufacturer, Invitrogen (Jurkat = 1.1 µg, 
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Figure 2.4 The functionality of using the IRES bicistronic expression system among the three cell 
lines (Jurkat, C2C12, and HEK293) can be compared by plotting the expression of DsExDR and 
secretion of hIL2, each normalized by the respective data point at which the recommended transfection 
level was made (Jurkat = 1.1 mg, C2C12 & HEK293 = 0.8 mg).  A slope of unity indicates that both 
proteins are accumulating at equal rates.  Jurkat cells have the most balanced accumulation rate, while 
C2C12 and HEK293 cells accumulated slightly more fluorescent protein per hIL2 secreted. 
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 1:1 correspondence for accumulated proteins.  That is, for every DsExDR 
expressed and accumulated, an hIL2 protein was also expressed and secreted.  As 
discussed earlier, the highest level of hIL2 secretion was found in C2C12 and 
HEK293 cells, while Jurkat cells secreted comparatively much less hIL2.  When 
examining the normalized correlations among the cell lines, however, the Jurkat cells 
achieved a more balanced accumulation of both hIL2 and DsExDR molecules (1:2), 
as seen by a slope of 0.52 in Figure 2.4.  C2C12 and HEK293 cells, though higher 
producers overall, accumulated slightly smaller proportions of hIL2 with respect to 
DsExDR (1:3).  In general, the bicistronic plasmid, pF2, was successful in effecting a 
consistent and comparable accumulation of both marker and therapeutic proteins in 
three distinct mammalian cell lines. 
Observations based on Figures 2.3 and 2.4 indicated that the latter two cell 
lines, C2C12 and HEK293, were intrinsically more efficient in protein expression, 
such that even low amounts of transfected DNA were sufficient for actuation.  
Because of these elevated efficiencies, the highest level of DNA transfected (2.0 µg) 
caused DsExDR, an internally accumulated protein, to reach a saturation limit, at 
least with respect to its fluorescence signal.  hIL2, which is secreted from the cells, is 
unbound by the internal constraints or capacities of the cells, and continued to 
accumulate in the supernatant.  Although this phenomenon created a divergence in 
the relationship between the amount hIL2 secreted and the DsExDR fluorescence at 
the highest DNA transfection level, the bicistronic system functioned quite well at all 
lower transfection levels (0.2 to 1.6 µg).  Thus, applications of the pF2 vector can 
utilize a wide range of transfection concentrations in order to take advantage of the 
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bicistronic marker.  Jurkat cells, which were not as efficient in secreting hIL2 as the 
previous cell lines, equally approached a limitation in hIL2 secretion and DsExDR 
expression at the highest DNA concentration (5.1 µg).  In this case, modulating the 
level of transfected DNA produced a proportionally similar response in both hIL2 
secretion and DsExDR accumulation. 
It is noteworthy that linear correlations were obtained for all three cell lines 
(Figures 2.3, 2.4).  A simple scaling analysis of the marker half-life ( t1/2 ), assuming 
linear production and first order degradation rates for a continuously expressing 
stable cell line, shows that a measurement made at any time beyond steady state (τ ≡ 
t/t1/2 ~ 6) is equal to the quantity of protein expressed within a time frame of the 
immediate [ t1/2/ln(2) ] hours.  In the case of DsExDR, which has a reported half-life 
of ~12 hr, a measured fluorescence signal is then representative of how much protein, 
such as hIL2, was expressed in approximately the last 17 hr.  The value of using a 
destabilized marker becomes more apparent when this bicistronic system is used in 
applications such as medical devices, where measurements will indicate how much 
therapeutic was secreted within the last 17 hr rather than over the life time of the 
device.  Furthermore, a 17-hr window is a relatively short period when compared to 
the lifetime of an implant, which may be on the order of months.  This in essence 
gives a much more responsive indication of the therapeutic production rate, as 
compared to reporter systems that may utilize a stable marker.  As the half-life of a 
marker protein decreases, so does this window of representation, which in effect gives 
an even more discrete measurement of a system’s therapeutic protein secretion rate.  
However, a marker protein should also not have too short of a half-life, lest it may not 
44 
accumulate enough molecules to produce a detectable fluorescent signal.  Because 
DsExDR has an appreciable turnover rate, though long enough to accumulate a 
detectable signal, and also preserves the linearity of the response to hIL2 secretion, it 
is suggested that it is indeed highly suitable for indicating the secretion levels of a co-
expressed therapeutic. 
Due to the effectively discrete and linear attributes of the DsExDR signal, it is 
reasonable to believe that this marker is a good platform for non-invasively detecting 
natively secreted proteins.  The generality of this approach was also demonstrated by 
pF2’s functionality in three distinct cell lines, which varied in species, as well as 
attachment requirements.  Such findings are thus valuable for applications such as 
traditional bioreactor designs, biohybrid artificial organs and regenerative tissue 
engineering. 
2.4 Conclusions 
Three common mammalian cells lines, HEK293, C2C12, and Jurkat were 
transfected with a bicistronic vector, which enabled expression of a DsExDR red 
fluorescent protein marker and secreted hIL2.  Both DsExDR and hIL2 were 
expressed from all three cell lines.  The level of secreted hIL2, per total cell number, 
was significantly higher in C2C12 cells than in the other two. The levels expressed in 
Jurkat cells were by far the lowest among the three.  It was found that DsExDR 
fluorescence was a good indicator of intracellular hIL2 in HEK293 cells.  Further, it 
was found that DsExDR fluorescence was linearly correlated with secreted hIL2 from 
all three cell lines.  Finally, by plotting protein levels on a normalized basis, it was 
determined that the Jurkat cell line had the most balanced accumulation of DsExDR 
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protein molecules and hIL2 molecules, with a 1:2 ratio.  Though HEK293 and C2C12 
cell lines had approximately 1:3 DsExDR to hIL2 accumulation ratios, they were also 
not far from equalized production, and may also be suitable hosts for the bicistronic 
system developed here.  These results thus show promise for further developing in-
situ and non-invasive methods of monitoring therapeutic protein secretion in various 
applications such as tissue engineering.  
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3. Counteracting Apoptosis and Necrosis with Hypoxia Responsive 
Expression of Bcl-2∆ 
3.1 Introduction 
Biohybrid artificial organs are implantable medical devices designed to 
secrete therapeutic proteins from encapsulated cells, typically mammalian in origin.  
In this encapsulated environment, cells often encounter a deficiency in the availability 
of oxygen [127] resulting in hypoxia.  Since mammalian cells can only tolerate 
hypoxia for only a few days at best [89], necrosis and apoptosis quickly ensue.  The 
propensity towards either cell death pathway, however, is highly dependent on the 
cell type [3].  The first pathway is typically the result of severe and prolonged 
exposure to stimuli such as oxygen deprivation.  Characteristics of necrosis are cell 
membrane disruption, mitochondrial swelling, and lost of cytosolic structures.  
Apoptosis, also known as programmed cell death, is a more gradual and organized 
process, marked by chromatic condensation, DNA cleavage, cell size shrinkage, and 
cell membrane blebbing.  Several extracellular strategies have been designed to 
deliver more oxygen to the encapsulated cells.  These include inducing 
vascularization around the implant [4], electrochemically generating oxygen by 
decomposing water [5, 6], as well as using synthetic oxygen carriers [90].  An 
alternate method of helping cells survive hypoxia may be intracellular in nature, 
involving the metabolic engineering of encapsulated cells to become intrinsically 
more resistance oxygen deprivation. 
Bcl-2 belongs to a family of regulatory proteins that have the ability to 
prevent or delay apoptosis.  Its activity was first described by Vaux et al. in 1988 as 
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being able to protect cells from apoptosis induced by deprivation of the hormone IL3 
[91].  It was later discovered that Bcl-2 could prevent apoptosis induced by other 
factors, including serum deprivation, heat shock, chemotherapy agents, ethanol, and 
hypoxia [89, 92-95].  More recently, Bcl-2 has also been shown to inhibit necrosis 
induced by hypoxia and inhibition of mitochondrial respiration [96].  Since the 
discovery of Bcl-2, other members of this family of regulatory proteins have been 
discovered.  Members include proteins that are anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w) 
and pro-apoptotic (Bax, Bak, Bik, and Bid) in nature.  A commonality among the 
members is four Bcl-2 homologous domains, BH (1-4), which may all be present but 
not all active in a single protein.  Activity of BH3 is necessary for efficacy of pro-
apoptotic members [96-98], while BH1, 2, and 4 are required for anti-apoptotic 
effects [9, 99].  Recent studies also indicate that a nonconserved region of peptides 
between BH3 and BH4, encoding an unstructured loop, is responsible for attenuating 
the anti-apoptotic effects of Bcl-2 and Bcl-xL.  Bcl-2∆ is a deletion mutant (residues 
32-80) of the human Bcl-2 protein, yielding a variant devoid of this loop, a putative 
negative regulatory domain used for post-translational modifications [7-9].  In 
comparison to the full-length protein, the deletion mutant shows enhanced ability to 
inhibit apoptosis [10, 128].   
The objective of this work is to investigate how Bcl-2∆ can be used to relieve 
hypoxic stress.  To test the effects of Bcl-2∆ on the levels of protein production, 
necrosis, and apoptosis, a mouse myoblast cell line, C2C12, was transfected to 
express a yellow fluorescent protein (EYFP) with or without Bcl-2∆ under the control 
of a strong constitutive CMV promoter.  To prevent continual or unnecessary over-
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production of this protein, however, the regulation of its expression was then placed 
under the control of a hypoxia sensitive promoter, 5HRE-hCMVmp.  These vectors 
allowed cells to differentially express either EYFP or EYFP-Bcl-2∆ based on the 
level of oxygen that is sensed.  These vectors were ultimately designed for use in 
encapsulated cells such that they can conserve their metabolic energy and produce 
Bcl-2∆ only when necessary. 
3.2 Materials and Methods 
3.2.1 Cell Culture Media and Maintenance 
A murine myoblast cell line, C2C12, was used for all experiments.  C2C12 
was subcloned from the skeletal leg muscle cells of an adult C3H mouse, and was 
obtained from American Type Cell Culture (ATCC; CRL-1772, MD, USA).  The 
myoblasts are non-carcinomas and remain undifferentiated.  Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) supplemented with 1.5 
g/L of NaHCO3 and 5% fetal bovine serum (FBS, Sigma).  Regular maintenance of 
the cells required subculturing every two days in 75 cm2 tissue culture flasks as the 
population approached 80-90% confluency.  To detach the cells, spent media was first 
aspirated, and the culture rinsed with Dulbecco’s Phosphate Buffer Solution (DPBS) 
without Ca2+ and Mg2+ (DPBS-cm) (Invitrogen).  Rinsed cells were then incubated in 
a 0.25% Trypsin with 0.03% EDTA solution (Sigma) for 5 minutes at 37 oC.  Cells 
were passaged at a 1:10 split ratio, with 12 mL of fresh media. 
3.2.2 Construction of Recombinant Plasmids 
Four plasmids were constructed in order to test the ability of the Bcl-2∆ 
protein to be differentially induced under low oxygen conditions, as well as 
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counteract the ensuing apoptotic and necrotic cellular events.  All plasmids contained 
the gene for an enhanced yellow fluorescent protein (EYFP), which served as a 
marker for promoter induction and protein expression.  The first two plasmids (Figure 
3.1) utilized the strong constitutive cytomegalovirus (CMV) promoter, which was 
part of the backbone vector, pIRESpuro3 (Clontech).  The first construct, pCYp, 
contains only the EYFP gene.  This gene was obtained through a polymerase chain 
reaction (PCR) from a plasmid, dubbed pCYbn, which was generously donated by 
M.J. Betenbaugh (Johns Hopkins University), using the following primers: 5'- AGA 
TCC GCT AGC GCT AC -3' and 5'- GTA GCG CTA GCG GAT CT -3'.  These 
primers respectively included the NheI and EcoRI restriction enzyme sites.  The PCR 
product was digested at these restriction sites and ligated into the corresponding sites 
in pIRESpuro3.  The second plasmid constructed was pCYbp, which contained an 
EYFP-bcl2-∆ fusion gene.  This fusion was obtained by directly digesting NheI and 











Figure 3.1 Two plasmids, pCYp and pCYbp, contain strong constitutive CMV promoters, which 
permit the continual expression of protein in transfected cells.  The first vector, pCYp, serves as a 
negative control for the effects of Bcl-2∆ with respect to pCYbp. 
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The last two plasmids, pO2Yp and pO2Ybp, (Figure 3.2) were built as 
analogs to the first two plasmids with only a difference in the promoter used.  These 
vectors were constructed by replacing the CMV promoters with a hypoxia-inducible 
promoter, 5HRE-hCMVmp (5HRE), found in the p5HRE-d2EGFP vector generously 
provided by J.M. Brown (Stanford University) [129].  This promoter contains five 
hypoxia responsive elements (HRE) fused upstream of a human cytomegalovirus 
minimal promoter, and is induced only under low oxygen conditions.  In each case of 
building the last two plasmids, the original CMV promoters were first excised 
throught digestion of the flanking restriction enzymes sites, NruI and NheI, and 
replaced with 5HRE-hCMVmp.  The hypoxia-inducible promoter was obtained 
through PCR of p5HRE-d2EGFP using the following primers: 5'- TAA TTC GCG 
ACA TAT GGG TAC CGA GCT TTT CT -3' and 5'- GCA ATG CTA GCG AAT 











Figure 3.2 Hypoxic induction of protein expression is achieved with the p5HRE-hCMVmp 
promoter, which is composed of five tandem hypoxia responsive elements (5HRE) fused to a human 
CMV minimal  promoter (hCMVmp).  The pO2Yp vector serves a negative control to pO2Ybp with 
respect to Bcl-2∆. 
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3.2.3 Transfections 
C2C12 myoblasts were transfected in both 6- and 12-well tissue culture plates 
(Costar) in an attached state (Table 3.1).  Cells were passaged at most two days 
before inoculation so that they remain in a non-confluent, growing state.  Cultures 
were harvested by trypsinization (0.5 – 1.0 mL/well of Trypsin/EDTA, 5 min, 37oC) 
and resuspended in fresh complete media at a concentration of 6 x 104 cells/mL.  6-
well plates were inoculated with 1mL/well of this cell solution while 12-well plates 
were inoculated with 0.5 mL/well.  Inoculated plates were incubated for 12 hours 
before transfection to ensure attachment of cells.  Upon transfection, a media 
exchange was performed on all wells, whereby the respective volumes of complete 
media were replaced by a serum-free media, OptiMEMI (Invitrogen).  Antibiotics 
were never used during routine passaging nor during transfection.  Transfections were 
accomplished by using a cationic lipid reagent, LipofectAmine Plus (Invitrogen).  
DNA was first combined with Plus reagent in a solution of OptiMEMI.  This mixture 
incubated for 15min at room temperature and was added to a second vial containing 
LipofectAmine in a solution of OptiMEMI.  Specific amounts for transfecting either 
6-well or 12-well plates are detailed in Table 3.1.  This final mixture was also 
allowed to incubate for 15min at RT for the DNA-Lipid complexes to form, and then 
pipetted into each well drop-wise such that it did not disturb the attached C2C12 
cells. 
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Table 3.1 Transfection Protocol for C2C12 in 6- and 12-well tissue culture plates. 
 
Format Plasmid Plus OptiMEMI LipofecAmine OptiMEMI
(µg) (µL) (µL) (µL) (µL)
6-well 1.2 6 100 3.4 100
12-well 0.7 5 50 2.0 50
 
 
3.2.4 Hypoxic Chambers 
In order to simulate the various hypoxic conditions needed to induce 
apoptosis, as well as promoter response, cell culture plates were placed in individual 
hypoxic chambers within a CO2 incubator.  Each chamber was connected to its own 
particular mixture of gas.  As the gas enters the incubator, it is first passed through a 1 
liter fine bubble column, where it is humidified and heated before entering the 
individual hypoxic chambers.  Each chamber was fashioned from a 1-L plastic tray 
with a non-hermetic lid.  As the gas enters the chamber, it fills and saturatesthe 
headspace before exiting.  Gas exchange was facilitated by placing all hypoxic 
chambers on a rocker platform (Boekel).  The entire experimental assembly is 
depicted in Figure 3.3.  A kinetic measurement of the dissolved oxygen concentration 
in a mock culture, which contained 1 mL of complete media, showed that steady state 
was reached at approximately one hour for a 0% O2 gas mixture flowing at 0.5 L/min 
(Figure 3.4).  Dissolved oxygen was measured using a Clark-type dissolved oxygen 








Figure 3.3 The hypoxic incubation system is composed of individual hypoxic chambers placed upon 
a rocker platform within a CO2 incubator.  Each chamber is connected to its own gas tank via a bubble 
column, which humidifies and warms the incoming air.  The gas environment within each chamber is 
determined by the premixed composition of the compressed gas cylinders.  Mix gas flows at 0.5 L/min.  
The chambers and bubble columns are each 1L in volume.  Dissolve oxygen content in tissue cultures 

















Figure 3.4 Kinetic measurements of dissolved oxygen content within a 1mL mock culture were 
made to ensure that cells were exposed to the intended hypoxic environments.   A 0 % O2 gas mixture 
was directed into a rocking hypoxic chamber (0.5 L/min, 37 oC), which contained the mock culture.  




3.2.5 Flow Cytometry of EYFP Recombinant Proteins 
The choice of using EYFP as a fusion partner to Bcl-2∆ enabled the tracing of 
its production by means of flow cytometry.  When EYFP was produced alone, its 
fluorescence serves as an indicator of overall cell productivity.  Cell samples were 
collected by aspirating the culture media and rinsing with DPBS-cm.  To detach the 
cells, wells were filled with either 300 uL of Trypsin/EDTA for 6-well plates or with 
500 uL of Trypsin/EDTA for 12-well plates.  Samples were incubated for 5 min at 
37oC before centrifuging (500 x g, 5min) and fixing the cells in 300 µL of DPBS-cm 
+ 3.7% paraformaldehyde (DPBS-cmf).  Samples were stored in 5mL polystyrene 
culture tubes at 4oC until they were ready for analysis.  All analyses were performed 
with a FACSCalibur (Becton Dickinson, Immunocytometry) three-color flow 
cytometer (FL1=530/30, FL2=585/42, FL3=670LP) equipped with a single Argon 
laser (488nm), generously provided by D.M. Mosser (University of Maryland, 
College Park).  Ten thousand cells were analyzed in each sample.  The detectors were 
used with the following settings: FSC = 1, SSC = 350, and FL1 = 380 to 412. 
3.2.6 Viability Assay 
Cell viability was determined by a dye exclusion assay using 7-amino-
actinomycin D (7-AAD) (Beckton Dickinson, Pharmingen).  Cells samples were 
collected by centrifuging the combined supernant media and trypsinized cells.  This 
ensures that any cells that may have died and detached from the wells were taken into 
consideration for viability measurements.  Samples were then resuspended in DPBS-
cm + 5% FBS (DPBS-cms) in order to neutralize any trypsin that may have remained.  
100 µL of a 10 x dilution of 7-AAD in DPBS-cms was added to each sample, and 
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allowed to incubate for 10min in the dark at room temperature.  Formaldehyde was 
not used in this procedure.  Samples were immediately placed on ice and analyzed 
after collection.  Fresh cells that were not transfected were processed in the same way 
to serve as a negative control for 7-AAD.  The FACSCalibur flow cytometer with an 
FL3 = 400 setting was used to detect the viability dye. 
3.2.7 Apoptosis Assay 
The level of apoptosis in the cell samples was assessed with an anti-caspase-3 
apoptosis kit (BD Pharmingen).  Cells were collected similarly to the viability assay.  
Samples were resuspended in a cold Cytofix/Cytoperm (500 µL) solution for 20 min 
on ice, in order to fix the cells, as well as to permeate the membranes for the 
subsequent antibody staining.  Cells were washed with a Perm/Wash Buffer (PWB) 
(500 µL, RT) before 120 µL of the anti-caspase-3 antibody solution was added to 
each sample.  This was allowed to incubate for 30 min at RT before the samples were 
washed twice with cold PWB (4 oC).  Final samples used for flow cytometry analyses 
were resuspended in PWB.  The antibody, which was conjugated to phycoerythrin 
(PE) was detected on FL2 = 493.  As a positive control, cells were incubated for 4 
hours with a 6 µM (final concentration) solution of camptothecin (Sigma), which is a 
potent inducer of apoptosis [10].  Since all transfected cells produced EYFP, which 
has some overlapping emissions from FL1 into FL2, it was necessary to have one 
complete set of samples that were not stained with the conjugated antibody to serve as 
a background fluorescence reading for all apoptosis data. 
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3.2.8 Fluorescence Microscopy 
EYFP fluorescence was helpful as an indicator for successful transfection of 
cells.  Fluorescence was verified with an Olympus BX60 fluorescent microscope 
equipped with a UMNB filter cube (Exciter BP470-490, Dichroic DM500, Emitter 
BA515 LP).  Cell cultures were removed from tissue culture plates by trypsinization 
and washed with  DPBS-cm in order to minimize the background autofluorescence of 
media.  Cells were then placed on a microscope slide with a cover slip before 
imaging.   
3.3 Results and Discussion  
3.3.1 Differential Hypoxic Induction of Protein Production 
In order to verify the sensitivity of the 5HRE promoter within the vector 
constructs to hypoxic induction, C2C12 cells transfected with either p5HRE-d2EGFP 
or pO2Ybp were compared for their levels of fluorescent protein production under 
five oxygen conditions.  Cells inoculated in 6-well plates were placed in individual 
hypoxic chambers with gas mixtures containing either 0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 
% O2 plus 5% CO2, and a balance of N2.  Cells were first incubated under ambient 
oxygen conditions for 36 hours post-transfection (hpt) before they were exposed to 
the various oxygen conditions for another 18 hours.  Under these environments, the 
level of protein induction from the highest to lowest oxygen concentrations were 
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Figure 3.5 C2C12 cells transfected with pO2Ybp and p5HRE-d2EGFP were compared for their 
ability to hypoxically induce fluorescent protein production.  Cells were exposed to five oxygen 
concentrations (0.0, 0.5, 1.0, 2.0, 5.0, 21.0 %) and assayed after an 18 hour incubation.  C2C12 
cultures transfected with pO2Ybp produced enhance yellow fluorescent protein (EYFP) in a similar 
fashion to those transfected with p5HRE-d2EGFP produced destabilized enhance green fluorescent 
protein (d2EGFP).  EYFP fluorescence, however, was higher than EGFP at every O2 concentration.  
This is most likely due to the short, 2-hour half-life of the destabilized EGFP.  Both transfections 
indicated that a decrease in O2 content is able to exponentially induce fluorescence.
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The fluorescence in cells transfected with pO2Ybp was consistently higher 
than those transfected with p5HRE-d2EGFP at every oxygen level despite their 
similar quantum yields (61% and 60%, respectively).  This difference was most likely 
due to the fact that the latter plasmid expressed a destabilized form of EGFP, with a 
half-life of only two hours rather than over 24 hours as is the case with EYFP.  The 
decrease in the partial pressure of oxygen did not induce a linear response in the level 
of fluorescence, but was more exponential in nature.  This trend was supported by 
previous studies made with the 5HRE promoter [69, 130, 131].  Furthermore, there 
appeared to be a slightly higher than expected rise in fluorescence at the 5.0% O2 
level, resulting in a non-monotonic rise in the otherwise exponential trend for both 
d2EGFP and EYFP induction.  This phenomenon may reflect the evolutionarily 
optimized state for cellular metabolism, since the 5% O2 gas environment more 
closely simulated natural mammalian physiological conditions [12]. 
Upon verifying that the hypoxia inducible promoter was functioning properly 
within pO2Ybp, we compared how each of the four constructed vectors responded to 
variations in oxygen partial pressure.  Cells inoculated in 6-well plates were placed in 
individual hypoxic chambers with gas mixtures containing either 0.0, 0.5, 1.0, 2.0, 
5.0, or 21.0 % O2 plus 5% CO2, and a balance of N2 for 30 hours starting from 24 hpt.  
C2C12 transfected with pO2Yp showed similar trends in expression of EYFP as those 




























Figure 3.6 C2C12 cells were transfected with either pCYp, pCYbp, pO2Yp, or pO2Ybp expression 
vectors and incubated for 30 hrs under various hypoxic conditions (0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 % O2 
plus 5% CO2, and a balance of N2 ) beginning at 24 hours post-transfection (hpt).  Cells that were 
transfected with the hypoxia sensitive promoters showed increased fluorescence with a decrease in O2 
concentration.  Cells that contained the CMV promoter, however, displayed an opposite trend despite 
their overall higher levels of fluorescence at all oxygen concentrations.  This decrease in fluorescence 
was indicative of metabolic stress due to hypoxia.  In all C2C12 culture, it was clear that the presence 
of Bcl-2∆ was helpful to the cells’ protein production capabilities. 
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The characteristic bump at the 5% O2 condition, however, was not as 
apparent.  Nevertheless, the culture that expressed Bcl-2∆ showed a consistently 
higher level of protein production at all oxygen concentrations.  This difference 
became even more dramatic as the oxygen level decreased and hypoxia-induced 
apoptosis came into effect.  Thus, the presence of Bcl-2∆ apparently gave these cells 
a metabolic advantage.  Myoblasts that were transfected with pCYbp and pCYp, 
showed an overall higher level of fluorescence compared to the hypoxia sensitive 
transfectants.  As expected, the CMV promoter allows a significant level of protein 
production despite limited oxygen availability.  Thus, despite the strength of the 
promoter, the trend in production suffered as the level of oxygen also decreased.  
Similar to the relationship among cells transfected with the 5HRE promoter, Bcl-2∆ 
conferred a metabolic advantage to the cells transfected with pCYbp over those with 
pCYp. 
3.3.2 Transient Expression of Heterologous Proteins under Hypoxic Condition 
C2C12 myoblasts were transfected with the four constructed plasmids, pCYp, 
pCYbp, pO2Yp, and pO2Ybp, were monitored over a 24 hour period to study their 
transient behavior under hypoxic conditions.  Cells were placed under a 2% O2 gas 
mixture environment for 24 hours post-transfection (hpt), and monitored ever 8 hours 
thereafter.  Myoblasts that contained the plasmids with the CMV promoter had 
significantly higher fluorescence intensities compared to those containing the 5HRE 




































Figure 3.7  C2C12 cells were transfected with either pCYp, pCYbp, pO2Yp, or pO2Ybp expression 
vectors and monitored for 24 hrs when grown under a 2% O2 hypoxic environment beginning at 24 
hpt.  All transfections, besides pO2Yp, showed an increase in EYFP fluorescence within the 24 hours.  
Although this phenomenon was expected for cells containing hypoxia inducible promoters, those 
without were apparently unencumbered within the exposure period.  All myoblasts that were able to 
express Bcl-2∆ were able to produce more EYFP than their deficient counterparts.  This indicated the 
production advantage of having the anti-apoptotic protein.  Myoblasts that were transfected with 
pO2Yp, had neither the bcl-2∆ gene, nor the brute capability of the CMV promoter, and thus lagged in 
EYFP production as time progressed. 
 
 
Within each pair of promoter constructs, the cells that contained the Bcl-2∆ 
gene produced more fluorescence in comparison to those without.  All plasmids 
beside pO2Yp showed an increase in EYFP production as a function of time, up to 48 
hpt.  This phenomena in cultures that did not have the hypoxia inducible promoter 
indicated that the strength of the CMV promoter was not hindered by the 2% O2 
environment within the 24 hour exposure.  Among the cells that contained the 5HRE 
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promoter, only those that produced Bcl-2∆ showed an increase in fluorescence as a 
function of time.  Thus, without the enhancement of Bcl-2∆, the induction of the 
5HRE promoter was not enough to overcome the detriment of hypoxia over a 24 hour 
period. 
3.3.3 Bcl-2∆ Protection of Cells under Hypoxic Stress 
In order to truly gauge the applicability of producing Bcl-2∆ for protecting 
encapsulated cells, which face extended periods of hypoxia, it was important to not 
only examine the level of protein production, but also the levels of cell viability and 
apoptosis in treated cultures.  These parameters will give a better measure of the long-
term health and metabolic productivity of the cells.  To accomplish this, cells 
transfected with the hypoxia inducible promoter vectors were placed under five 
different oxygen conditions and analyzed for their viability as well as their apoptotic 
levels.   As hypothesized, the cells that produced Bcl-2∆ had a consistently higher 
level of viability than those that were without the anti-apoptotic protein.  
Furthermore, these cells had lower levels of apoptosis (Figure 3.8).  Thus, the 
production of Bcl-2∆ was not only able to enhance the immediate protein productivity 
of its host, but also provided long term protection by reducing hypoxia induced 
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Figure 3.8  The protective nature of Bcl-2∆ against hypoxia can be more accurately accessed through 
measurements of necrosis and apoptosis in the host.  C2C12 cells that were transfected with either 
pO2Ybp and pO2Yp were exposed to five hypoxic environments (0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 % O2 
plus 5% CO2, balance N2 ) for 30 hours beginning at 24 hpt.  Myoblasts that were able to express Bcl-
2∆ were able to sustain both a higher level of viability, as well as lowered levels of apoptosis.  Thus, 
Bcl-2∆ was successful in not only enhancing protein production, but also the long term health of the 




C2C12 mouse myoblasts transfected with pO2Ybp were compared to those 
transfected with the original plasmid vector, p5HRE-d2EGFP, in order to verify the 
sensitivity of the hypoxia inducible construct.  Both transfectants show a similar trend 
for upregulation of fluorescence protein production as the oxygen level dropped from 
21% to 0%.  The induction was exponential in nature, showing a dramatic rise below 
the 5% O2 level.  Three additional vectors were constructed in order to compare the 
efficacy of Bcl-2∆, as well as the hypoxia inducible promoters.  When cells were 
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placed under the various oxygen conditions (0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 %), those 
that contained the vectors with CMV promoters (pCYbp, pCYp) produced 
significantly more fluorescence than those with the 5HRE promoters (pO2Ybp, and 
pO2Yp).  However, cells that contained the hypoxia sensitive promoters were able to 
produce more protein as the oxygen levels decreased, where as those with the 
constitutive CMV promoters declined in protein expression.  Within each type of 
promoter construct, cells that were able to manufacture Bcl-2∆ were always able to 
out-produce EYFP as compared to those that were unable.  This indicated that Bcl-2∆ 
was crucial for helping the cell’s metabolic functions despite the promoter system 
used.  An examination of the transient expression of EYFP by these four plasmids 
also indicated the same effects of Bcl-2∆ and 5HRE.  In order to prove the utility of 
Bcl-2∆ in counteracting hypoxia in an encapsulation environment, it was necessary to 
examine the long-term health of the transfected cells.  Cells transfected with pO2Ybp 
not only indicated a higher viability when compared to those transfected with pO2Yp, 
but also a lower level of apoptosis at every oxygen level tested.  Thus, the differential 
expression of Bcl-2∆ using the 5HRE promoter has been shown to enhance not only 
protein productivity under hypoxic conditions, but also resistance to necrosis and 
apoptosis. 
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4. Biocompatible Cellular Scaffold for Encapsulating Cells  
4.1 Introduction 
In the field of tissue engineering there is great interest in designing cellular 
scaffolds that are not only biocompatible, but also physically and biochemically 
robust.  Hydrogels made from thermally cooled gelatin are one of the most commonly 
used support matrices for mammalian cell growth [12].  The prevalence of gelatin 
hydrogels is due mainly to their ability to closely simulate the native environment of 
mammalian cells since gelatin is the basic building block of collagen, a major 
component of the extracellular matrix (ECM) [12-14].  The employment of these 
natural biopolymers thus offers a growth medium that is highly biocompatible with 
encapsulated cells, as well as host tissues.  Nevertheless, these physical gelatin 
hydrogels are prone to premature degradation by proteolytic enzymes, such as 
gelatinase and collagenases or by simply melting [12].  Many researchers have sought 
to create more permanent hydrogels by using either uv-light or chemical crosslinkers 
(e.g. glutaraldehyde, carbodiimide, diphenylphosphoryl azide) [13, 20, 117].  Despite 
the improved mechanical strength and proteolytic stability of these hydrogels, the 
crosslinkers often elicit either cytotoxic side-effects or immunological responses from 
the host [15-20].  These effects in turn diminish their overall applicability as 
crosslinking agents.  Thus, there is a need to develop cellular scaffolds that do not 
make concessions for either the biocompatibility or the physical and biochemical 
stabilities of the hydrogel.   
To overcome the need to compromise either property, a naturally occurring 
protein crosslinking enzyme, transglutaminase, was used in this part of the work to 
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form thermally stable hydrogels from gelatin.  Transglutaminase functions by 
catalyzing the formation of covalent N ε-(γ-glutamyl) lysine peptide bonds between 
individual gelatin strands in order to form a permanent network of polypeptides [21, 
22].  This enzyme is ubiquitous in nature, being found among many species of the 
plant and animal kingdoms (e.g. peas, oysters, shrimps, tunas, chickens, cows, and 
humans) [23].  Microbial transglutaminase (mTG) is one form of the protein that is 
also innocuous [23].  This enzyme is commonly used in food manufacturing 
processes that are approved for human consumption by the US Food and Drug 
Administration [21].  The functional independence of mTG with respect to 
proenzymes or calcium ions, and its high level of activity over a wide range of 
temperatures (~50% at 37oC, max at 50oC) and pH values (~90% between 5 to 8), 
makes the enzyme amenable to a wide variety of gel formation and cell encapsulation 
techniques and conditions [132-134].  The improved mechanical strength and short 
amount of time (< 30 min for 4% gelatin at 37 oC) that mTG needs to form a 
permanent gelatin network also makes this type of hydrogel appropriate for live 
surgery procedures, as well as injectable tissue engineering applications [135].  To 
advance the usage of mTG towards these applications, the work here seeks to (1) 
demonstrate the biocompatibility of mTG crosslinked gelatin hydrogels as 3D cellular 
scaffolding media, and (2) to characterize the tuneable degradability of these 
hydrogels.  Biocompatible cellular scaffolds with customizable degradation rates can 
potentially be utilized in a wide variety of applications, ranging from the immuno-
isolative encapsulation of cells to time-released delivery of cells for regenerative 
medicine. 
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4.2 Materials and Methods 
4.2.1 Maintenance of Cell Cultures 
The attachment dependent human embryonic kidney cell line, HEK293 (Flp-
In™-293, Invitrogen) was cultured in Dulbecco’s Modified Eagle’s Media containing 
high glucose (4.5 g/L), GlutMAX™ I (3.97 mM) (DMEM, Invitrogen), with added 
fetal bovine serum (10%, FBS, Sigma), and zeocin (100 mM, Invitrogen) (complete 
media).  Cells were cultured in 75 cm2-tissue culture flasks (Costar) and subcultured 
every two to three days as the population approached 80-90% confluency.  Cells were 
passaged by first aspirating the spent media and then rinsing with Dulbecco’s 
Phosphate Buffer Solution without Ca2+ or Mg2+ (DPBS-cm, Invitrogen).  Rinsed 
cells were then incubated in 2 mL of a 0.25% Trypsin with 0.03% EDTA solution 
(Sigma) for 5 minutes under their normal growth environment (37 oC, 8% CO2 
incubator).  Cells were passaged with a 1:10 split ratio and supplemented with fresh 
complete media up to 12 mL for further growth.  
4.2.2 Cell Encapsulation and Culture 
Three dimensional cell encapsulates were formed by mixing HEK293 cells 
with 4% gelatin and mTG solutions.  Both gelatin and mTG stock solutions were 
sterile filtered and equilibrated in a 37 oC water bath for 20 min prior to mixing with 
cells in order to prevent heat shock.  Encapsulates were formed in white-wall, clear-
bottom, 96-well tissue culture plates (Costar) with 60 µL/well.  HEK293 cells were 
used at a density of 2,000 cells per 60 µL.  Mixtures of cells and gel were 
immediately aliquoted into well plates in order to avoid thermal cooling.  The cell 
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encapsulates were incubated under normal cell culture conditions (37 oC, 8% CO2) 
with an overlay of 100 µL of complete media. 
4.2.3 In Situ Cell Proliferation Assay 
The proliferation of encapsulated HEK293 cells was monitored with two 
membrane-permeable nucleic acid dyes, SYTO-16 and Hoechst 33342 (Molecular 
Probes; Invitrogen).  Although both dyes can bind DNA, SYTO-16 can also stain 
RNA, cytoplasm, and mitochondria.  Both dyes have the property of fluorescing only 
when bound to nucleic material, but not while they are free nor simply interacting 
with proteins such as gelatin.  Cell encapsulates were stained within the 96-well 
plates by first aspirating the media overlays and then incubating each well with 60 µL 
of either dye at 2x concentrations (SYTO-16 = 2 µM, max Ex/Em = 489/520 nm; 
Hoechst 33342 = 20 µg/mL, max Ex/Em = 350/460 nm).  Stock reagents were made 
with Dulbecco’s Phosphate Buffer Solution (DPBS, Invitrogen), and stored in the 
dark at 4 oC until needed.  The fluorescence of stained cells was measured with a 
LS55 fluorescence microplate reader (Perkin Elmer).  Since fluorescence intensity 
measurements were found to vary with incubation time (data not shown), an arbitrary 
incubation period of 4 hr was fixed for all in situ assays.  Calibration curves between 
cell number and fluorescence intensity within each well were developed for both 
SYTO-16 and Hoechst 33342 stains.  SYTO-16 staining produced a nonlinear 
correlation between cell number and fluorescence, presumably due to saturation 
(Figure 4.1).  This was less suitable as a calibration curve as compared to Hoechst 





















Figure 4.1  In situ monitoring of proliferation for gelatin encapsulated cells was attempted with both 
SYTO-16 and Hoechst 33342 nucleic acid dyes.  SYTO-16 staining produced a non-linear 
relationship, while Hoechst 33342 staining generated a linear correlation of 5.05 x 105 cells/RFU (r2 = 
0.98).  This calibration curve was generated from HEK293 cells encapsulated in 60 µL of 4% mTG-
Gel in 96-well plate using a 4 hr incubation period. 
 
4.3 Results and Discussion 
The proliferation of mTG-Gel encapsulated HEK293 cells, with an initial 
concentration of 2,000 cells/well, was monitored with Hoechst 33342 staining for a 
three week period.  Negative controls using gelatin hydrogels without any cells were 
made for each sampling time point.  Cell numbers were calculated by multiplying the 
normalized ratio of fluorescence intensity (RFUsample / RFUnegative control) by the initial 
cell concentration.  A plot of these values indicated that HEK293 cells were indeed 

















Figure 4.2  HEK293 cells (2,000 cells/well) were encapsulated in the mTG crosslinked gelatin 
hydrogels (60 µL/well) were initially seeded into 96-well plates with white walls and clear bottoms.  
Hoechst 33342 staining (4 hr incubation) showed that encapsulated cells were growing in clusters, and 











Figure 4.3  HEK293 cells stained with Hoechst 33342 nuclear dye can be seen proliferating while they 
are encapsulated in mTG crosslinked gelatin hydrogels.  Cells formed spherical clusters and 
proliferated linearly with time. 
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Images of the fluorescently stained cells (Figure 4.3) showed that singly 
encapsulated cells were replicating in place and forming cellular clusters within the 
hydrogels.  Similarly, encapsulated HEK293 cells that were cast in 6-well tissue 
culture plates and grown for over one month were also observed to form clusters 1-2 
mm in diameter.  When the hydrogels were masticated and incubated in a 0.25% 
Trypsin + 0.03% EDTA solution at 37 oC for 20 minutes, the cell clusters were 
released.  These clusters, when incubated under normal cell culturing conditions, 
were able to spread out and re-colonize plate surfaces (Figure 4.4A).  Released cells 
that were of smaller cluster sizes or even singlets were also able to re-attach and 
propagate (Figure 4.4B).  Since clusters could only have formed within the 3D 
environment of the hydrogels, these results definitively prove that HEK293 cells were 














Figure 4.4  Encapsulated HEK293 cells were released by masticating the mTG-Gels followed by a 20 
minute incubation with a 0.25% Trypsin + 0.03% EDTA solution at 37 oC.  Released cells appeared as 
clusters (A), as well as singlets (B).  Both of these forms of released cells were able to re-attach to 
tissue culture plates under normal incubation conditions (37 oC, 8% CO2).
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4.4 Conclusions 
The objective of this portion of the work was to demonstrate that gelatin 
hydrogels, crosslinked by microbial transglutaminase (mTG), were biocompatible 
towards encapsulated cells, such that they may be used as a 3D cellular scaffold.  The 
ability of HEK293 cells to proliferate within the hydrogel, as well as to re-attach to 
cell culture surfaces once released from encapsulation proved that mTG crosslinked 
hydrogels were indeed biocompatible. 
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5. Transglutaminase Crosslinked Gelatin Hydrogels as Tissue 
Engineering Scaffolds 
5.1 Introduction 
From previous work we have demonstrated that mTG-Gels are indeed 
compatible with encapsulated mammalian cells.  To further extend the applicability of 
mTG-Gels, however, it is also important to demonstrate how well these hydrogels can 
withstand thermal and proteolytic degradation, which are major concerns for natural 
biopolymer-based hydrogels.  It is also interesting to see how the degradation rate of 
mTG-Gels may be controlled to suit different applications.  Hydrogels with slow 
degradation rates may serve well as an immuno-protective encapsulation material, 
whereas hydrogels with longer degradation rates, on the order of days or weeks, can 
be utilized for slow delivery of cells in regenerative medicine.  This portion of the 
work investigates how, and at what rate, mTG-Gels are degraded under simulated 
physiological conditions, as well as seeks a mean for controlling its degradability. 
 
5.2 Material and Methods 
5.2.1 Transglutaminase Crosslinked Gelatin Hydrogels 
Gelatin hydrogels were made by three different methods, giving rise to 
thermal hydrogels (T-Gels), mTG crosslinked hydrogels (mTG-Gels), and hydrogels 
that are initially cooled before crosslinking with mTG (HybriGels).  T-Gels are 
common physical gels formed by first dissolving 300-bloom gelatin (Type A, Sigma) 
in DMEM+FBS at 70 oC for 10 min, followed by sterile filtration through 0.22 µm 
SteriFlip (Millipore) media filters before thermally setting at 4 oC for 24 hr.  These 
76 
hydrogels are not permanent and are thermally reversible.  Enzyme crosslinked mTG-
Gels are made by mixing dissolved gelatin with a 10% (m/v) stock solution of mTG 
(Ajinomoto, Inc.).  Stock mTG solution is made by first dissolving mTG powder in 
DMEM+FBS at 50 oC for 10 min and then sterile filtering through a 0.22µm Millex 
(Millipore) syringe filters.  Dissolved gelatin and mTG solutions are mixed with a 
final mass ratio of 0.2 g-mTG/g-gelatin.  The crosslinking reaction is allowed to take 
place in a cell culture incubator set at 37 oC for 24 hours.  HybriGels were formed by 
first cooling a gelatin solution at 4 oC for 12 hours without mTG.  Afterwards, an 
equal volume of a 10% mTG stock solution was overlaid on top of the thermal 
hydrogel to start the crosslinking.  This reaction phase was allowed to take place 
within an incubator at 37 oC for another 12 hour. 
5.2.2 Thermal and Proteolytic Degradation of mTG Crosslinked Hydrogels 
The three types of gelatin hydrogel were tested for their ability to resist 
thermal and proteolytic degradation.  Two milliliter volumes of each hydrogel were 
cast in individual 35mm Petri dishes (9.6 cm2) and allowed to set overnight before 
placing each into their respective treatments.  Thermal stability was examined by 
incubating the hydrogels under a DPBS solution at 37 oC.  Proteolytic stability was 
examined by incubating the hydrogels in a 200 mL bath of 0.25% Trypsin plus 0.03% 
EDTA at room temperature (RT).  To elucidate the mechanism by which degradation 
occurred, mTG crosslinked hydrogels were examined for characteristics of either 
surface or bulk degradation.  Surface dependence was examined by setting 10% 
HybriGels in Petri dishes with variable surface areas (9.6, 28.3, and 78.5 cm2) while 
maintaining a fixed height (0.2 cm).  Bulk degradation was studied by setting the 
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same gel in dishes with variable volumes (1, 3, and 4 mL), while maintaining a fixed 
surface area (9.6 cm2).  All treatments were performed on an orbital shaker (75 rpm).  
Petri dishes were weighed on an analytical balance (Mettler Toledo AE50) before 
gels were cast and every 30 min after formation until the gel has fully degraded. 
5.3 Results and Discussion 
5.3.1 Thermal and Proteolytic Stability of mTG-Gels 
Beyond exploring the biocompatibility of mTG crosslinked hydrogels, it was 
also important to characterize the thermal and proteolytic stability of this novel 
cellular scaffold.  Four percent T-Gels placed in a DPBS bath, equilibrated at 37 oC, 






















Figure 5.1 Exposure of the three hydrogels (T-Gel, mTG-Gel, and HybriGel) in a 37 oC bath of 




The same 4% gelatin hydrogels that were crosslinked with mTG (4% mTG-
Gel), however, were extremely stable at 37 oC.  The mass of these hydrogels was 
essentially unchanged over a 4 hr period.  On the basis of these results, it was 
predicted that the mTG-Gel would also be more resistant to degradation by the model 
proteolytic enzyme, trypsin.  However, the mTG-Gel was slightly less stable as 
compared to the thermally formed T-Gel, resulting in respective degradation rates of 

























Figure 5.2 Although 4% mTG-Gels were thermally stable, they were slightly less resistant to 
proteolysis by trypsin.  HybriGels were developed by first thermally cooling gelatin and then 
crosslinking with a 10% mTG overlay.  The resultant hydrogel was both thermally stable and as 





Figure 5.3 Gelatin hydrogels formed with initial cooling, to create a physical gel, before crosslinking 
with mTG were found to be consistently more resistant to proteolysis as compared to hydrogels that 
were crosslinked before cooling (mTG-Gels).  An explanation may be that thermal cooling allows 
gelatin to first self-organize into a tight network of polypeptides through hydrogen bonding.  Once 
gelatin has formed this network, there are more potential junction points where crosslinking can occur, 
creating a denser permanent hydrogel.  mTG-Gels, however, were unable to form this tight network 
since mTG is immediately crosslinking gelatin polypeptides.  The result is a less tightly packed 
hydrogel with a larger mesh size, which may be more susceptible to proteolytic attack 
80 
Given the same finding upon multiple replications of the experiment, it was 
hypothesized that mTG-Gels may be more susceptible to degradation because the 
mTG is creating crosslinks before the gelatin polypeptides have a chance to form a 
tight network (Figure 5.3).  Thus, mTG-Gels would have a higher mesh size than T-
Gels, allowing them to be even more susceptible to proteolytic attack despite being 
thermally stable.  To challenge this hypothesis, 4% gelatin solutions were allowed to 
cool completely, for 12 hr, before adding an overlay of an equal volume of a 10% 
mTG enzyme solution.  The mTG overlay was allowed to incubate with the thermal 
gel for another 12 hr at 37 oC, creating a hydrogel that would theoretically have the 
same mesh size as a thermally cooled hydrogel along with the proteolytic stability of 
crosslinked mTG-Gels.  When these new hybrid hydrogels (dubbed HybriGels) were 
subjected to the same trypsin bath as before, they were found to be consistently more 
resistant to proteolytic degradation.  The rate of degradation was in fact similar to T-
Gels (Figure 5.4).  To confirm that these gels were thermally stable they were 
exposed to a 37 oC DPBS solution.  These HybriGels proved to be resistant to thermal 
degradation, as no mass was lost over a 4 hr period. 
5.3.2 Tuneable Degradability of HybriGels 
Since degradation rates of hydrogels can typically be influenced by polymer 
and crosslinking densities (mesh size), increasing gelatin concentration may be a 
simple method of retarding gel degradation rates.  Four concentrations of HybriGels 
(4, 10, 15, and 25% gelatin) were tested for their resistance to proteolytic degradation 
by trypsin.  Measurements of fractional mass remaining in the hydrogels showed that 
degradation rates decreased as a function of increasing gelatin concentration, as 
81 
expected (Table 5.1).  The reduction in degradation rate, however, was not linear with 
respect to gelatin concentration, where a sharp deceleration in proteolysis was 





Table 5.1 Thermal and enzymatic degradation rates for various forms of hydrogels 
 
Hydrogel Form 37oC DPBS
Gelatin (m/v % ) 4 4 10 15 25
T-Gel 43.30 16.47  --  --  --
mTG-Gel -0.15 19.00  --  --  --
HybriGels 0.22 17.41 3.03 2.12 0.92
Pre-Soaked HybriGels  --  -- 6.32 3.28  --
Degradation Rates (µg/min)

























Figure 5.4 The proteolytic degradation rate of HybriGels was found to be adjustable based on the 
amount of gelatin in the hydrogel (4, 10, 15, and 25%).  A disproportionate drop in degradation rate 
between 4% and 10% HybriGels may indicate that below a critical mesh size the trypsin may be 
limited to the surface of denser gels. 
 
 
This disproportionate decrease in the degradation rate may reflect a critical 
mesh size necessary for trypsin to penetrate the hydrogel beyond the surface.  To 
investigate whether or not proteolysis was occurring mainly due to surface or bulk 
mechanisms, 10% HybriGels were set in Petri dishes with either fixed gel height and 
variable surface areas or fixed area and variable volumes.  Indeed, the degradation 
rate was strongly affected by the change in surface area and than by the change in 
volume of the hydrogel (Figure 5.5).  This indicates that the degradation of 10% 
HybriGels is dominated by surface erosion, but there is still slight bulk erosion.  This 
phenomenon would likely apply to the HybriGels of higher concentrations, whereby 
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further increasing the gelatin content only serves to linearly decrease the rate of 

































Figure 5.5 A study to elucidate the mechanism by which trypsin degrades 10% HybriGels.  
Proteolysis occurs mainly by surface erosion. 
 
 
To extend the applicability of using mTG crosslinked hydrogels as cellular 
scaffolds in vivo, it was interesting to see how degradation rates may be affected by 
hydration content.  To examine this factor, 10% and 15% HybriGels were formed as 
before and with pre-soaking in DPBS overnight before performing degradation 
experiments with trypsin.  As Figure 5.6 shows, the pre-soaking in DPBS tended to 
swell the hydrogels, making them more susceptible to proteolytic degradation in both 
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gelatin concentrations.  This result indicates that HybriGels may have slightly higher 



















10% HybriGel 10% HybriGel*
15% HybriGel 15% HybriGel*
  
Figure 5.6 Swelling studies were done to determine how proteolytic degradation rates would be 
affected by water content.  10% and 15% HybriGels that were pre-soaked in DPBS overnight (*) were 




The discovery of a process to first thermally set a gelatin solution followed by 
enzymatic crosslinking with mTG (HybriGels), resulted in a hydrogel that was both 
thermally stable and slightly more resistant to proteolytic attack than hydrogels 
formed by concurrently mixing mTG with dissolved gelatin (mTG-Gels).  
Measurement of degradation rates under conditions of either variable surface areas or 
volumes of 10% HybriGels indicated that degradation occurred mainly through 
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surface-dependant mechanisms.  This demonstrated that encapsulated cells would be 
well insulated from proteolysis should they be implanted into a host body.  
Furthermore, degradation rates of HybriGels were found to be customizable based on 
the level of gelatin used to form the hydrogel.  Gelatin concentrations above 10% 
were found to be much more resistant to degradation compared to the 4% hydrogels.  
Although the ability of cells to survive direct encapsulation by these denser hydrogels 
was not examined, they may serve as an outer protective coating for cells that are 
encapsulated by 4% mTG-Gels.  Thus, successive layers of hydrogels with different 
densities can serve as either a cellular scaffold (4%) or a protective encapsulation 
(25%) biomaterial.  Utilizing mTG-Gels with customizable degradation rates may 
also provide a method of delivering regenerative cells in a controlled manner. 
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6. Diffusion of hIL2 from Encapsulated Cells 
6.1 Introduction 
To develop a biomaterial that is suitable for encapsulating cells, it is not only 
important to provide biocompatibility, but also functionality.  One such functionality 
is the ability of the biomaterial to retain engineered cells while maintaining a low 
level of diffusion barrier.  This functionality is important with respect to facilitating 
nutrient and oxygen transport, as well as diffusion of therapeutic proteins that 
engineered cells are secreting.  As shown previously, mTG-Gels made by 
enzymatically crosslinking gelatin with transglutaminase, appear to have high 
biocompatibility, as well as tunable resistance to proteolytic degradation.  In this 
portion of the work, the diffusivity of human interleukin 2 from engineered cells 
through 4% mTG-Gels was examined in order to characterize its protein transport 
capabilities.  To accomplish this, HEK293 cells were transfected with either one of 
two plasmids.  The first is pF2, which encodes a secreteable hIL2 gene along with a 
bicistronically expressed destabilized DsRed-Express fluorescent marker.  The 
second, pF3, is an analogous plasmid, having the additionally ability to induce the 
production of an anti-apoptotic protein, Bcl-2∆, based on increasing degrees of 
hypoxia.  Diffusion cells containing three different thicknesses of mTG-Gels were 
used to determine the diffusion coefficient of hIL2 for comparison to that obtained 
from the encapsulated cells.  A mathematical model was also developed to describe 
both the transient and steady state hIL2 transport behavior through the hydrogel 
membrane.
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6.2 Materials and Methods 
6.2.1 Maintenance of Cell Cultures 
The attachment-dependent human embryonic kidney cell line, HEK293 (Flp-
In™-293, Invitrogen), was cultured in Dulbecco’s Modified Eagle’s Media 
containing high glucose (4.5 g/L), GlutMAX™ I (3.97 mM) (DMEM, Invitrogen), 
with added fetal bovine serum (10%, FBS, Sigma), and zeocin (100 mM, Invitrogen) 
(complete media).  Cells were cultured in 75 cm2-tissue culture flasks (Costar) and 
subcultured every two to three days as the population approached 80-90% 
confluency.  Cells were passaged by first aspirating the spent media and then rinsing 
with Dulbecco’s Phosphate Buffer Solution without Ca2+ or Mg2+ (DPBS-cm, 
Invitrogen).  Rinsed cells were incubated in 2 mL of a 0.25% Trypsin with 0.03% 
EDTA solution (Sigma) for 5 minutes under their normal growth environment (37 oC, 
8% CO2 incubator).  Cells were passaged with a 1:10 split ratio, and supplemented 
with fresh complete media up to 12 mL for further growth.  
6.2.2 mTG-Gel Formation 
Enzyme crosslinked gelatin hydrogels (mTG-Gels) as both cell overlays and 
diffusion cell membranes were formed by mixing 300-bloom gelatin (Type A, Sigma) 
and microbial transglutaminase (mTG, lot # 97.12.04, Ajinomoto) dissolved in 
complete media.  Each solution was heated to 50 oC for 10 min, and sterile filtered 
through 0.22 µm SteriFlip (Millipore) media filters.  The mTG-Gels have a final 
gelatin concentration of 4% (g/mL) and an mTG mass ratio of 0.2 g-mTG/g-gelatin.  
The crosslinking reaction was performed in a cell culture incubator set at 37 oC for 24 
hours. 
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6.2.3 Plasmid Constructs 
The first expression vector used in this study, pF2, contains an assembly of 
four gene elements:  the human interleukin-2 (hIL2) gene, its Ig- κ secretion signal, 
an internal ribosome entry site (IRES), and a Destabilized DsRed-Express (DsExDR) 
fluorescent protein marker.  The secreteable hIL2 (ShIL2) fragment was first derived 
from a previously constructed vector called pSIEG.  This vector was made by PCR 
extraction of the hIL2 gene from pBlueBacHis2-GFPuv/hIL2 [123], using the 
following primers:  5’- AAT GTC GAC AAA TGG CAC CTA CTT CAA GTT CTA 
CAA A -3’ and 5’- ATT ACC GGT TTC TTG TCA TCG TCA TCT CAA GTT AGT 
GTT GAG ATG ATG CTT TG -3’.  The first primer contained a Sal I restriction site 
and the second primer has enterokinase (EK) and Age I restriction sites.  The blunt 
PCR fragment was first ligated to pCR-Blunt II-TOPO (pCR, Invitrogen) before 
digesting with Sal I and Age I restriction enzymes.  The digested fragment was then 
ligated into the corresponding unique cloning sites of pEGFP1-N1 (Clontech).  Hind 
III and Not I were then used to restrict the hIL2-EK-EGFP fusion gene for ligation 
into pSecTag2A/hygro (Invitrogen) in order to add on the Ig-κ secretion signal.  The 
following primers were used to extract ShIL2 from pSIEG: 5’- GAA GAT CTG CCG 
CCA CCA TGG AGA CAG ACA CAC TCC TGC TAT -3’ and 5’- GGA TCC GCG 
TTA TCA AGT TAG TGT TGA GAT GAT GCT TTG ACA AAA -3’.  The first 
primer contained a Bgl II restriction site and a Kozak consensus sequence, which was 
used to further increase translation efficiency in eukaryotic cells [51].  The second 
primer introduced a BamH I restriction site.  The pCR plasmid was again used as an 
intermediary cloning vector.  The secreteable hIL2 gene was excised with Bgl II and 
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BamH I digestion and ligated into pIRES2-DsRed2 (Clontech) in order to add the 
IRES bicistronic element.  The ShIL2-IRES fragment was then re-extracted via PCR 
and ligated to pDsRed-Express-DR (Clontech) in order to add on the red fluorescent 
protein marker gene.  The following primers: 5’-GAA GAT CTG CCG CCA CCA 
TGG AGA CAG ACA CAC TCC TGC TAT -3’ and  5’- TCC CCG CGG GGA TGT 
GGC CAT ATT ATC ATC GTG TTT TTC AAA G -3’ were used.  The first primer 
was the same as the one used in the previous cloning procedure.  The second primer 
contained a Sac II restriction site.  The pCR plasmid was used as an intermediary 
cloning vector.  The final expression vector, pF2, was constructed by using PCR to 
extract the ShIL2-IRES-DsExDR fragment using the following primers: 5'- CGA 
CAA ATG GCA CCT ACT TCA A -3' and 5'- GTC GCG AAT TTT AAC AAA 
ATA TTA ACG C -3', and directly ligating it to the host vector, pSecTag/FRT/V5-
His-TOPO (Invitrogen). 
The second vector, pF3, contains all the same genetic elements of pF2, with 
the addition of an anti-apoptotic gene, bcl-2∆, place downstream of a hypoxia 
inducible promoter, 5HRE-hCMVmp (5HRE).  A vector, dubbed pCYbn, which was 
generously donated by M.J. Betenbaugh (Johns Hopkins University), was digested 
with NheI and EcoRI restriction enzymes to obtain bcl-2∆.  This gene was then 
ligated downstream of a human cytomegalovirus (CMV) promoter in the pIRESpuro3 
(Invitrogen) cloning vector, using the respective enzyme sites, forming the vector in 
pCYbp.  The CMV promoter was subsequently replaced with the 5HRE promoter 
derived from the p5HRE-d2EGFP vector, generously provided by J.M. Brown 
(Stanford University).  This promoter was originally constructed by fusing five 
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hypoxia responsive elements (HRE) in tandem upstream of a minimal CMV 
promoter.  This promoter was extracted by PCR from p5HRE-d2EGFP using the 
following primers: 5'- TAA TTC GCG ACA TAT GGG TAC CGA GCT TTT CT -3' 
and 5'- GCA ATG CTA GCG AAT GCC AAG CTT CTA GT -3', which contained 
NruI and NheI restriction sites, respectively.  The exchange of the promoters was 
mediated by digestion and ligation of the respective NruI and NheI sites on the PCR 
product and pCYbp, to form pO2Ybp.  Since this vector contains an EYFP gene 
between the hypoxia inducible promoter and bcl-2∆, it was removed by first using 
PCR to extract the bcl-2∆ gene with the following primers: (+Nhe I) 5'- TTG CTA 
GCA TGG CGC ACG CTG -3' and (+Not I) 5'- AAG CGG CCG CGG ATC CGA A 
-3' (+Not I) and re-ligating it back into pCYbp, which effectively deleted the EYFP 
gene.  The 5HRE- bcl-2∆ fragment was then extracted by PCR using the following 
primers: (+NruI) 5'- TCG CGA TCG AGC CAC AGT G -3' and 5'- TCA CTT GTG 
GCC CAG ATA GG -3', and ligated into pSecTag/FRT/V5-His-TOPO (Invitrogen).  
A large gene segment upstream of 5HRE-bcl-2∆, flanked by two NruI sites, was 
excised, and replaced with the respective fragment from pF2, which contained the 
CMV-ShIL2-IRES-DsExDR gene fragment.  The resultant vector, pF3, thus contains 
all the elements of pF2 along with the capability to produce Bcl-2∆ in response to low 
oxygen conditions. 
6.2.4 Cell Transfection and Encapsulation 
To study the diffusion of hIL2 from HEK293 cells transfected with the pF2 
and pF3 vectors, 2D cell cultures were overlaid with various heights of 4% mTG-Gels 
(0, 0.16, 0.32, and 0.64 cm).  Cells were seeded in black walled, clear bottom, 96-well 
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tissue culture plates (Costar), as shown in Figure 6.1, at a density of 4 x 104 
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Figure 6.1 To study the diffusion of hIL2, HEK293 cells were initially plated in 96-well tissue 
culture plates and transfected with either pF2 or pF3 expression vectors.  The transfected cells were 
then overlayed with various heights of 4% mTG-Gels and a top layer of liquid media.  Human IL2 
secreted from the cell are then measured in the liquid overlay once it has diffused through the 
hydrogel.  DsExDR fluorescence can be quantified photometrically through the clear-bottomed wells. 
 
 
Since fluorescence measurements are to be taken from the cells, it was 
important to obtain an even distribution of cells.  This was achieved by immediately 
centrifuging the 96-well plates after inoculation.  The plates were spun at 500 x g 
(5810R, Eppendorf) using the slowest acceleration setting (# 9) and immediately 
92 
decelerated as slowly as possible (# 9).  This centrifugation procedure quickly placed 
cells at the bottom surface of each well with a uniform distribution. Twenty-four 
hours after inoculation, HEK293 cells were transfected with either pF2 or pF3 vectors 
(0.2 µg/well) using LipofectAmine 2000 (0.5 µL/well, Invitrogen) and OptiMEMI 
(50 µL/well, Invitrogen).  Thirty hours post-transfection, the spent media in each well 
were aspirated, and replaced with the appropriate volumes of 4% mTG-Gels (0, 50, 
100, 200 µL/well, respectively).  After a 6 hr gelation period, the hydrogels were 
overlaid with 100 µL/well of complete media.  All gels and cells were incubated 
under normal cell culturing conditions.  
6.2.5 Fluorescence Microscopy and ELISA 
The transient expression of DsExDR by mTG-Gel overlayed cells was 
monitored with an inverted fluorescence microscope (IX71, Olympus) equipped with 
a TRITC filter cube (Ex: HQ545/30x, Dichroic: Q570LP, Em = HQ620/60m, 
Chroma).  Images of fluorescencing cells were captured by a monochrome digital 
camera (DP30, Olympus) set for a 3 s exposure.  Fluorescence intensity was then 
analyzed with ImageJ (NIH Image) software.  HEK293 cells that were not transfected 
but overlayed with various heights of mTG-Gel were used for background 
fluorescence intensities.  Each vector transfection and gel height combination was 
reproduced in triplicates. 
The detection of hIL2 secretion and diffusion through the hydrogels was 
examined by an Enzyme-Linked Immunosorbent Assay (ELISA).  Supernatant 
samples containing secreted hIL2 were collected from the media overlays within each 
well (50 µL/well).  Samples were stored in a -20oC freezer until the end of the 
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experiment and assayed immediately with an OptEIA Human IL-2 ELISA Kit II (BD 
Pharmingen).  Human IL2 standards within the kit were diluted to eight 
concentrations, ranging from 0 to 500 pg/mL, producing a highly linear fit for the 
standards (r2 > 0.98).  Standards were assayed in duplicates, as instructed by the 
manufacturer, while supernatant samples were always assayed in triplicates. 
6.2.6 Diffusion Cell Experiments 
Diffusion membranes were formed by casting 4% mTG-Gels of various 
thicknesses (0.20, 0.25, and 0.30 cm) in BD Falcon Cell Culture Inserts (BD 






Well-insert with 3µm 
membrane
hIL2 is sampled from 
media within the Well-
insert over time
Well contains media 
with hIL2
mTG-Gels of various 
heights are cast in inserts
 
 
Figure 6.2 A diffusion cells is composed of an outer well, which contains a stock solution of hIL2, 
and an inner well-insert, which contains mTG-Gels of various heights and a liquid overlay.  The liquid 
overlay is sampled over time in order to determine the effective diffusion coefficient of hIL2. 
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Each insert has a polyethylene terephthalate (PET) membrane, which has a 
low protein binding affinity and high permeability.  The membranes each have an 
area of 4.2 cm2, containing 3.0 µm pores at a density of 8 x 105 pores/cm2.  Once the 
hydrogels have been crosslinked for 24 hr, the inserts were lightly rinsed with DPBS 
(2 x 3mL) and placed into individual wells of 6-well tissue culture plates.  A 3 mL 
solution of hIL2 (10 ng/mL, Roche) was then add to the each well, while 3 mL of 
DMEM was added to the inserts.  Supernatant samples (200 µL) were taken from the 
inserts every 4 hours, for 28 contiguous hours.  Equal volumes of DMEM were used 
to replenish each well after each sampling time point.   
The insert arrangement approximates a stirred diffusion cell provided the 
membrane is the controlling transport resistance.  The change in concentration of 
hIL2 due to diffusion across the membrane can be simply described by the following 
mass balance: 
[Rate of hIL2 Leaving Well] = [Rate of hIL2 Transported Across Membrane] (6.2.2.1) 





=−  (6.2.2.2)  
Where: V1 is the volume of the well (cm 3), C1 is the concentration of hIL2 in the well 
(ng cm -3), Am is the area of the membrane (cm2), and Nm is the flux across the 
membrane (ng cm -2 s -1) defined as: 
dx
dC
DN mmm −≡  (6.2.2.3) 
To solve this equation and relate the concentration of hIL2 that is within the 
membrane (Cm) to measurable quantities, such as the concentration on both sides of 
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the membrane (C1 and C2), the diffusion equation across the membrane must first be 













∂  (6.2.2.4) 
If the diffusion time scale across the membrane is assumed to be much smaller than 
the time scale for a concentration change within the wells, a Quasi Steady State 














∂  (6.2.2.5) 
The solution of this second order ordinary differential equation with the boundary 
conditions (Cm= C1 Φ at x = 0) and (Cm = C2 Φ at x = L), where Φ is the partition 
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mm −=−≡Thus:  (6.2.2.7) 
Substituting the right hand side of Equation (6.2.2.7) for Nm in Equation (6.2.2.2) 







dC 11 −=  (6.2.2.8)  
Since it is assumed that there is no accumulation of hIL2 in the membrane, the 
concentration in the insert (C2) must be equal to the initial concentration of hIL2 in 
the well (C0) minus the insert well concentration (C1) for equal insert and well 
volumes.  Using this relationship (C2 = C0 – C1), Equation (6.2.2.5) can be rewritten 










=−  (6.2.2.9) 
Solving this differential equation, using an initial condition of (C1 = C0 at t = 0), 























−  (6.2.2.10)  
After again using the relation (C1 = C0 - C2), the equation above can be expressed in 

























  (6.2.2.10) 
Given the known values of Am = 4.2 cm2, V1 = 3 cm3, Lm = (0.20, 0.25, or 0.30 cm), 
and C0 = 14 ng/cm3, and the measured concentrations of hIL2 in the insert (C2), the 
expression on the left can be plotted again time.  A simple linear regression plot will 
then result in a slope that is equal to the effective diffusion coefficient (Deff ≡ Dm Φ). 
 
6.3 Results and Discussion 
6.3.1 Therapeutic Protein Secretion by Encapsulated HEK293 
Based on measurements of DsExDR fluorescence, transfected HEK293 cells 
that were not overlaid with any mTG-Gel were the least metabolically productive.  
This was true for cells transfected with both pF2 (Figure 6.3) and pF3 vectors (Figure 






















Figure 6.3 Transient DsRed fluorescence in HEK293 cells transfected with the pF2 expression 























Figure 6.4 Transient DsRed fluorescence in HEK293 cells transfected with the pF3 expression 
vector, and overlayed with three mTG-Gel thicknesses. 
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This phenomenon may be attributed to the ability of the gelatin hydrogels to 
simulate a growth environment that is closer in nature to the native conditions of the 
extracellular matrix.  The advantage is of such significance that cells with any amount 
of gelatin were able to produce more fluorescent protein in comparison to cells that 
were simply cultured on a traditional tissue culture surface.  However, as the gelatin 
layer increased in height, the level of fluorescence protein production began to 
decrease proportionally.  This is reasonable given that the gelatin also serves as a 
diffusion barrier for oxygen and nutrients in the liquid media above the gel to reach 
the cells at the bottom of the wells.  Invariably though, HEK293 cells that were 
transfected with pF3, and thus capable of expressing Bcl-2∆, always produced more 
fluorescence at each respective gel thickness.  This finding is consistent with previous 
portions of this work, which showed that Bcl-2∆ not only lessened necrosis and 
apoptosis, but also increased protein production levels in several mammalian cell 
lines.  It is also noteworthy that cells that were either not overlayed or overlayed with 
only a thin layer of mTG-Gel (0.16 cm) were able to sustain an even level of 
fluorescence protein production as time progressed.  Cells that were overlayed with 
more gelatin (0.32 and 0.64 cm) showed a slight decrease in production levels for 
both pF2 and pF3 transfections.  This trend also indicated the effects of either nutrient 
or oxygen deprivation in the thicker overlays. 
With respect to hIL2 secretion and subsequent diffusion, HEK293 cells that 
were not encapsulated had the highest level of protein accumulation (Figures 6.5 – 
5.8).  As the thickness of the gelatin overlay is increased, the amount of hIL2 
accumulation begins to dramatically decrease.  This result is expected since the 
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accumulation rate of a diffusing species is classically proportional to 1/L2, where L is 
the thickness of the overlay.   Consistent with the fluorescence data, cells that were 
transfected with pF3 were able to consistently secrete and accumulate higher levels of 



























Figure 6.5 HEK293 cells were transfected with the pF2 expression vector, and overlayed with three 
mTG-Gel thicknesses.  hIL2 was measured in the media that was covering the mTG-Gel overlays.  



























Figure 6.6 HEK293 cells were transfected with the pF2 expression vector, and overlayed with three 
mTG-Gel thicknesses.  hIL2 was measured in the media that was covering the mTG-Gel overlays.  




























Figure 6.7 HEK293 cells were transfected with the pF3 expression vector, and overlayed with three 
mTG-Gel thicknesses.  HIL2 was measured in the media that was covering the mTG-Gel overlays.  




























Figure 6.8 HEK293 cells were transfected with the pF3 expression vector, and overlayed with three 
mTG-Gel thicknesses.  HIL2 was measured in the media that was covering the mTG-Gel overlays.  
Rates have units of ng/hr-106 cells. 
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6.3.2 Mathematical Modeling of hIL2 Release 
 
The diffusion of hIL2 from the bottom of the well (z = 0), to the top of the 















∂  (6.3.2.1) 
with these initial and boundary conditions: 
 




∂ 0-D=(L,t)Cm  IC, BC1, BC2           
The first boundary condition (z = L) assumes that the volume of media above the 
overlay is very large relative to the volume of gel and the second boundary condition 
(z = 0) assumes that the cells produce hIL2 at a constant rate, as shown in Figures 6.3 
and 6.4 for no overlays.  By introducing the following dimensionless variables:  
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To solve the PDE of (6.3.2.2), the Finite Fourier Transform (FFT) method can be 
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+ ∫  (6.3.2.7b)  
By utilizing Equation (6.3.2.5), BC1’ and BC2’, respectively, the 1st, 2nd, and 4th 



















∫  (6.3.2.7c) −=
which are further reduced by again applying Equation (6.3.2.5) for η = 1: 
ηηλτηθλ [ ),(
0  n ∫ )]dcos( 2)1(2
2
n
1 2−−−=  (6.3.2.7d)  
  (6.3.2.7e) nχλ ⋅−= 2n2







n 2  (6.3.2.8)  
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The general solution of this non-homogeneous first-order ordinary differential 







nχ ⋅= eCn  (6.3.2.9) 
To obtain an expression for the constant of integration, Cn, a transformed initial 
condition based on IC’  must be applied using Equation (6.3.2.4): 0=ηθ



















τχ −=  (6.3.2.11) and 
The solutions obtained for φn(η) in (6.3.2.5) and χn(τ) in (6.3.2.11) can be substituted 
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θ(η,τ) can be reverted to the dimensional concentration, expressed as Cm , by 























































     (6.3.2.13) 
To apply this equation to the experimental data, one must obtain an expression 
for the accumulation, or Q(t), defined as: 
dtCDtQ mm
∂
−= ∫)(  z LZ =∂
 (6.3.2.14)  
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6.3.3 Obtaining the Fluxes and Diffusion Coefficient of hIL2 Secreted by HEK293 
As indicated by the positive x-intercepts of all regression lines in Figures 6.5 
to 6.8, the accumulation of hIL2 in the liquid overlay was marked by an initial lag 
period where no protein was detected.  This lag period can be attributed to both non-
steady state diffusion, as well as a delay in protein expression, since proteins are not 
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immediately produced upon transfection (t = 0).  This expression time lag (texpr) is not 
related to the molecular transport resistance that this study hopes to elucidate, and 
must first be subtracted from all time values in order to obtain data that are 
representative of only diffusional characteristics of the system.  The expression time 
lag can be readily determined by calculating the x-intercepts of regression lines in 
Figures 6.5 and 6.7 for samples that were not overlayed with gelatin, which is 
approximately 11 hr.   
Utilizing the transformed data, which now has no expression time lag, the 
fluxes of hIL2 from transfected cells were determined from samples with the thinnest 
overlays (0.16 cm) presented in Figures 6.5 and 6.7 by applying the steady state 
model expressed in equation (6.5.3.18).  First, the level of hIL2 accumulation, Q, was 
calculated by normalizing all hIL2 (ng/106 cells) values by the unit area of the wells 
(0.3156 cm2).  The data for the two thicker gels were rescaled by the ratio L12/L22, 
where L1 is the thickness of the thinnest gel (0.16 cm) and L2 is the thickness of the 
other two.  A plot of Q versus t is displayed in Figure 6.9 and 6.10 for all three gels. 
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Figure 6.9 Normalized hIL2 accumulation and time were plotted to reveal a transition from transient 
to steady state diffusion of hIL2.  An analysis of the steady state flux, indicated by the linear regression 
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Figure 6.10 Analysis of the steady state flux (circled points), show that HEK293 cells transfected 
with pF3 were producing hIL2 at double the rate (1.83 pg/cm2 hr) of cells transfected with pF2. 
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The linear trend in Q at longer times indicates a steady state rate of hIL2 
accumulation.  Based on equation (6.5.3.18), the slope of the line regressed through 
these data is the flux (No).  HEK293 cells transfected with pF2 had a hIL2 flux of 
0.94 ng/cm2-hr-106 cells.  Cells transfected with pF3 had nearly twice the flux of 1.83 
ng/cm2-hr-106 cells.  To obtain the diffusion coefficient, Equation (6.5.3.18) can be 






=      (6.5.3.19)  
Where L is the thickness of the thinnest gel (0.16 cm), from which the steady 
state assumption was applied and tss is diffusional time lag, represented by the x-
intercept from the regression lines.  Using equation 6.5.3.19, the diffusion coefficients 
of hIL2 (Dm) were 3.5 x 10-7 cm2/s (for pF2 transfections) and 4.1 x 10-7 cm2/s (for 
pF3 transfections), which agree well with each other, as would be expected.   
To demonstrate the validity of the steady state analysis, the diffusion 
coefficients can be plugged into Equation (6.5.3.17) to see how closely it can simulate 
the non-steady state data represented by the two thicker overlays.  As seen in Figures 
6.3 and 6.4, however, the level of DsExDR fluorescence is attenuated as the overlay 
thickness increases, indicating lowered overall level of protein expression.  Thus, the 
fluxes obtained from the thinnest gel cases were rescaled by the level of DsExDR 
fluorescence in each gel thickness with respect to the thinnest gel, as shown in Table 
6.1.  
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Table 6.1 hIL2 flux determined form the thinnest overlay (0.16 cm) must be rescaled by the level of 
DsExDR fluorescence found in the thicker overlays. 
 
pF2 pF3








Utilizing the rescaled fluxes and the diffusion coefficients found from the 





























































Figure 6.11 Comparison of data with simulated hIL2 accumulation using diffusion coefficients 
obtained from steady state analysis and fluxes scaled by DsExDR fluorescence for each overlay 
thickness. 
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As shown in Figure 6.11, the simulated curve fits closely with data obtained 
from the 0.32 cm-overlay, but not from with the 0.64 cm-overlay. 
6.3.4 Measuring Diffusion Coefficient of hIL2 in mTG-Gel 
To better characterize the transport characteristics of the mTG-Gels, diffusion 
cells based on cell culture inserts were modified to measure the effective diffusion 
coefficient of hIL2.  As shown in Figure 6.12, the amount of hIL2 detected on the 
insert-side (C2) was plotted against time in accordance to Equation (6.4.2.10).  The 
initial concentration of hIL2 on the well-side (C0) was also measured by ELISA, and 
found to be 14,518 pg/mL.  The remaining parameters necessary for calculating 
Equation (6.4.2.10) are as follows: Am=4.2 cm2, V1 = 3 cm3, Lm = (0.20, 0.25, and 
0.30 cm).  As expected, the data expressed as the left-hand side of (6.4.2.10) for all 
the gelatin thicknesses fell along the same linear regression line.  The slope of this 
regression is the effective diffusion coefficient, DmΦ = 3.2 x 10-7 cm2/s.  This value is 
well within the expected range of proteins that have similar molecular weights as 
hIL2 (~15 kDa) .  The ratio of this effective diffusion coefficient and the Dm value 
determined from the previous gelatin-overlay experiments reveal that the partition 
coefficient, Φ, for hIL2 between a 4% mTG-Gel and DMEM media is 0.84, which is 
































Figure 6.12 Well inserts filled with three thicknesses of 4% mTG-Gels were used as diffusion cells to 
measure the diffusion coefficient of hIL2. 
 
6.4 Conclusions 
Various methods were used to calculate the diffusion coefficient of hIL2 in 
4% mTG-Gels.  Utilizing a steady state analysis of hIL2 diffusion from HEK293 cells 
overlaid with 0.16 cm of gelatin, average diffusion coefficient of 3.8 x 10-7 cm2/s was 
obtained.  Simulations of the non-steady state data was found to be very consistent 
0.32 cm overlays, but not with 0.64 cm overlays.  This may simply be due to an 
insensitivity in measuring hIL2 diffusion in thick gels, or that cell metabolism is 
affected in a way that is not accountable by scaling the flux by the DsExDR 
fluorescence.  Diffusion cells made from well inserts, however, independently 
showed a very similar effective diffusion coefficient of hIL2 is DmΦ = 3.2 x 10-7 
cm2/s.  Using the results from these two experiments, the partition coefficient is 0.84, 
which is very consistent with a highly hydrated hydrogel (~96% water).
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7. Summary 
7.1 Integrated Non-Invasive System for Quantifying Secreted Human 
Therapeutic hIL2  
Cell encapsulation has been used to treat diabetes, amyotrophic lateral 
sclerosis, and other chronic ailments by the secretion of therapeutic proteins in vivo.  
Detection of these proteins typically requires invasive procedures such as blood 
sampling or device extraction, however.  In this paper, a non-invasive means of 
measuring secreted protein concentration using a co-expressed red fluorescent protein 
marker is developed.  A bicistronic expression vector was constructed for the 
intracellular production of a red fluorescent protein marker and the secreted 
production of human interleukin-2 (hIL2).  The destabilized red fluorescent protein, 
DsExDR, was selected for its rapid turnover, as well as its ability to emit red light, 
which is readily transmitted through mammalian tissue.  Transfections of this 
bicistronic vector into three cell lines C2C12, HEK293, and Jurkat showed linear 
correlations between the expressed proteins, DsExDR (intracellular) and hIL2 
(secreted), with transfection DNA concentration. Correspondingly, there was a linear 
correlation between secreted product (hIL2) and intracellular marker (DsExDR). As 
transfection DNA was increased, Jurkat cells were found to increase secreted hIL2 in 
direct proportion to the accumulated DsExDR.  HEK293 and C2C12 cells expressed 
and secreted significantly more hIL2 than the Jurkat cells, while still maintaining a 
linear relationship. Thus, all three cell lines were suitable hosts for the bicistronic 
expression of DsExDR and expression and secretion of therapeutic hIL2. This 
reporting strategy may find the greatest use in cell encapsulation therapy.
113 
7.2 Counteracting Apoptosis and Necrosis with Hypoxia Responsive 
Expression of Bcl-2∆ 
In the encapsulated environment of a biohybrid artificial organ, cells often 
encounter a deficiency in the availability of oxygen.  This hypoxic condition leads to 
necrosis and apoptosis, and is a fundamental challenge to designing a viable device.  
Several strategies such as inducing vascularization around the implant, 
electrochemically generating oxygen by decomposing water, as well as using 
synthetic oxygen carriers have already been taken to mitigate the detrimental effects 
of hypoxia.  These methods seek to change the environment rather than adapt to it.  
An alternative method is to genetically engineer cells to withstand hypoxia induced 
apoptosis and necrosis.  Specifically, four plasmid vectors were constructed to 
investigate the efficacy of cells producing the anti-apoptotic protein, Bcl-2∆.  The 
first two plasmids contained a constitutive CMV promoter and were either able to 
produce Bcl-2∆ plus a yellow fluorescent marker protein (EYFP) (pCYbp) or simply 
the just EYFP without Bcl-2∆ (pCYp).  Two analogous vectors with hypoxia 
responsive promoters in lieu of the CMV promoters were also constructed (pO2Ybp, 
pO2Yp).  Although these last two vectors showed lower level of EYFP protein 
production at the all oxygen levels (0.0, 0.5, 1.0, 2.0, 5.0, or 21.0 %), they were able 
to increase expression as the oxygen decreased.  The vectors with the CMV 
promoters showed an attenuated level of expression as oxygen levels dropped.  In 
both promoter systems, the presence of Bcl-2∆ enhanced protein production.  When 
examining the amount of protection offered by Bcl-2∆, cells transfected with pO2Ybp 
showed a significantly higher viability and lowered apoptosis as compared to those 
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transfected with pO2Yp.  In summary, Bcl-2∆ was effective at prolonging cell 
viability.  Also, while not a specific objective of our work, we found that Bcl-2∆ 
increased production of hIL2. 
7.3 Biocompatible Cellular Scaffold for Encapsulating Cells 
Gelatin is one of the most commonly used biomaterials for creating cellular 
scaffolds due to its innocuous nature.  In order to create permanent hydrogels, 
however, harmful crosslinking agents are typically used.  To circumvent this problem, 
and create cellular scaffolds that are both physiologically robust and biocompatible, a 
recombinant microbial transglutaminase (mTG) was used as an enzymatic crosslinker 
of gelatin.  The biocompatibility of mTG crosslinked hydrogels (mTG-Gels) was 
demonstrated by observing the proliferation of encapsulated HEK293 cell for over a 
three week period (0.03 day-1).  Released cells were then also able to re-colonized 
tissue culture flasks.   
7.4 Transglutaminase Crosslinked Gelatin Hydrogels as Tissue Engineering 
Scaffolds 
The thermal and proteolytic stabilities of mTG-Gels were challenged by 
submersion in a 37 oC saline solution or a 0.25% trypsin + EDTA enzyme bath at RT.  
mTG-Gels were found to be resistant to both forms of degradation.  A novel 
technique for creating gelatin hydrogels, by first cooling dissolved gelatin followed 
by crosslinking with a 10% mTG overlay, produced hydrogels (HybriGels) that are 
consistently even more resistant to proteolysis.  Further investigation showed that 
degradation occurred mainly through surface-dependent mechanisms.  Degradation 
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rates were found to be adjustable based on gelatin content, such that HybriGels may 
be used for permanent cell encapsulation or time-released regenerative cell delivery. 
7.5 Diffusion of hIL2 from Encapsulated Cells 
Fluorescence measurements of DsExDR from transiently transfected HEK293 
cells showed that 0.16-cm mTG-Gel overlays were more conducive to protein 
production than cells without overlays.  This indicated that the cells may benefit from 
being surrounded by a natural cellular scaffolding biomaterial.  Further increasing the 
gel height led to relatively less fluorescence, most likely due to increased diffusional 
resistances for nutrients and oxygen to the cells.  The increased diffusion barrier was 
readily noted by drastically decreased hIL2 accumulation in the media as the gel 
thickness increased.  For either measurements, intracellular DsExDR fluorescence or 
secreted hIL2 accumulation, it was clear that cells that were able to express Bcl-2∆ 
had a higher level of protein production.  This phenomenon was also observed in the 
rate of hIL2 production from layer of cells without gel overlay: 0.94 pg/cm2-s for pF2 
and 1.83 pg/cm2-s for pF3.  From diffusion cell experiments, the effective diffusion 
coefficient of hIL2 in a 4% mTG-Gel was 3.2 x 10-7 cm2/s.  This value agrees well 
with the diffusion coefficient of 3.9 x 10-7 cm2/s, which was determined from a steady 
state model of protein diffusion from the cell layer through the gel overlay.  The ratio 
of these values represents the partition coefficient, which is equal to 0.82.  The 
diffusion coefficient regressed from the steady state hIL2 data was used to calculate 
values for the unsteady state accumulation, which compared favorably with data 





[1] Aebischer, P., E. Buchser, J.M. Joseph, J. Favre, N. de Tribolet, M. Lysaght, S. Rudnick, and 
M. Goddard, Transplantation in humans of encapsulated xenogeneic cells without 
immunosuppression. A preliminary report. Transplantation, 1994. 58;11: p. 1275-7. 
[2] Aebischer, P., N.A. Pochon, B. Heyd, N. Deglon, J.M. Joseph, A.D. Zurn, E.E. Baetge, J.P. 
Hammang, M. Goddard, M. Lysaght, F. Kaplan, A.C. Kato, M. Schluep, L. Hirt, F. Regli, F. 
Porchet, and N. De Tribolet, Gene therapy for amyotrophic lateral sclerosis (ALS) using a 
polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther, 
1996. 7;7: p. 851-60. 
[3] Clark, H., T.A. Barbari, K. Stump, and G. Rao, Histologic evaluation of the inflammatory 
response around implanted hollow fiber membranes. Journal of Biomedical Materials 
Research, 2000. 52;1: p. 183-192. 
[4] Wu, H., E.S. Avgoustiniatos, L. Swette, S. Bonner-Weir, G.C. Weir, and C.K. Colton, In situ 
electrochemical oxygen generation with an immunoisolation device. Ann N Y Acad Sci, 
1999. 875105-25. 
[5] Mathy-Hartert, M., M.P. Krafft, C. Deby, G. Deby-Dupont, M. Meurisse, M. Lamy, and J.G. 
Riess, Effects of perfluorocarbon emulsions on cultured human endothelial cells. Artif Cells 
Blood Substit Immobil Biotechnol, 1997. 25;6: p. 563-75. 
[6] Patton, J.N. and A.F. Palmer, Engineering temperature-sensitive hydrogel nanoparticles 
entrapping hemoglobin as a novel type of oxygen carrier. Biomacromolecules, 2005. 6;4: p. 
2204-2212. 
[7] Banasiak, K.J., T. Cronin, and G.G. Haddad, bcl-2 Prolongs neuronal survival during 
hypoxia-induced apoptosis. Molecular Brain Research, 1999. 72;2: p. 214-225. 
[8] Oehler, M.K., C. Norbury, S. Hague, M.C.P. Rees, and R. Bicknell, Adrenomedullin inhibits 
hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion 
mechanism for tumour growth. Oncogene, 2001. 20;23: p. 2937-2945. 
[9] Figueroa, B.J., T.M. Sauerwald, A.J. Mastrangelo, J.M. Hardwick, and M.J. Betenbaugh, 
Comparison of Bcl-2 to a Bcl-2 deletion mutant for mammalian cells exposed to culture 
insults. Biotechnol Bioeng, 2001. 73;3: p. 211-22. 
[10] Shibata, T., A.J. Giaccia, and J.M. Brown, Development of a hypoxia-responsive vector for 
tumor-specific gene therapy. Gene Ther, 2000. 7;6: p. 493-8. 
[11] Cao, Y.J., T. Shibata, and N.G. Rainov, Hypoxia-inducible transgene expression in 
differentiated human NT2N neurons - a cell culture model for gene therapy of postischemic 
neuronal loss. Gene Therapy, 2001. 8;17: p. 1357-1362. 
[12] Lee, K.Y. and D.J. Mooney, Hydrogels for tissue engineering. Chem Rev, 2001. 101;7: p. 
1869-79. 
[13] Drury, J.L. and D.J. Mooney, Hydrogels for tissue engineering: scaffold design variables and 
applications. Biomaterials, 2003. 24;24: p. 4337-51. 
[14] Bruce Alberts, D.B., Julian Lewis, Martin Raff, James D. Watson, Molecular biology of the 
cell. 1994, New York: Garland Science. 
[15] Williams, C.G., A.N. Malik, T.K. Kim, P.N. Manson, and J.H. Elisseeff, Variable 
cytocompatibility of six cell lines with photoinitiators used for polymerizing hydrogels and 
cell encapsulation. Biomaterials, 2005. 26;11: p. 1211-8. 
[16] Gendler, E., S. Gendler, and M.E. Nimni, Toxic reactions evoked by glutaraldehyde-fixed 
pericardium and cardiac valve tissue bioprosthesis. J Biomed Mater Res, 1984. 18;7: p. 727-
36. 
[17] Liang, H.C., W.H. Chang, K.J. Lin, and H.W. Sung, Genipin-crosslinked gelatin 
microspheres as a drug carrier for intramuscular administration: in vitro and in vivo studies. J 
Biomed Mater Res A, 2003. 65;2: p. 271-82. 
[18] Barker, H., R. Oliver, R. Grant, and L. Stephen, Formaldehyde as a pre-treatment for dermal 
collagen heterografts. Biochimica et Biophysica Acta (BBA) - General Subjects, 1980. 632;4: 
p. 589-597. 
117 
[19] Choi, Y.S., S.R. Hong, Y.M. Lee, K.W. Song, M.H. Park, and Y.S. Nam, Study on gelatin-
containing artificial skin: I. Preparation and characteristics of novel gelatin-alginate sponge. 
Biomaterials, 1999. 20;5: p. 409-17. 
[20] Choi, Y.S., S.R. Hong, Y.M. Lee, K.W. Song, M.H. Park, and Y.S. Nam, Studies on gelatin-
containing artificial skin: II. Preparation and characterization of cross-linked gelatin-
hyaluronate sponge. J Biomed Mater Res, 1999. 48;5: p. 631-9. 
[21] Yokoyama, K., N. Nio, and Y. Kikuchi, Properties and applications of microbial 
transglutaminase. Appl Microbiol Biotechnol, 2004. 64;4: p. 447-54. 
[22] Yokoyama, K., Y. Kikuchi, and H. Yasueda, Overproduction of DnaJ in Escherichia coli 
improves in vivo solubility of the recombinant fish-derived transglutaminase. Biosci 
Biotechnol Biochem, 1998. 62;6: p. 1205-10. 
[23] Kobayashi, K., K. Hashiguchi, K. Yokozeki, and S. Yamanaka, Molecular cloning of the 
transglutaminase gene from Bacillus subtilis and its expression in Escherichia coli. Biosci 
Biotechnol Biochem, 1998. 62;6: p. 1109-14. 
[24] Henis-Korenblit, S., N.L. Strumpf, D. Goldstaub, and A. Kimchi, A novel form of DAP5 
protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome 
entry site-mediated translation. Mol Cell Biol, 2000. 20;2: p. 496-506. 
[25] Holcik, M. and R.G. Korneluk, Functional characterization of the X-linked inhibitor of 
apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP 
translation. Mol Cell Biol, 2000. 20;13: p. 4648-57. 
[26] Stoneley, M., S.A. Chappell, C.L. Jopling, M. Dickens, M. MacFarlane, and A.E. Willis, c-
Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis. 
Mol Cell Biol, 2000. 20;4: p. 1162-9. 
[27] Cornelis, S., Y. Bruynooghe, G. Denecker, S. Van Huffel, S. Tinton, and R. Beyaert, 
Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. 
Mol Cell, 2000. 5;4: p. 597-605. 
[28] Pyronnet, S., L. Pradayrol, and N. Sonenberg, A cell cycle-dependent internal ribosome entry 
site. Mol Cell, 2000. 5;4: p. 607-16. 
[29] Creancier, L., P. Mercier, A.C. Prats, and D. Morello, c-myc Internal ribosome entry site 
activity is developmentally controlled and subjected to a strong translational repression in 
adult transgenic mice. Mol Cell Biol, 2001. 21;5: p. 1833-40. 
[30] Vazquez, D., Inhibitors of protein synthesis. FEBS Lett, 1974. 40;0: p. suppl:S63-84. 
[31] Blobel, G., P. Walter, C.N. Chang, B.M. Goldman, A.H. Erickson, and V.R. Lingappa, 
Translocation of proteins across membranes: the signal hypothesis and beyond. Symp Soc 
Exp Biol, 1979. 339-36. 
[32] Deshaies, R.J. and R. Schekman, A yeast mutant defective at an early stage in import of 
secretory protein precursors into the endoplasmic reticulum. J Cell Biol, 1987. 105;2: p. 633-
45. 
[33] Garoff, H., Using recombinant DNA techniques to study protein targeting in the eucaryotic 
cell. Annu Rev Cell Biol, 1985. 1403-45. 
[34] Oliver, D.B. and J. Beckwith, E. coli mutant pleiotropically defective in the export of secreted 
proteins. Cell, 1981. 25;3: p. 765-72. 
[35] von Heijne, G., Protein targeting signals. Curr Opin Cell Biol, 1990. 2;4: p. 604-8. 
[36] Alberts, B., D. Bray, J. Lewis, M. Raff, K. Roberts, and J.D. Watson, Proteins Can Move 
Between Compartments in Different Ways Signal Peptides and Signal Patches Direct Proteins 
to the Correct Cellular Address, in Molecular Biology of The Cell, M. Robertson and S.M. 
Cobert, Editors. 1994, Garland Publishing, Inc.: New York. p. 556-558. 
[37] Coloma, M.J., A. Hastings, L.A. Wims, and S.L. Morrison, Novel vectors for the expression 
of antibody molecules using variable regions generated by polymerase chain reaction. J 
Immunol Methods, 1992. 152;1: p. 89-104. 
[38] Harvey, E.N., A General Survey of Bioluminescence - Introduction. Annals of the New York 
Academy of Sciences, 1948. 49;3: p. 329-336. 
[39] Herring, P.J., Bioluminescence in Action. 1978, New York: Academic. 
[40] Hastings, J.W. and J.G. Morin, Bioluminescence.  In Neural and Integrative Animal 
Physiology, ed. C.L. Prosser. 1991, New York: Wiley-Interscience. 131-170. 
118 
[41] Hastings, J.W., Biological diversity, chemical mechanisms, and the evolutionary origins of 
bioluminescent systems. J Mol Evol, 1983. 19;5: p. 309-21. 
[42] Prasher, D.C., V.K. Eckenrode, W.W. Ward, F.G. Prendergast, and M.J. Cormier, Primary 
structure of the Aequorea victoria green-fluorescent protein. Gene, 1992. 111;2: p. 229-33. 
[43] Chalfie, M., Y. Tu, G. Euskirchen, W.W. Ward, and D.C. Prasher, Green fluorescent protein 
as a marker for gene expression. Science, 1994. 263;5148: p. 802-5. 
[44] Davenport, D. and J.A.C. Nichol, Luminescence in Hydromedusae. Proceedings of the Royal 
Society, Series B, 1955. 144399-411. 
[45] Shimomura, O., F.H. Johnson, and Y. Saiga, Extraction, purification and properties of 
aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J Cell Comp 
Physiol, 1962. 59223-39. 
[46] Cutler, M.W., Characterization and energy transfer mechanism of the green-fluorescent 
protein from Aequorea victoria. 1995, Rutgers University: New Brunswick, NJ. 
[47] Yang, F., L.G. Moss, and G.N. Phillips, Jr., The molecular structure of green fluorescent 
protein. Nat Biotechnol, 1996. 14;10: p. 1246-51. 
[48] Ward, W.W., In Bioluminescence and Chemiluminescence: Basic Chemistry and Analytical 
Applications, in Properties of the coelenterate green-fluorescent protein., M. DeLuca and 
D.W. McElroy, Editors. 1981, Academic: New York. 
[49] Morise, J.G., Coelenterate bioluminescence, in Coelenterate Biology: Reviews and New 
Perspectives, L. Muscatine and H. Lenhoff, Editors. 1974, Academics: New York. p. 396-
438. 
[50] Heim, R., A.B. Cubitt, and R.Y. Tsien, Improved green fluorescence. Nature, 1995. 373;6516: 
p. 663-4. 
[51] Kozak, M., An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. 
Nucleic Acids Res, 1987. 15;20: p. 8125-48. 
[52] Haas, J., E.C. Park, and B. Seed, Codon usage limitation in the expression of HIV-1 envelope 
glycoprotein. Curr Biol, 1996. 6;3: p. 315-24. 
[53] Cormack, B.P., R.H. Valdivia, and S. Falkow, FACS-optimized mutants of the green 
fluorescent protein (GFP). Gene, 1996. 173;1 Spec No: p. 33-8. 
[54] Yang, T.T., L. Cheng, and S.R. Kain, Optimized codon usage and chromophore mutations 
provide enhanced sensitivity with the green fluorescent protein. Nucleic Acids Res, 1996. 
24;22: p. 4592-3. 
[55] Olson, K.R., J.R. McIntosh, and J.B. Olmsted, Analysis of MAP 4 function in living cells 
using green fluorescent protein (GFP) chimeras. J Cell Biol, 1995. 130;3: p. 639-50. 
[56] Rizzuto, R., M. Brini, F. De Giorgi, R. Rossi, R. Heim, R.Y. Tsien, and T. Pozzan, Double 
labelling of subcellular structures with organelle-targeted GFP mutants in vivo. Curr Biol, 
1996. 6;2: p. 183-8. 
[57] Cole, N.B., C.L. Smith, N. Sciaky, M. Terasaki, M. Edidin, and J. Lippincott-Schwartz, 
Diffusional mobility of Golgi proteins in membranes of living cells. Science, 1996. 273;5276: 
p. 797-801. 
[58] Ogawa, H., S. Inouye, F.I. Tsuji, K. Yasuda, and K. Umesono, Localization, trafficking, and 
temperature-dependence of the Aequorea green fluorescent protein in cultured vertebrate 
cells. Proc Natl Acad Sci U S A, 1995. 92;25: p. 11899-903. 
[59] Kaether, C. and H.H. Gerdes, Visualization of protein transport along the secretory pathway 
using green fluorescent protein. FEBS Lett, 1995. 369;2-3: p. 267-71. 
[60] Dodds, E., M.G. Dunckley, K. Naujoks, U. Michaelis, and G. Dickson, Lipofection of 
cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER. Gene Ther, 
1998. 5;4: p. 542-51. 
[61] Chiu, W., Y. Niwa, W. Zeng, T. Hirano, H. Kobayashi, and J. Sheen, Engineered GFP as a 
vital reporter in plants. Curr Biol, 1996. 6;3: p. 325-30. 
[62] Crameri, A., E.A. Whitehorn, E. Tate, and W.P. Stemmer, Improved green fluorescent protein 
by molecular evolution using DNA shuffling. Nat Biotechnol, 1996. 14;3: p. 315-9. 
[63] Elowitz, M.B., M.G. Surette, P.E. Wolf, J. Stock, and S. Leibler, Photoactivation turns green 
fluorescent protein red. Current Biology, 1997. 7;10: p. 809-812. 
[64] Sawin, K.E. and P. Nurse, Photoactivation of green fluorescent protein. Current Biology, 
1997. 7;10: p. R606-R607. 
119 
[65] Matz, M.V., A.F. Fradkov, Y.A. Labas, A.P. Savitsky, A.G. Zaraisky, M.L. Markelov, and 
S.A. Lukyanov, Fluorescent proteins from nonbioluminescent Anthozoa species. Nat 
Biotechnol, 1999. 17;10: p. 969-73. 
[66] Wall, M.A., M. Socolich, and R. Ranganathan, The structural basis for red fluorescence in the 
tetrameric GFP homolog DsRed. Nat Struct Biol, 2000. 7;12: p. 1133-8. 
[67] Yarbrough, D., R.M. Wachter, K. Kallio, M.V. Matz, and S.J. Remington, Refined crystal 
structure of DsRed, a red fluorescent protein from coral, at 2.0-A resolution. Proc Natl Acad 
Sci U S A, 2001. 98;2: p. 462-7. 
[68] Baird, G.S., D.A. Zacharias, and R.Y. Tsien, Biochemistry, mutagenesis, and oligomerization 
of DsRed, a red fluorescent protein from coral. Proc Natl Acad Sci U S A, 2000. 97;22: p. 
11984-9. 
[69] Colton, C.K., Engineering challenges in cell-encapsulation technology. Trends in 
Biotechnology, 1996. 14;5: p. 158-162. 
[70] Bevis, B.J. and B.S. Glick, Rapidly maturing variants of the Discosoma red fluorescent 
protein (DsRed). Nat Biotechnol, 2002. 20;1: p. 83-7. 
[71] Clontech, B.B., BD Living Colors User Manual Volume II: Reef Coral Fluorescent Proteins. 
July 2003. 
[72] Colton, C.K., Implantable Biohybrid Artificial Organs. Cell Transplantation, 1995. 4;4: p. 
415-436. 
[73] Dionne, K.E., C.K. Colton, and M.L. Yarmush, Effect of Hypoxia on Insulin-Secretion by 
Isolated Rat and Canine Islets of Langerhans. Diabetes, 1993. 42;1: p. 12-21. 
[74] Monaco, A.P., T. Maki, H. Ozato, M. Carretta, S.J. Sullivan, K.M. Borland, M.D. Mahoney, 
W.L. Chick, T.E. Muller, J. Wolfrum, and et al., Transplantation of islet allografts and 
xenografts in totally pancreatectomized diabetic dogs using the hybrid artificial pancreas. Ann 
Surg, 1991. 214;3: p. 339-60; discussion 361-2. 
[75] Sullivan, S.J., T. Maki, K.M. Borland, M.D. Mahoney, B.A. Solomon, T.E. Muller, A.P. 
Monaco, and W.L. Chick, Biohybrid artificial pancreas: long-term implantation studies in 
diabetic, pancreatectomized dogs. Science, 1991. 252;5006: p. 718-21. 
[76] Lanza, R.P., A.M. Beyer, J.E. Staruk, and W.L. Chick, Biohybrid artificial pancreas. Long-
term function of discordant islet xenografts in streptozotocin diabetic rats. Transplantation, 
1993. 56;5: p. 1067-72. 
[77] Acker, H., Mechanisms and Meaning of Cellular Oxygen Sensing in the Organism. 
Respiration Physiology, 1994. 95;1: p. 1-10. 
[78] Rolfs, A., I. Kvietikova, M. Gassmann, and R.H. Wenger, Oxygen-regulated transferrin 
expression is mediated by hypoxia-inducible factor-1. Journal of Biological Chemistry, 1997. 
272;32: p. 20055-20062. 
[79] Shweiki, D., A. Itin, D. Soffer, and E. Keshet, Vascular endothelial growth factor induced by 
hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992. 359;6398: p. 843-5. 
[80] Melillo, G., T. Musso, A. Sica, L.S. Taylor, G.W. Cox, and L. Varesio, A Hypoxia-
Responsive Element Mediates a Novel Pathway of Activation of the Inducible Nitric-Oxide 
Synthase Promoter. Journal of Experimental Medicine, 1995. 182;6: p. 1683-1693. 
[81] Lee, P.J., B.H. Jiang, B.Y. Chin, N.V. Iyer, J. Alam, G.L. Semenza, and A.M. Choi, Hypoxia-
inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in 
response to hypoxia. J Biol Chem, 1997. 272;9: p. 5375-81. 
[82] Wang, G.L. and G.L. Semenza, Purification and characterization of hypoxia-inducible factor 
1. J Biol Chem, 1995. 270;3: p. 1230-7. 
[83] Semenza, G.L., Perspectives on oxygen sensing. Cell, 1999. 98;3: p. 281-4. 
[84] Chandel, N.S., E. Maltepe, E. Goldwasser, C.E. Mathieu, M.C. Simon, and P.T. Schumacker, 
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad 
Sci U S A, 1998. 95;20: p. 11715-20. 
[85] Chandel, N.S., D.S. McClintock, C.E. Feliciano, T.M. Wood, J.A. Melendez, A.M. 
Rodriguez, and P.T. Schumacker, Reactive oxygen species generated at mitochondrial 
complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - A mechanism of O-2 
sensing. Journal of Biological Chemistry, 2000. 275;33: p. 25130-25138. 
[86] Semenza, G.L., Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. 
Annu Rev Cell Dev Biol, 1999. 15551-78. 
120 
[87] Agani, F.H., P. Pichiule, J.C. Chavez, and J.C. LaManna, The role of mitochondria in the 
regulation of hypoxia-inducible factor 1 expression during hypoxia. Journal of Biological 
Chemistry, 2000. 275;46: p. 35863-35867. 
[88] Haddad, J.J.E., R.E. Olver, and S.C. Land, Antioxidant/pro-oxidant equilibrium regulates 
HIF-1 alpha and NF-kappa B redox sensitivity - Evidence for inhibition by glutathione 
oxidation in alveolar epithelial cells. Journal of Biological Chemistry, 2000. 275;28: p. 
21130-21139. 
[89] Shimizu, S., Y. Eguchi, W. Kamiike, Y. Itoh, J. Hasegawa, K. Yamabe, Y. Otsuki, H. 
Matsuda, and Y. Tsujimoto, Induction of apoptosis as well as necrosis by hypoxia and 
predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res, 1996. 56;9: p. 2161-
6. 
[90] Vaux, D.L., S. Cory, and J.M. Adams, Bcl-2 gene promotes haemopoietic cell survival and 
cooperates with c-myc to immortalize pre-B cells. Nature, 1988. 335;6189: p. 440-2. 
[91] Tsujimoto, Y., Stress-resistance conferred by high level of bcl-2 alpha protein in human B 
lymphoblastoid cell. Oncogene, 1989. 4;11: p. 1331-6. 
[92] Shimizu, S., Y. Eguchi, H. Kosaka, W. Kamiike, H. Matsuda, and Y. Tsujimoto, Prevention 
of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature, 1995. 374;6525: p. 811-3. 
[93] Shimizu, S., Y. Eguchi, W. Kamiike, S. Waguri, Y. Uchiyama, H. Matsuda, and Y. 
Tsujimoto, Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE 
inhibitors: possible involvement of common mediators in apoptotic and necrotic signal 
transductions. Oncogene, 1996. 12;10: p. 2045-50. 
[94] Shimizu, S., Y. Eguchi, W. Kamiike, S. Waguri, Y. Uchiyama, H. Matsuda, and Y. 
Tsujimoto, Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at 
a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene, 
1996. 13;1: p. 21-9. 
[95] Kane, D.J., T. Ord, R. Anton, and D.E. Bredesen, Expression of bcl-2 inhibits necrotic neural 
cell death. J Neurosci Res, 1995. 40;2: p. 269-75. 
[96] Hunter, J.J., B.L. Bond, and T.G. Parslow, Functional dissection of the human Bc12 protein: 
sequence requirements for inhibition of apoptosis. Mol Cell Biol, 1996. 16;3: p. 877-83. 
[97] Huang, D.C., J.M. Adams, and S. Cory, The conserved N-terminal BH4 domain of Bcl-2 
homologues is essential for inhibition of apoptosis and interaction with CED-4. Embo J, 1998. 
17;4: p. 1029-39. 
[98] Borner, C., Diminished cell proliferation associated with the death-protective activity of Bcl-
2. J Biol Chem, 1996. 271;22: p. 12695-8. 
[99] Chang, B.S., A.J. Minn, S.W. Muchmore, S.W. Fesik, and C.B. Thompson, Identification of a 
novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J, 1997. 16;5: p. 968-77. 
[100] Hillman, G.G., G.P. Haas, W.H. Wahl, and D.M. Callewaert, Adoptive Immunotherapy of 
Cancer - Biological Response Modifiers and Cytotoxic-Cell Therapy. Biotherapy, 1992. 5;2: 
p. 119-129. 
[101] Kaplan, G., Z.A. Cohn, and K.A. Smith, Rational immunotherapy with interleukin 2. 
Biotechnology (N Y), 1992. 10;2: p. 157-62. 
[102] Waldmann, T.A., The IL-2/IL-2 receptor system: a target for rational immune intervention. 
Immunol Today, 1993. 14;6: p. 264-70. 
[103] Smith, K.A., The interleukin 2 receptor. Annu Rev Cell Biol, 1989. 5397-425. 
[104] Graham, F.L., J. Smiley, W.C. Russell, and R. Nairn, Characteristics of a human cell line 
transformed by DNA from human adenovirus type 5. J Gen Virol, 1977. 36;1: p. 59-74. 
[105] O'Gorman, S., D.T. Fox, and G.M. Wahl, Recombinase-mediated gene activation and site-
specific integration in mammalian cells. Science, 1991. 251;4999: p. 1351-5. 
[106] Sauer, B., Site-specific recombination: developments and applications. Curr Opin Biotechnol, 
1994. 5;5: p. 521-7. 
[107] Craig, N.L., The mechanism of conservative site-specific recombination. Annu Rev Genet, 
1988. 2277-105. 
[108] Weiss, A., R.L. Wiskocil, and J.D. Stobo, The role of T3 surface molecules in the activation 
of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at 
a pre-translational level. J Immunol, 1984. 133;1: p. 123-8. 
121 
[109] Robb, R.J. and K.A. Smith, Heterogeneity of human T-cell growth factor(s) due to variable 
glycosylation. Mol Immunol, 1981. 18;12: p. 1087-94. 
[110] Trinchieri, G., M. Matsumoto-Kobayashi, S.C. Clark, J. Seehra, L. London, and B. Perussia, 
Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med, 
1984. 160;4: p. 1147-69. 
[111] Rosenstein, M., I. Yron, Y. Kaufmann, and S.A. Rosenberg, Lymphokine-activated killer 
cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes 
cultured in interleukin 2. Cancer Res, 1984. 44;5: p. 1946-53. 
[112] Grimm, E.A., A. Mazumder, H.Z. Zhang, and S.A. Rosenberg, Lymphokine-activated killer 
cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-
activated autologous human peripheral blood lymphocytes. J Exp Med, 1982. 155;6: p. 1823-
41. 
[113] Ritz, J., R.E. Schmidt, J. Michon, T. Hercend, and S.F. Schlossman, Characterization of 
functional surface structures on human natural killer cells. Adv Immunol, 1988. 42181-211. 
[114] Smith, K.A., E.L. Jacobson, R. Emert, M. Giordano, E. Kovacs, N. Mumneh, F. Pilaro, T. 
Sohn, and D. Warren, Restoration of immunity with interleukin-2 therapy. AIDS Read, 1999. 
9;8: p. 563-72. 
[115] Jacobson, E.L., F. Pilaro, and K.A. Smith, Rational interleukin 2 therapy for HIV positive 
individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U 
S A, 1996. 93;19: p. 10405-10. 
[116] Petite, H., I. Rault, A. Huc, P. Menasche, and D. Herbage, Use of the acyl azide method for 
cross-linking collagen-rich tissues such as pericardium. J Biomed Mater Res, 1990. 24;2: p. 
179-87. 
[117] Elisseeff, J., K. Anseth, D. Sims, W. McIntosh, M. Randolph, and R. Langer, Transdermal 
photopolymerization for minimally invasive implantation. Proc Natl Acad Sci U S A, 1999. 
96;6: p. 3104-7. 
[118] de Kock, J.P., K.J. Reynolds, L. Tarassenko, and J.T. Moyle, The effect of varying LED 
intensity on pulse oximeter accuracy. J Med Eng Technol, 1991. 15;3: p. 111-5. 
[119] Severinghaus, J.W. and P.B. Astrup, History of blood gas analysis. VI. Oximetry. J Clin 
Monit, 1986. 2;4: p. 270-88. 
[120] Cirone, P., J.M. Bourgeois, F. Shen, and P.L. Chang, Combined immunotherapy and 
antiangiogenic therapy of cancer with microencapsulated cells. Hum Gene Ther, 2004. 15;10: 
p. 945-59. 
[121] Valentina Ciccarone, Y.C., Kevin Schifferli, and P.H.-N. Jean-Pierre Pichet, Krista Evans, 
Linda Roy, Shelley Bennett, LIPOFECTAMINE™ 2000 Reagent: For Rapid, Efficient 
Transfection of Eukaryotic Cells. Focus, 1999. 21;2: p. 54-55. 
[122] Cha, H.J., N.G. Dalal, V.N. Vakharia, and W.E. Bentley, Expression and purification of 
human interleukin-2 simplified as a fusion with green fluorescent protein in suspended Sf-9 
insect cells. J Biotechnol, 1999. 69;1: p. 9-17. 
[123] Cha, H.J., N.G. Dalal, M.Q. Pham, and W.E. Bentley, Purification of human interleukin-2 
fusion protein produced in insect larvae is facilitated by fusion with green fluorescent protein 
and metal affinity ligand. Biotechnol Prog, 1999. 15;2: p. 283-6. 
[124] Gelman, M.S., E.S. Kannegaard, and R.R. Kopito, A principal role for the proteasome in 
endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis 
transmembrane conductance regulator. J Biol Chem, 2002. 277;14: p. 11709-14. 
[125] Zhuang, X., T. Ha, H.D. Kim, T. Centner, S. Labeit, and S. Chu, Fluorescence quenching: A 
tool for single-molecule protein-folding study. Proc Natl Acad Sci U S A, 2000. 97;26: p. 
14241-4. 
[126] Cha, H.J., T. Gotoh, and W.E. Bentley, Simplification of titer determination for recombinant 
baculovirus by green fluorescent protein marker. Biotechniques, 1997. 23;5: p. 782-4, 786. 
[127] Leach, R.M. and D.F. Treacher, Oxygen transport-2. Tissue hypoxia. Bmj, 1998. 317;7169: p. 
1370-3. 
[128] Shibata, T., A.J. Giaccia, and J.M. Brown, Hypoxia-inducible regulation of a prodrug-
activating enzyme for tumor-specific gene therapy. Neoplasia, 2002. 4;1: p. 40-8. 
122 
[129] Beidler, D.R. and Y.C. Cheng, Camptothecin Induction of a Time-Dependent and 
Concentration-Dependent Decrease of Topoisomerase-I and Its Implication in Camptothecin 
Activity. Molecular Pharmacology, 1995. 47;5: p. 907-914. 
[130] Haddad, H., D. Windgassen, C.G. Ramsborg, C.J. Paredes, and E.T. Papoutsakis, Molecular 
understanding of oxygen-tension and patient-variability effects on ex vivo expanded T cells. 
Biotechnol Bioeng, 2004. 87;4: p. 437-50. 
[131] Treacher, D.F. and R.M. Leach, Oxygen transport-1. Basic principles. Bmj, 1998. 317;7168: 
p. 1302-6. 
[132] McDermott, M.K., T. Chen, C.M. Williams, K.M. Markley, and G.F. Payne, Mechanical 
properties of biomimetic tissue adhesive based on the microbial transglutaminase-catalyzed 
crosslinking of gelatin. Biomacromolecules, 2004. 5;4: p. 1270-9. 
[133] Elisseeff, J., Injectable cartilage tissue engineering. Expert Opin Biol Ther, 2004. 4;12: p. 
1849-59. 
[134] Broderick, E.P., D.M. O'Halloran, Y.A. Rochev, M. Griffin, R.J. Collighan, and A.S. Pandit, 
Enzymatic stabilization of gelatin-based scaffolds. J Biomed Mater Res B Appl Biomater, 
2005. 72;1: p. 37-42. 
[135] Truskey, G.Y., F; Katz, DF, Transport Phenomena in Biological Systems. 2004, Upper Saddle 











Chong Wing Yung 
US Citizen 
3421 Tulane Dr. #13, Hyattsville, MD 20783 




• Post-doctoral Fellow in Chemical Engineering 2005-Present 
University of Maryland, College Park (UMCP) 
• Ph.D. in Chemical Engineering 2005 
University of Maryland, College Park (UMCP) 
• BS in Chemical Engineering 1996 
University of California, Irvine 
 
 
ACADEMIC & INDUSTRIAL RESEARCH EXPERIENCES 
Post-doctoral Fellow 2005-Present 
Department of Chemical and Biomolecular Engineering, UMCP  
• Develop RNAi metabolic engineering techniques 
• Develop smart-protein separation membranes 
• Lead and train graduate students in individual research projects 
Graduate Research Assistant 2000-2005 
Department of Chemical and Biomolecular Engineering, UMCP  
• Develop cell lines for tissue engineering and biohybrid artificial organ applications 
• Construct expression vectors for constitutive and inductive mammalian protein expression 
• Create transient and stable mammalian cell lines (e.g. C2C12, HEK293, Jurkat) 
• Design hydrogels with tuneable degradation characteristics for cellular scaffolds and 
encapsulation 
• Proficient with flow cytometer, uv, visible and fluorescence spectrometry, confocal    
microscopy, ELISA, apoptosis and proliferation assays, Western-Blotting, etc. 
Pilot Plant Biochemical Technician 1996-1999 
Genentech, Inc., South San Francisco, CA 
• GMP-certified mammalian cell culture techniques 
• Leader for technical training 
• Operate and troubleshoot bioreactors (2-1000-L scales) for process optimization research 
• Conduct research development of novel media sterilization process (High Temperature           
Short Time; flash sterilization)  
Undergraduate Researcher 1992-1995 
Department of Chemical and Biochemical Engineering, UC Irvine  
• Design and built functional packed bed bioreactor from all custom parts 
• Assist in the writing of grant proposals 
• Develop skills in aseptic and bacterial cell culture techniques 
 
AWARDS AND HONORS 
• Merck Award for Best Student Poster March, 2004 
Engineering Conferences International (ECI),  
Cell Culture Engineering IX Conference, Cancun, Mexico 
• Featured Article on Research and Patent 2002 
A New Dish for the Laboratory, Maryland Research Journal, Fall 2002 Vol III, No.1 
• Albertus Magnus Award for Excellence in Teaching (1st Runner-up) 1999-2000 
Department of Chemistry, University of Maryland, College Park  
• Undergraduate Research and Creative Project Grant 1993 
Department of Chemical Engineering, University of California, Irvine 
• NSF Research Experience for Undergraduates Award 1992 
Department of Chemical Engineering, University of California, Irvine 
 
PUBLICATIONS  
• Yung CW, Barbari TA, and Bentley WE; Utilizing intracellular red fluorescence protein 
markers to quantify therapeutic protein secretions for applications in biohybrid artificial 
organs (In Review at: Biotechnology and Bioengineering) 
• Yung CW, Barbari TA, and Bentley WE; Counteracting hypoxia-induced apoptosis, 
prevalent in biohybrid artificial organs, with the oxygen sensitive expression of Bcl-2∆ 
(In Submission to: Metabolic Engineering) 
• Yung CW, Wu LQ, Payne GF, Bentley WE, and Barbari TA; Transglutaminase 
crosslinked gelatin hydrogels for tissue engineering (In Submission to:  Biomaterials) 
• Yung CW, “Tissues and Metabolic Engineering of Biohybrid Artificial Organs”, PhD 
Thesis, University of Maryland, College Park, 2005.  
• Yung CW, Bentley WE, and Barbari TA; Metabolic Engineering of Biohybrid Artificial 
Organs, (In Preparation for: Tissue Engineering) 
• Yung CW, and Bentley WE; Metabolic Engineering Review, (Invited review, in 
submission to: Biotechnique) 
• Luu PP, Yung CW, Sun AK, and Wood TK: Monitoring trichloroethylene mineralization 
by Pseudomonas cepacia G4 PR1. Appl. Microbiol. Biotechnol. 1995, 44:259-264. 
 
PATENTS 
• Patent for Recessed Petri Dish Lid (Filed) – The recessed lid permits fluorescence 
imaging of mammalian cells attached to bottoms of a Petri Dish using a standard Upright 
microscope rather than a specialized inverted fluorescence microscope. 
 
PROFESSIONAL MEMBERSHIPS 
• American Chemical Society (ACS) - Student Member Since 2002 
• American Institute of Chemical Engineers (AIChE) - Student Member Since 2002 
• Biomedical Engineering Society - Student Member Since 2005 
 
PRESENTATIONS 
• American Institute of Chemical Engineers  Fall 2005 
Food, Pharmaceutical & Bioengineering Division 
Tissue Engineering Area (15D12), Cincinnati, OH  
Oral Presentation:  Traceable hIL2 secretion from enzyme crosslinked 
gelatin cellular scaffolds 
• American Chemical Society  Spring 2005 
Division of Biochemical Technology 
Tissue Engineering/Biomaterials Session, San Diego, CA  
Oral Presentation:  Engineering “smart” cells to produce non-invasively 
traceable human therapeutic proteins in a hypoxic environment for 
biohybrid artificial organs 
• Engineering Conferences International (ECI) March, 2004 
Cell Culture Engineering IX Conference, Cancun, Mexico 
Poster Title:  Counteracting hypoxia-induced apoptosis in biohybrid artificial organs 
• American Chemical Society Spring 2003 
Division of Biochemical Technology, New Orleans, LA  
Poster Title:  Applications of HcRed fluorescence for measuring hIL2 secretion 
levels and pericellular oxygen concentrations 
• Bioscience Research & Technology Review Day, UMCP  
Poster Title:  Counteracting hypoxia-induced apoptosis in biohybrid artificial 
organs 2003 
Poster Title:  Applications of HcRed fluorescence for measuring hIL2   
secretion levels and pericellular oxygen concentrations 2002 
• Mid-Atlantic Biochemical Engineering Consortium (MABEC)  Mar 22, 2002 
Drexel University, 15th Annual Meeting  
Poster Title:  Utilizing EGFP to model oxygen and drug release profiles in 




• Graduate Mentor Summer 2003 - 2005 
Research for Undergraduates (REU) Program  
Department of Chemical Engineering, UMCP 
− Guide four students in conducting various research projects and experiments. 
− Two students have moved on to graduate programs in Chemical Engineering 
− A third student will enter a Biomedical Engr. graduate program in the Fall of 2006 
• Substitute Lecturer Fall 2001 & 2002 
ENCH 648B - Advanced Biochemical Engineering 
Department of Chemical Engineering, UMCP 
− Design my own lectures for mammalian cell culture research and industrial 
applications. 
• Teaching Assistant 1999-2000 
CHEM 103 - General Chemistry I 
Department of Chemistry & Biochemistry, UMCP  
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